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The present dissertation is resulting from the work performed during the Ph.D. research activity 
carried out at the Italian Institute of Technology (IIT) under the supervision of Dr. Teresa Pellegrino 
(Nanomaterials for biomedical research line) of the Italian Institute of Technology and Fabio Canepa 
of the University of Genova. The thesis has been conducted in the framework of the ERC-founded 
project ICARO (ERC starting grant n° 678109, Principal Investigator: Dr. Teresa Pellegrino), whose 
main purpose is the development of novel inorganic nanostructures for radiotherapy and 
chemotherapy of cancer. Thus, this thesis aims to progress the field of nanomedicine. In particular, 
the first goal of this work is to synthesize innovative water stable chalcogenide nanoparticles, with 
the purpose of achieving nano-sized platforms capable of incorporating radioactive 64Cu ions, which 
would make such systems suitable for the use in radiotherapy and for positron emission 
tomography. The second goal is to explore the coupling of such chalcogenide nanocrystals with 
magnetic nanoparticles, which are already part of the nanoparticles’ portfolio available in the 
research group where this thesis was carried out. These nanoparticles have shown great potential 
for magnetic hyperthermia treatment of cancer and, in combination with radiotherapy, could result 
in a synergic and more effective cancer treatment. Thus, this thesis provides new ground in the 
rational design of multifunctional nano-heterostructures for cancer diagnosis and therapy. 
The first chapter of this thesis deals with the synthesis, water transfer and radiolabeling of ZnS 
nanoparticles. A non-hydrolitycal thermal decomposition synthesis route was exploited in order to 
obtain quasi-spherical nanoparticles. Such nanoparticles have hydrophobic ligands on their surface 
and thus are stable in organic solvents. In order to successfully transfer them to water phase, the 
ligands were exchanged through a procedure that employs a multi-dentate amphiphilic polymer 
(cysteamine-poly(isobutylene-alt-maleic anhydride)-polyethylene glycol, CYS-PIMA-PEG), which 
resulted in inorganic colloids with perfect stability in aqueous phase. On this system, cation 
exchange reactions with both radioactive and non-radioactive copper were carried out. The 
optimized protocol for the radiolabeling of ZnS nanocrystals with 64Cu permitted to obtain high 
values of radiochemical yield (93%), defined as the percentage of the total activity used that is 
incorporated in the crystals, without losing colloidal stability during radiolabeling reaction or 
subsequent concentration and purification process. The results obtained indicate ZnS nanoparticles 
as an efficient nano-platform for the use in radiotherapy and positron emission tomography, given 
the fast, reproducible and easily clinical-translatable radiolabeling procedure resulting in 
quantitative incorporation of 64Cu ions. 
In the second chapter we report the research activity carried out to couple in a single nano-
heterostructure, the  ZnS nanoparticles or copper-deficient copper sulfide nanoparticles (previously 
reported to be exploitable as radioisotopes carriers) with highly performing magnetic nanoparticles 
(iron oxide nanocubes, IONCs) or nano-heterostructures (gold-iron oxide dimers, Au@FeOy). 
Although the direct growth of ZnS domains on IONCs, through colloidal two-pot seeded-growth 
synthesis procedures, was not possible, this thesis succeeds on merging the different nanoparticles 
in a single nano-platform by exploiting the use of gold NPs as “linkers” between magnetic iron oxide 
domains and copper deficient Cu2-xS domains, using Au@FeOy dimers as seeds for the growth of 




trimers, with the additional possibility to tune the size of the Cu2-xS domain by changing precursors’ 
concentration. These trimers were thoroughly characterized through diverse structural and 
magnetic analysis techniques (transition electron microscopy, X-ray diffraction, SQUID 
magnetometry and UV-VIS-NIR spectroscopy). In particular, magnetic properties measurements, 
allowed to conclude that the magnetic properties of the FeOy@Au@Cu2-xS trimers are comparable 
to the ones of the Au@FeOy dimers (used as seeds for the subsequent reaction of growth of Cu2-xS 
domain). In addition, the trimers display two localized surface plasmon resonance absorption bands, 
one assigned to the gold domain and the other assignable to the copper deficient copper sulfide 
domain, respectively localized in the first and second NIR biological windows and, consequently, 
exploitable in photothermal therapy. 
In the third chapter, the newly synthesized trimers were transferred to water phase and tested for 
the application as carriers for 64Cu and as heating probes in magnetic hyperthermia and 
photothermal therapy. Different strategies were explored in order to develop a reproducible and 
high-yield water transfer protocol. Among them, a two-step ligand exchange procedure employing 
methoxy-poly(ethylene glycol)-thiol and poly(catechol)-poly(ethylene glycol) as amphiphilic ligands 
resulted in aqueous phase stable trimers with high water transfer procedure yield (> 80 %). 
FeOy@Au@Cu2-xS trimers were also successfully transferred to water, although with lower yields if 
compared to previous procedure, using a polymer coating procedure and employing commercially 
available and cost-effective poly-(maleic anhydride-alt-1-octadecene). Lastly, the developed nano-
platform showed great relevance in the field of nanomedicine. Indeed, when employed in magnetic 
hyperthermia, trimers resulted in high SAR values, preserving the excellent hyperthermia 
performances of the Au@FeOy used as seeds for their synthesis and thus in line with the best 
magnetic nano-heterostructures reported so far. Radiolabeling reactions were performed on 
trimers, resulting in a radiochemical yield of 97 %, higher than any value reported so far for 64Cu 
incorporation in water stable nanocrystals. Furthermore, the stability of the trimers during the 
radiolabeling and subsequent purification procedures was likewise ensured by the use of CYS-PIMA-
PEG as stabilizing agent, permitting to recover quantitatively the nanocrystals and the associated 
radioactivity. The performances of FeOy@Au@Cu2-xS trimers when used in photothermal heating 
were also tested under the exposure to 808 nm laser irradiation. Although when using high power 
density (4.67 W/cm2), a temperature increase of 33°C in five minutes was registered, the 
performances obtained with lower laser’s power density were limited. However, the possibility to 
tune the absorption wavelengths by means of changing gold and copper sulfide domain’s 
properties, gives space to further improvements for these multifunctional nano-heterostructures. 
To the best of our knowledge, the here described FeOy@Au@Cu2-xS trimers are the first ever 
reported nano-heterostructures able to combine in one single nano-object the possibility to 
perform magnetic hyperthermia, photothermal therapy and radiotherapy/positron emission 





Nanoparticles for cancer therapy and diagnosis 
Cancer is one of the leading causes of death worldwide accounting for 9.6 million of deaths (almost 
17 % of all deaths globally, 20 % of all deaths in Europe) in 20181. Beside surgery, the most commonly 
used therapies for the tumor treatment, are chemotherapy and radiotherapy. However, together 
with the large heterogeneity of cancers, many factors, such as, for example, multidrug resistance 
(MDR) in the case of chemotherapy and, for what regards radiotherapy treatments, the low 
sensitivity of hypoxic cancers to the ionizing radiations, can reduce the effectiveness of these 
treatments.2 This calls for the development of new innovative cancer treatments, with higher 
specificity and consequently causing less damage to surroundings healthy tissues. Among the 
different strategies investigated, the use of nanoparticles as remote probes for cancer diagnosis and 
treatment (nanomedicine) has widely attracted the attention of the research community in last two 
decades.3,4 An advantage of the use of nanoparticles is their tunable size (from few to hundred 
nanometers) that place them in the range of dimensions of biological targets such as cells (10 – 100 
µm), viruses (20 – 450 nm), proteins (5 – 50 nm) or genes (2 nm wide and 10 – 100 nm long).5 
Moreover, thanks to their small size, the surface to volume ratio of nanoparticles is orders of 
magnitude higher than the one of bulk materials, this increasing the number of surface atoms with 
respect to the one of atoms composing the core. This large surface/volume ratio increases the 
importance of interface and surface phenomena and gives, for example, the possibility to increase 
the number of molecules of anti-cancer drugs that can be loaded on a single nanoparticle used as 
carrier.6 For these reasons, in last two decades, nanoparticles were widely studied to improve the 
efficacy of chemotherapeutic7–9 and radiotherapeutic10,11 treatments and the number of FDA 
approved nanomedicines has increased drastically.12 
Among the different classes of nanoparticles studied, inorganic nanoparticles are of particular 
importance for their peculiar and tunable chemical and physical properties that confer  additional 
Figure 1: Trends in the development of nanomedicines. (a) FDA approved nanomedicines per time period, stratified by category; (b) 




therapeutic and diagnostic features to the nano-formulations.13 Consequently, other than being 
functionalized and used as carriers for chemotherapeutic drug delivery,14 inorganic nanoparticles 
can be exploited for a new generation of biomedical applications relying on their peculiar properties 
such as, for example, magnetic resonance, photoacoustic tomography and computed tomography 
for diagnosis or magnetic hyperthermia, photothermal therapy and photodynamic therapy for 
therapy. Moreover, inorganic nanoparticles can be coated with biocompatible polymers15 in order 
to improve their stability,16 increase their blood circulation time,17 reduce their toxicity,18 and  
enhance their target specificity.19  
Among the wide range of inorganic nanoparticles having different composition studied for 
biomedical applications, three main classes have been of particular interest for their chemical and 
physical properties: noble metal nanoparticles,20 semiconductors nanoparticles21 and magnetic 
nanoparticles.22 
Noble metal (Au, Ag, Pt) nanoparticles have been widely investigated for biomedical applications23 
because of the large portfolio of synthesis procedure reported,24,25 the broad possibility of 
functionalization26–28 and because of their biocompatibility.29 Silver nanoparticles have been mainly 
studied for their antimicrobial activity30,31 while the DNA damaging effect has been reported for 
platinum nanoparticles.32 Among noble metal nanoparticles, the most studied for their possible 
applications in cancer treatment and diagnosis are gold-based NPs.33 Indeed, gold nanoparticles 
(GNPs) of different size and shapes have been reported to be exploitable in both cancer therapy and 
diagnosis. For what regards diagnosis, they have been reported to be efficient when used as contrast 
agents in computed tomography (CT)34,35, in photoacoustic tomography36,37 and in surface enhanced 
Raman scattering (SERS) imaging38,39. On the other hand, GNPs have also been reported to be 
candidate nanomaterials for the use in cancer therapy through photothermal therapy (PTT, see 
Chapter 3),40,41 in photodynamic treatments (PDT)42,43 and as radiosensitizing agents in radiation 
therapy.44,45 
Second class of nanoparticles employed in biomedical applications is provided by semiconductor 
nanocrystals. Although they have lower biocompatibility than gold-based materials,46 numerous 
studies investigated the possibility of the use of semiconductor nanocrystals in biomedical 
applications.47–50. Their optical adsorption and emission properties, tunable in the visible and 
infrared range, have made them optimal as imaging probe. In particular, less cytotoxic copper-based 
chalcogenides nanocrystals have been reported as probes for cancer cells imaging through 
photoacoustic tomography51 and as effective when used in PDT52,53 and in PTT.54,55 Recently, copper 
sulfide nanocrystals have been also reported as effective for the incorporation of 64Cu 56  and, 
consequently, to be exploitable in the development of radiopharmaceutical nano-formulations for 
positron emission tomography (PET) and targeted radionuclide therapy (TRT). A new 64Cu 
radiolabeling procedure for chalcogenide nanocrystals, allowing to incorporate 64Cu on water stable 
CuS crystal exploiting a fast and easily clinical-translatable protocol has been recently developed in 
the research group where this thesis work was carried out.57 
Magnetic nanoparticles (MNPs) are the third class of widely used nanoparticles of particular interest 
in the field of nanomedicine for the possibility of being remotely manipulated by the application of 
a static or an alternated magnetic field that can permeate human body.58–60 Other than for magnetic 




hyperthermia treatments (MHT, see Chapter 3)64,65. Another possibility related to the use of 
magnetic nanoparticle in cancer nanomedicine is the possibility to exploit them in cancer diagnosis 
as contrast agents in magnetic resonance imaging (MRI)66,67 or as tracers in magnetic particles 
imaging (MPI).68,69 Among all the MNPs with different composition reported in literature (such as, 
for example Fe(0)70, FePt71 FeC and mixed ferrite nanoparticles, obtained from iron oxide by partial 
replacement of the Fe2+ ions in the inverse spinel structure with other transition metal ions 72–74), 
FDA approved iron oxide nanoparticles (IONPs) are the most studied75,76 for biological applications 
given the large portfolio of reported procedures for their synthesis and surface functionalization77 
and their proven biocompatibility.78 The group where this thesis work was carried out has 
developed, over the last decade, a wide knowhow on the synthesis and functionalization of 





Multimodal therapy through nano-heterostructures 
Some of the nanoparticles reported for biomedical applications have intrinsic multimodal diagnosis 
and therapy features.83 Some examples include  a single composition nanomaterial like gold 
nanorods, that have been reported to be exploitable both in cancer cell imaging and photothermal 
therapy84, or copper sulfide nanocrystals that have been exploited for dual PDT and PTT treatment85 
or for photoacoustic imaging-guided photothermal therapy.86 Iron oxide nanoparticles are also 
commonly studied for theragnostic, exploiting MRI (or MPI) as imaging technique and MHT for 
therapy87 and have recently been reported to be exploitable in dual MHT and PTT treatments.88 
The possibility to obtain through one single nano-object multiple treatment and diagnosis 
modalities is of key interest for the future development of nanomedicine. Indeed, the development 
of multimodal treatment and diagnosis nano-platform, would permit to increase the efficiency of 
the treatments, this scaling down the amount, and related cytotoxicity,89 of the nanoparticles 
used.90 In order to further enhance this possibility, researchers working on nanoparticles for 
biomedical applications started putting efforts on the development of nano-heterostructures (NHs) 
composed of different nano-domains with different properties.91 Different strategies to fulfill this 
aim were developed, such as coupling the two domains though a silica matrix 92–94 or embedding 
nanoparticles with different composition in a polymeric shell.95 This work was focused on the study 
of nano-heterostructures having different domains joint through a solid interface (Janus 
nanoparticles, see Chapter 2), this allowing to obtain multifunctional nano-objects with reduced size 
and to tune properties arising from the formation of the solid heterojunction.96 Moreover, particular 
interest was directed towards nano-heterostructures developed in order to combine multiple 
therapeutic modality overcoming the intrinsic limitations of each single therapy, with a special focus 
on the ones having a magnetic domain with good efficiency when used in magnetic hyperthermia. 
Nano-heterostructures coupling magnetic nanoparticles with noble metals have been widely 
reported to be exploitable in biomedical applications.97–99 However, in most of them the therapy is 
performed exploiting photothermal 100,101 or photodynamic102 therapies since only few have 
magnetic properties suitable to be used in magnetic hyperthermia with good efficiencies.103–105 
Similarly, among the reported NHs including a magnetic and a semiconductor domain,106–108 most 
of them have been reported for magnetically guided (through MRI) photothermal therapy109,110 and 
only recently, Curcio et al. reported rattle-type iron oxide@CuS hybrids able to combine PTT and 
PDT with magnetic hyperthermia.111 Knowing the  lack of reports on tri-functional nano-systems 
able to merge in one single NHs magnetic hyperthermia, photothermal therapy and radiotherapy 
(through the possibility to incorporate 64Cu in the nanocrystals, without the addition of further 
functionalization) we have been working on the development and proof of principle of application 
of such NHs.  
The results obtained from the research activity carried out during my PhD, focused on the 
development of multifunctional nano-heterostructures for cancer therapy and diagnosis, are here 
described and are organized in three chapters: 
In Chapter 1 I will report on the development new chalcogenide nanomaterials (ZnS nanoparticles) 




In Chapter 2 I will focus on the development of non-hydrolitycal colloidal synthesis approaches in 
order to couple chalcogenide nanocrystals (demonstrated to be able to carry 64Cu ions) with 
magnetic nanoparticles having excellent performances in magnetic hyperthermia. 
In chapter 3 I will describe the results obtained by the applications of newly developed 
FeOy@Au@Cu2-xS trimers in magnetic and photothermal hyperthermia as well as the results 
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1 Chapter 1: ZnS nanoparticles as vectors for 
radioactive 64Cu 
1.1. Introduction 
1.1.1. Application of radioisotopes in nuclear medicine 
In the medical practice, radioisotopes can be used for two main applications: nuclear imaging and 
targeted radionuclide therapy (TRT). In both cases, an appropriate radioisotope is bound to a carrier 
that has the role to specifically bring the radioisotope to the tissue selected as target of the 
treatment or as area of interest for diagnosis. These pharmaceutical radiolabeled drugs are 
commonly referred to as radiopharmaceuticals. 
Nuclear imaging techniques1 rely on the fact that biomolecules inside the body are essentially not 
radioactive, consequently, any tissue in which radioactive atoms (i.e. radioisotopes) are present can 
have nearly infinite contrast with respect to neighboring tissues. This is a clear advantage if 
compared to other imaging techniques (e.g. CT) where the contrast is arising from the difference 
between the intensities of the signals that the tissues are providing2. One of the most common 
nuclear imaging techniques is positron emission tomography (PET)3. Positron emission tomography 
is performed using radioisotopes that are decaying through the emission of positrons (i.e. positive 
electrons, β+). After being emitted (see Figure 1.1), these β+ particles lose their energy while 
traveling through tissues (the range varies depending on the tissue and on the positron energy4). 
Once positrons have lost most or all of their kinetic energy, they are mutually annihilating with 
electrons and two γ-rays with energy of 0.511 MeV5 are emitted. 
 
Figure 1.1: Scheme of Fluorine-18 (18F) positron emission and consequent annihilation. Reprinted with 




These γ-rays couples, that are emitted in opposite direction (approximately with a 180° angle), are 
then detected through a ring of detectors placed around the patient, the signals are then processed 
and the PET image generated (see, as reference, PET imaging study performed on brains of patients 
with different neurodegenerative diseases shown in figure 1.2)6 
External beam radiation therapy, is widely used in clinical practice: approximately 50% of cancer 
patient undergo radiation therapy treatments and 40 % of the curative treatments are involving its 
use7. The working principle of radiation therapy8 is the emission of a ionizing radiation. This radiation 
is then damaging DNA triggering cell death. The damage to DNA could be obtained following two 
different pathways (see Figure 1.3). In the first case, the so-called “direct damage”, the ionizing 
radiation is directly hitting DNA helix causing breaks. In the second case, DNA breaks are caused by 
free radicals or reactive oxygen species (ROS) that are generated by the interaction between the 
ionizing radiation and water molecules. 
Figure 1.2: 18F-Fluorodeoxyglucose PET detecting common neurodegenerative diseases. These axial images were obtained from the 
Austin Hospital Nuclear Medicine Department, Australia. Reprinted, with permission, from reference 6. 





Targeted radionuclide therapy9–12 is a radiation therapy treatment performed using 
radiopharmaceuticals to deliver therapeutic radiation to targets inside the body. Main important 
advantage of targeted radionuclide therapy, when compared to standardly used external beam 
therapy, is its selectivity, allowing to ideally affect mainly cancer cells, reducing the unspecific 
damage to healthy tissues.13 
1.1.2. Commonly used radionuclides in PET and in TRT 
In order to be used as tracer in positron emission tomography, a radionuclide has to decay through 
the emission of β+ with low energy, this permitting to achieve good spatial resolution. Indeed, a low 
energy of the positron guarantee a short path of the particle before annihilating with an electron 
and emitting the two 0.511 MeV γ-rays. Another important parameter, that has to be considered 
when developing a radiopharmaceutical as tracer for PET, is the possibility to have a radioisotope 
half-life matching with the blood circulation time of the targeting unit used. Consequently, the 
clearance of the radiopharmaceutical is important too, since it has to be slow enough for the 
radiopharmaceutical to be able to reach the target but should also be fast enough in order to avoid 
long and unspecific exposure of healthy tissues to radiation. All of these parameters have to be 
considered, depending on the target tissue and on the radionuclide carrier, when choosing a 
radioisotope for the use as tracer in PET. 18F is ubiquitously used with this intention14–16 for its low 
energy (0.6 MeV) positron emitted with high branching ratio (97 %, t1/2 =110 min). Other non-
metallic radioisotopes, used due their ease of being incorporated in biomolecules, are 11C (99.8 %, 
1 MeV, t1/2 = 20.4 min)17, 15O (mainly used as water, 100 %, 1,7 MeV, t1/2 = 2 min)18 and 13N(used as 
ammonia, 100 %, 1.2 MeV, t1/2 = 10 min).19 However, all of these radionuclides have short half-life 
that require the presence of an on-site radioisotope production and radiolabeling facility. This limit 
their usage to the monitoring of short length biochemical processes. In order to be able to overcome 
these limitations, radiometals, having longer half-lives than non-metals, were extensively 
studied20,21 in last decades. Different radioactive metals such as 89Zr (22.7 %, 0.396 MeV, t1/2 = 78.4 
hours)22, 68Ga (87.7 %, 0.84 MeV, t1/2=1.03 hours)23, 86Y (11.9 %, 0.53 MeV, t1/2 = 14.7 hours)24 and 
64Cu (17.4 %, 0.655 MeV, t1/2 = 12.7 hours)25 are commonly used with this purpose. 
A large variety of radioisotopes, with different type of emission and half-lives, is used in targeted 
radionuclide therapy. Three different kinds of emission are of interest for radioisotopes used in 
therapy: α emission, β- emission and Auger or conversion electron emission. These particles differ 
for their different linear energy transfer value (LET, keV/µm). This value indicates the energy 
transferred by the particles in ionization events per unit of path length. LET values for α particles, β- 
particles and Auger or conversion electron emission are of ≂ 80 keV/ µm, 0.2-2 keV/µm and 4 - 26 
keV/µm respectively. Another important parameter that have to be considered is the penetration 
length of the radiation in the target tissue: while β- particles can travel for few mm in tissue, the 
ranges of α particles and Auger electron are respectively reduced to 40-100 µm and below 5 µm. 
Consequently, the type and the extension of the tumoral mass that have to be treated dictate the 
choice of a radionuclide for therapy. One of the most used β- emitters in targeted radiotherapy is 
131I, proposed already in 194226 for the treatment of hyperthyroidism with the advantage of being 
naturally incorporated in thyroid without the use of a carrier being necessary. Similarly, other 
radioisotopes such as α-emitter 223Ra or β- emitting 89Sr are spontaneously accumulated in bone 




employed in targeted radionuclide therapy are 90Y and 177Lu, respectively used for hepatocellular 
carcinoma29 and prostate cancer.30 
Among all the radiometals used in PET imaging and TRT of particular interest is 64Cu for its desirable 
relatively long half-life (12.7 h) and for the possibility to be used in theragnostic applications. Indeed, 
together with positron emission (17 % 0.655 MeV) suitable for PET imaging, 64Cu is decaying also 
through β- emission (39 %, 0.573 MeV) and electron capture (44 %) that can be exploited in targeted 
radionuclide therapy. Another important advantage of 64Cu is that it is currently produced in many 
cyclotron facilities on a routine basis,31–33 making it an ideal candidate for the production of radio-
therapeutic agents.34–36 
1.1.3. Nanoparticles as carriers for 64Cu in TRT and PET 
Most common carriers used in order to deliver 64Cu to the target tissues are peptides37,38 or 
immunoglobulins and antibodies.39 Recently, great interest was shown40–42 towards the use of 
functionalized nanoparticles as radionuclide carriers. The use of nanoparticles as carriers for the 
radioisotopes in radiopharmaceuticals has many advantages such as the possibility to tune 
clearance length and pathways by changing their composition and size and the possibility to increase 
target specificity by nanoparticle’s surface functionalization. Another important advantage of using 
nanoparticles as carriers for radioisotopes, is the possibility to attach chemotherapeutic drugs to 
the particle’s surface (in order to combine TRT and PET with chemotherapy)43 and to exploit the 
physical and chemical properties of the nanoparticle for other cancer treatments such as magnetic 
hyperthermia (MHT), photothermal therapy (PTT) or photodynamic therapy (PTT) and diagnosis 
techniques such as computer tomography (CT) or  magnetic resonance imaging (MRI)44,45. Most used 
strategy in order to radiolabel with 64Cu different nanocrystals is the use of suitable metal chelators 
anchored to the surface of the nanoparticles. Following this path, metal46, quantum dots47 and 
magnetic nanoparticles48 were successfully radiolabelled with 64Cu. However, issues related to the 
leakage of the radioisotopes from the nanoparticle associated chelators were initially reported.49,50 
To overcome this issue, new generation chelators, with improved stability, have been developed51. 
Recently, new approaches for the incorporation of radioactive ions in nanocrystals were reported. 
Zhou et al52 in 2010 reported the synthesis of 64CuS nanocrystals using a mixture of “hot” 
(radioactive) and “cold” (non-radioactive) CuCl2 while Sun et al53 in 2014 reported the feasibility of 
a cation exchange reaction performed at 60°C in organic solvent in order to introduce radioactive 
64Cu in pre-synthesized CdSe/ZnS quantum dots. Main limitation of these procedures is the fact that 
the radioactive nuclide is introduced at an early stage of the material preparation pathway. This 
causes two drawbacks: first, the presence of complicated chemistry facilities as well as specialist 
radiochemists inside the hospitals are required and second, the exposure of operators to radiations 
can be high in case further functionalization, such as attachment of target biomolecules or phase 
transfer, in the case of 64Cu added in organic phase, is needed. For this reason the possibility of 
radiolabelling nanocrystals with 64Cu as last step of the material production and functionalization 
pipeline with simple and fast water phase intercalation reaction was investigated by researchers 
from the group in which this research activity was carried out.54 By means of intercalation reactions 
in aqueous solution it has been possible to successfully radiolabel CuS covellite nanocrystals with 
excellent results. Following this previous study, new chalcogenides nanomaterials for the 




radiolabelling trials were performed on their stable aqueous dispersion. Results related to synthesis, 
water transfer and radiolabelling of zinc sulfide nanoparticles are reported in this chapter. 




1.2. Results and discussion 
1.2.1. Synthesis of ZnS nanoparticles 
Zinc sulfide nanoparticles were synthesized following the procedure reported by Joo et al.55 with 
minor modifications. Briefly, ZnCl2 was dissolved in oleyl amine (OA) with tri octyl phosphine oxide 
(TOPO) and degassed at 120°C. Then, a previously degassed solution of sulfur powder (with sulfur 
content tuned in order to have Zn:S ratio = 1 : 3) was injected, and the temperature increased to 
290°C. After 60 minutes of annealing, the reaction mixture was cooled to room temperature and 
the formed nanoparticles separated from reaction mixture by means of centrifuge washings. 
Particles’ dispersion is extremely stable (up to years) after addition of a minor amount of oleyl amine 
(usually 1 mL of OA is added to 20 mL of particles’ dispersion in hexane). TEM analyses (see Figure 
1.4), indicated that particles obtained following this route have a quasi-spherical shape with typical 
average diameter of 9 nm ± 1 nm and a narrow size distribution. 
Crystalline phase of the as synthesized ZnS nanoparticles was also investigated through XRD 
analyses (Figure 1.5). 





All the Bragg peaks found in the Experimental X-Ray diffraction pattern obtained from the ZnS NPs 
are perfectly matching the expected ones for ZnS with a Sphalerite cubic structure (ICSD card n° 
77082). Through ICP-OES analyses, Zn:S ratio was found to be 1:1 for all the particles synthesized, 
furtherly confirming the composition of the obtained particles. 
1.2.2. Water transfer of ZnS nanoparticles 
Any inorganic nanoparticle which purpose is to be used in biomedical applications, has to be stable 
in aqueous media without forming aggregates or losing its properties. Since most of the particles 
are synthesized by colloidal synthesis methods and have ligands stabilizing them in organic solvents 
(usually chloroform, hexane or toluene), procedures to reproducibly phase transfer in water 
nanoparticles are continuously developed. These procedures, relying on the use of amphiphilic 
ligands, differ depending on many parameters such as the starting dispersion solvent, the chemistry 
of nanoparticles’ surface and the procedure used to add the new amphiphilic ligands (by substituting 
the previous ligands or by intercalation between amphiphilic and hydrophobic ligands). All of these 
parameters are determining the particles’ stability in aqueous media. In the case of ZnS sulfide, a 
ligands exchange procedure was used, substituting the hydrophobic ligands, stabilizing the particles 
in organic solvent (tri octyl phosphine oxide and oleyl amine), with a water-soluble polymer. As 
amphiphilic ligand, a multi-dentate ligand was preferred to a mono-dentate one in order to achieve 
better stability56. The chosen ligand, cysteamine-poly-(isobutylene-alt-maleic anhydride)-
polyethylene glycol, (CYS-PIMA-PEG2000, see Figure 1.6) is composed by a chain of poly isobutylene 
maleic anhydride (PIMA) coupled with cysteamine (CYS) units as anchoring groups for the NC surface 
and with methoxy-poly-(ethylene glycol)-amine (CH3O-PEG2000-NH2) molecules as water soluble 
units. The synthesis of this polymer was achieved adapting a reported procedure (see experimental 
section)57. 
Figure 1.5: Experimental XRD pattern obtained from as synthesized ZnS nanoparticles compared 




A key parameter in order to develop and standardize a procedure of nanocrystals water transfer is 
the ratio between the number of molecules of amphiphilic ligands used and the surface of particles 
that has to be covered with those ligands (ligands/nm2 ratio). To obtain this data is necessary to 
calculate the number of ZnS nanoparticles contained in the volume of solution that has to be 
transferred to water (in the case of these water transfer procedures it was typically 100 µl). First 
step of this calculation was to determine the volume of each particle starting from the average 
spheres’ diameter obtained from TEM analyses. Then, the calculated average volume of the 
particles is divided by the unit cell volume (obtained through XRD analyses) and multiplied by the 
number of unit formula per cell (Z =4 in ZnS ICSD n° =77082) and by the stoichiometric coefficient 
of the target element (ν= 1 for Zn in ZnS) in order to obtain the number of target element (Zn) atoms 
per particle. This number was then divided by Avogadro number (NA) in order to obtain the number 




































Equation 1.1: Formula to calculate moles of target element atoms per particle. 
Second step of these calculations was to multiply NZn by Zinc molecular weight (65.39 g/mol) 
obtaining the mass of Zinc contained in each particle. Dividing by this last value the Zinc 
concentration value for the sample ([Zn] in Equation 1.2), obtained through ICP analyses, the 















Equation 1.2: Formula for the calculation of the number of particles per liter. 




Finally, through the volume of particles that were transferred, the sphere surface formula and the 
number of ligands used, the number of ligands per nanometer squared of particles’ surface, 
ligands/nm2 ratio can be obtained (see equation 1.3). The ratio used in the water transfer procedure 
for ZnS nanoparticles was calculated to be 67 ligands/nm2. 
𝐿𝑖𝑔𝑎𝑛𝑑𝑠/𝑛𝑚2 𝑟𝑎𝑡𝑖𝑜 =  
𝑙𝑖𝑔𝑎𝑛𝑑𝑠












Equation 1.3: Formula for the calculation of ligands/nm2 ratio. 
The procedure used for the water transfer of the particles relies on the mixing, by means of shaking 
at room temperature for 60 minutes, of particles’ dispersion in chloroform mixed with a dimethyl 
sulfoxide (DMSO) solution of CYS-PIMA-PEG2000. Mixture is then precipitated using excess hexane 
and dispersed in Milli-Q water. Stable aqueous solution of particles is then purified from unreacted 
polymer through centrifuge washings in 30 kDa MWCO Amicon filter. 
TEM analyses of the water stable particles (Figure 1.7a) show monodisperse particles with no 
appreciable change in shape or size with respect to organic-stable samples (Figure 1.4a). 
Hydrodynamic size distribution graph, measured though DLS (Figure 1.7b), shows a single peak, 
Figure 1.7: a) Representative TEM picture of the water stable CYS-PIMA-PEG2000 coated ZnS NPs; b) related DLS 
hydrodynamic size distribution graph by intensity; c) Experimental XRD pattern obtained from water stable ZnS 







centered at 80 nm. Although the value for hydrodynamic diameter of the particles is quite high if 
compared to the value of 9 nm ± 1 nm obtained by TEM, the absence of additional peaks and the 
representative TEM picture shown in Figure 1.7a clearly indicate the absence of particles’ 
aggregates. XRD pattern obtained from the water stable sample shows all the expected peaks for 
sphalerite structure with no clear modification if compared with the one obtained from chloroform 
dispersed particles (Figure 1.5). All these data confirmed the excellent quality of the water 
transferred sample and, consequently, the possibility to use the ligand exchange procedure 
employing CYS-PIMA-PEG2000 for the phase transfer in water of ZnS quasi-spherical nanoparticles. 
1.2.3. Cation exchange from ZnS to Cu2-xS 
In order to check the feasibility of the substitution of Zn (II) ions in ZnS nanoparticles with 64Cu(I) 
ions, cation exchange experiments with non-radioactive copper (“cold” copper) were performed. 
Since 64Cu used in the radiolabeling experiments was provided from cyclotron facility (Acom) as 
64Cu:CuCl2, also “cold” experiments were performed using CuCl2 as copper source. In all the 
experiments, the molar ratio between CuCl2 used and sulfur content in nanocrystals (SNCs) was fixed 
in order to have Cuused:SNCs = 1.8. Reduction of Cu (II) to Cu(I) was obtained using the biocompatible 
mild reducing agent vitamin C (ascorbic acid, AA) in concentration equal to 5 equivalents of Cu (II) 
ions used in the reaction. After 60 minutes of incubation at 37°C, reaction mixture was purified, 
from released zinc ions and excess ascorbic acid, through centrifuge washings using a 0.5 mL 100 
kDa MWCO Amicon filter, following the procedure shown in Figure 1.8. The fate of all the elements 
involved in the CE experiment (Cu2+, Zn+ and S2-) was traced by doing ICP-OES analyses on the final 
recovered solutions and on all the solutions resulting from Amicon washings. 
Results obtained from the ICP analyses performed on all the fractions are shown in Figure 1.9. 
Figure 1.8: Scheme of the washing procedure used in order to purify exchanged ZnS NPs sample from released zinc ions and from 




Results shown in Figure 1.9 clearly indicate that almost 90 % of the copper is incorporated in the 
nanocrystals and that corresponding percentage of Zinc is eliminated from the nanocrystals solution 
already during the first washing. These results are showing not only the feasibility of the cation 
exchange reaction but also the possibility of the reaction byproduct ions (Zn2+) to be almost 
completely washed away already with the first washing, making this reaction particularly interesting 
for clinical applications were a fast injection after the CE reaction and as few cleaning steps as 
possible would be required. Moreover, the loss of Cu2+ and S2- ions in the nanocrystals’ solution is 
low, and the percentages of these ions found in the washings (around 5 %) are in the range of ICP-
OES analyses technique error. This last result asses the excellent stability of the ZnS particles in 
water, even after CE reaction and three centrifugation steps at 4000 RCF. 
In order to furtherly confirm the exchange, XRD analyses were performed on exchanged sample. 
Experimental pattern obtained was compared with the ones obtained from fresh water transferred 































Figure 1.9: Results of ICP analyses performed on the different fractions obtained from Amicon washings of a ZnS NPs sample after 60 
minutes incubation at room temperature with CuCl2 (ratio Cuused : SNCs = 1.8) and ascorbic acid (ratio AA : Cuused = 5:1). NCs solution 
indicates the fraction recovered at the end of the washings while 1st, 2nd and 3rd wash indicate the fraction recovered on the bottom 




After the cation exchange (see Figure 1.10c), main Bragg peaks that were found in the water stable 
sample are still present. However, all the Bragg peaks are shifted and with different relative 
intensities. In particular, all Bragg peaks are shifted towards lower angles (e.g. [022] peak moved 
from 47.5° to 46.1°) and, while in pattern acquired before CE reaction the peak with higher intensity 
was [111], after the reaction higher diffraction intensity is registered for [022]. This change in 
reflections position and in their relative intensity can be explained with the transformation of 
sphalerite ZnS structure (ICSD code 77082) into cubic Cu1.8S phase (ICSD code 57213). Bragg peaks 
in exchanged sample are broader if compared to the ones of the starting material. This could be due 
either to low crystallinity of the resulting particles or to the presence of few unreacted ZnS crystals. 
1.2.4. Radiolabeling of ZnS nanoparticles with 64Cu  
In order to assess the possibility to use the produced water stable ZnS nanoparticles for the 
incorporation of 64Cu (I) ions, the particles were tested in radiolabeling experiments similar to the 
ones previously used for ZnSe and CuFeS2 nanoparticles (paper under submission). 
The amount of activity used in any radiolabeling reaction was 18.5 MBq (0.500 mCi), in the range of 





Figure 1.10: Experimental XRD pattern of a sample of ZnS nanoparticles before (b) and after (c) cation exchange reaction 
with Cu (Cuused : SNCs = 1.8), in comparison with expected reflections for cubic ZnS (a, ICSD code: 77082) and cubic Cu1.8S 




a specific activity of 140 GBq/μmolCu. First important value that had to be calculated was the amount 
of total copper corresponding to the activity used. Number of moles of total copper (Cuused) 
employed in a radiolabeling reaction, with fixed amount of activity used and known specific activity, 
can be extrapolated from the formula reported in equation 1.4 where AMBq is the activity used 








] =  [𝑚𝑜𝑙] 
Equation 1.4: Formula used for the calculation of total moles of copper used in radiolabeling reactions. 
Another important parameter that has to be known in order to standardize radiolabeling reaction, 
is the number of moles of radioactive copper corresponding to the activity used (in our case 18.5 
MBq). This value (64Cuused) is calculated following the formula reported in equation 1.5 where ABq is 
the activity used expressed in Becquerel (decay/s), NA is Avogadro number (6.022×1023 mol-1) and 








] = [𝑚𝑜𝑙]64  
Equation 1.5: Formula used for the calculation of moles of radioactive copper (64Cu) used in radiolabeling reactions. 
Considering the activity used (18.5 MBq) in each experiment performed, the total amount of copper 
used, based on specific activity, was 1.32×10-10 moles, while the amount of radioactive copper used 
is 2.03×10-12 moles. 
Most important parameter when evaluating the results of a radiolabeling reaction is the 
radiochemical yield (RCY): This is defined as the percentage of the total activity used in the reaction 
that is effectively incorporated in the nanocrystals. Radiochemical yield is a parameter of key 
importance when evaluating the results of a radiolabeling reaction for the translation to clinics. 
Indeed, if RCY of a radiolabeling reaction is high (≥90 %), meaning that majority of the 64Cu 
introduced in the reaction is incorporated in nanocrystals, purification steps can be reduced or 
removed, decreasing the time between the labeling of the crystals and the injection to the patient 
and, consequently, reducing the manipulation time of the radioisotope and reducing the 
radioactivity in waste. RCY was evaluated through deposition of 1 μL of sample on instant Thin Layer 
Chromatography Silica Gel that is then run using 0.1 M EDTA (pH = 7.5) as mobile phase. 
Nanocrystals fraction is remaining in deposition spot while unbound copper migrates together with 
the eluent. In Figure 1.11 is shown the scheme of a TLC (Figure 1.11a) and the TLC obtained by a 
radiolabeling reaction with radiochemical yield of 25 % (Figure 1.11b) compared with the TLC 




The radiolabeling procedure for the ZnS NPs (see Figure 1.12 a) was performed by mixing in an 
Eppendorf vial an aqueous solution of 64Cu:CuCl2 in HCl 0.1 N, corresponding to an activity of 18.5 
MBq, with 150 μL of 0.3 M MES buffer. Then, if needed, pH of the solution was brought to a value 
around 6 by 2M NaOH addition. After obtaining the desired pH, ascorbic acid was added to reduce 
the 64Cu (II) to 64Cu (I). Finally, aqueous solution of the ZnS nanocrystals was added and the reaction 
mixture incubated at 37°C for 60 minutes. The amount of nanocrystal added was tuned in order to 
have the moles of radioactive (“hot”) copper used (2.03×10-12) equal to 0.2 % of the sulfur atoms in 
ZnS NPs. 
Similarly to what was done in “cold experiments”, in all the radiolabeling experiments performed, 
the washing and concentration of the radiolabeled nanocrystals was performed (see scheme in 
Figure 1.12c) through centrifugation in a 100 kDa MWCO Amicon tube at 4000 RCF for 4 minutes. 
Subsequently, in order to recover the nanocrystals solution, this first step was followed by 
nanocrystals’ solution recovery obtained through inverting the Amicon tube cartridge in a new 
Eppendorf vial and centrifugation for 2 minutes at 2000 RCF. These conditions, needed to clean the 
particles from unreacted reagents and to reduce the volume of the final solution, could be quite 
Figure 1.12: Scheme of the entire radiolabeling and purification procedure; a) addition of the reactants in the reaction vial; b) iTLC of 
the reaction product used to determine radiochemical yield (RCY); c) purification process by means of Amicon centrifugation. 
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Figure 1.11: a) Schematic representation of the TLC used to calculate radiochemical yield; b) TLC obtained by a radiolabeling 




“stressing” for the particles and could result in their aggregation with consequent accumulation in 
the filter membrane. Also, if 64Cu ions are not properly incorporated in the nanocrystal, the washing 
step could result in leakage of the radioactivity from the crystals. Consequently, the stability during 
the radiolabeling and the subsequent washing and concentration step was monitored by comparing 
the percentage of initial activity that was incorporated in the nanocrystals (RCY) to the one that was 
recovered at the end of the washing and concentration steps (purification yield, PY). To assess this 
value, activity of the samples after radiolabeling and of the recollected nanocrystals fraction were 
measured using a dose calibrator. Results (radiochemical yield and purification yield) obtained from 
the radiolabeling of ZnS nanoparticles are shown in Figure 1.13. 
Radiochemical yield of the radiolabeling reaction (light blue bar in Figure 1.13) is 93 % ± 2 meaning 
that only 7% of the used activity remained as free 64Cu in solution. The amount of radioactive copper 
recovered in final nanocrystals solution after purification (PY, green bar in Figure 1.13) is 87 % ± 6 
of the total activity measured after the radiolabeling reaction. This value is similar to the one 
obtained for the radiochemical yield, meaning that nearly all the radiolabeled nanocrystals were 
recovered and that only the free 64Cu ions were lost during the purification, even if no additional 
stabilizing agents were added. These results show the possibility to use ZnS NPs as carriers for 
radioactive 64Cu ions. The high radiochemical yield obtained demonstrate the possibility to use this 
water stable nanoparticles directly after radiolabeling since the amount of free 64Cu in reaction 
mixture is negligible. In case a concentration and purification step is needed, 64Cu:ZnS NPs can be 
easily washed through a fast washing procedure during which only a low amount of activity is lost.  
Figure 1.13: Radiochemical yield (RCY) and purification yield (PY) of radiolabeling 
experiments performed on ZnS NPs with 64Cu:CuCl2 (64Cu (II) ions added in amount 




1.3. Conclusions and outlook 
ZnS nanoparticle were synthesized following a reported procedure with minor modifications. As 
synthesized particles have a quasi-spherical shape and a cubic sphalerite crystal structure. Average 
diameter of the as-synthesized particles is 9 nm ± 1 nm and upon addition of small amount of oleyl 
amine the hexane solution of the sample is perfectly stable. 
In order to perform cation exchange experiments in aqueous media, ZnS NPs were phase transferred 
to water using a reproducible ligand exchange procedure. With this aim, multi-dentate cysteamine-
poly-(isobutylene-alt-maleic anhydride)-polyethylene glycol amphiphilic ligands were used. 
Particles were transferred to water with no appreciable modification in properties (TEM size or 
crystal structure) and avoiding the formation of aggregates. 
“Cold” (with non-radioactive copper) cation exchange reactions were performed on water stable 
ZnS NPs reproducing the conditions normally used in radiolabeling experiments. Quantitative 
exchange of Zn2+ ions to Cu+ ions has been achieved. Released Zn2+ ions are easily removed from 
nanoparticles’ suspension already after one centrifugation step with Amicon filter. 
Radiolabeling experiments, using an amount of 64Cu ions equal to 0.2 % or the sulfur amount in 
nanocrystals were performed. Through 60 minutes incubation at 37°C of water stable ZnS 
nanoparticles with radioactive copper source (64CuCl2) and using biocompatible Vitamin C as mild 
reducing agent, quantitative (average radiochemical yield = 93%) radiolabeling has been achieved. 
If needed, in order to remove exchanged zinc ions and excess ascorbic acid, fast (less than ten 
minutes) purification and concentration of the radiolabeled nanocrystals can be achieved through 
Amicon filter centrifugation. Only a small amount of activity is lost during this last process. 
These results candidate ZnS nanoparticles, together with previously reported CuS nanocrystals,54 as 
possible carrier of radioactive 64Cu ions for PET and targeted radiotherapy applications. Moreover, 
in the case only radiotherapy is of interest as target application, also 67Cu (100 % β-, t1/2=2.6 days, 
commonly used in targeted radiotherapy, especially in combination with immunotherapy,60–62) can 
be inserted in the developed ZnS nanoparticles. 
In next chapter are discussed the different strategies investigated to merge these chalcogenide 
nanocrystals with highly performing in magnetic fluid hyperthermia iron oxide nanocubes63 or 





1.4. Experimental procedures 
Synthesis of zinc sulfide (ZnS) nanoparticles 
ZnS particles were synthesized using the procedure reported by Joo et al.55 with minor modifications 
6 mmol of tri octyl phosphine oxide (TOPO) and 2 mmol of ZnCl2 were mixed in 10 mL oleyl amine 
(OA). The reaction batch was then heated to 120°C and degassed under vacuum for 90 minutes. 
Meanwhile, a solution of 6 mmol S powder in 6 mL OA was degassed at 80°C for the same time. 
After switching both the reaction batches to inert atmosphere (N2 gas), the sulfur powder solution 
was cooled to room temperature and then injected in the ZnCl2 solution. The mixture was then 
heated to 290°C and annealed for 60 minutes before cooling. The resulting product was washed 
through centrifugation (2600 RCF 10 minutes) using hexane as solvent and ethanol as precipitant. 
At the end of the three washing steps, the sample was dispersed in 20 mL Hexane within glass vial 
and, after the addition of 1 ml of oleyl amine, the dispersion resulted perfectly stable. 
Low-resolution Transmission Electron Miscopy (TEM) analyses 
Shape and size of the produced samples were analyzed exploiting Low-resolution Transmission 
Electron Microscopy operating in Bright field mode. All the pictures were acquired using a JEOL JEM-
1400Plus microscope operating at 120 kV and equipped with Gatan CCD camera Orius 830 (2048 x 
2048 active pixels). Both chloroform stable and water stable samples were prepared for TEM 
analyses by drying a drop of the diluted particle suspension on 400 mesh ultra-thin carbon coated 
TEM copper grids. Particles’ size distribution was evaluated through measurement of, when 
possible, at least 200 nanoparticles.  
X-Ray Diffraction (XRD) analyses 
Phase composition of all the samples synthesized was investigated employing X-Ray Diffraction 
analyses. XRD patterns were generally recorded on a PANalytical Empyrean X-ray diffractometer 
equipped with a 1.8kW Cu Kα ceramic X-ray tube, PIXcel3D 2x2 area detector and operated at 45 kV 
and 40 mA. The diffraction patterns were collected using Parallel- Beam (PB) geometry and 
symmetric reflection mode. On a set of selected samples, analyses were performed on a Rigaku 
Smart Lab diffractometer, equipped with a 9 kW Cu Kα rotating anode operating at 40 kV and 150 
mA. The patterns were acquired in a Bragg-Brentano geometry over an angular range of 2θ = 25°- 
95°, using a D-teX Ultra 1D silicon strip detector set in X-ray fluorescence reduction mode. In both 
cases, samples were prepared by drop casting the concentrated NC solution onto a zero-diffraction 
silicon substrate. XRD patterns were elaborate and compared with reference patterns using 
Highscore 4.1 software by Panalytical. 
CYS-PIMA-PEG synthesis 
Synthesis of CYS-PIMA-PEG was performed reproducing a literature reported procedure57 with 
some modifications. In a glass vial, 46 mg of poly-(isobutylene-alt-maleic anhydride) PIMA (MW 
6000 g/mol, 7.7 µmol, 0.3 mmol of monomer units) were dispersed in 2.5 mL of DMSO. PIMA was 
dissolved under gently heating and then degassed by nitrogen bubbling for 10 min. Solution was 




0.15 mmol) dissolved in 1 mL of DMSO in presence of 21 µL of try-ethyl amine, was added dropwise. 
After 20 min a solution of CH3O-PEG2000-NH2 (MW 2000 g/mol, 0.15 mmol) dissolved in 1 mL of 
DMSO was added dropwise and mixture let react overnight. Solution was let to cool down at RT and 
stored at -20 °C for further use. 
Phase transfer of zinc sulfide (ZnS) nanoparticles in water 
For the standard phase transfer of 100 µl of ZnS NPs sample in water using CYS-PIMA-PEG2000, the 
procedure used was the standard one developed in our group for the transfer of chalcogenides 
nanocrystals with this polymer. Sample solution in chloroform was mixed with a dimethyl sulfoxide 
solution of polymer. The amount of polymer added was calculated in order to have a ligand/nm2 
ratio of 67. Chloroform was then added to the mixture up to a total of 4 ml. The mixture was then 
left at room temperature under shaking. After 60 minutes of reaction, hexane was added to the 
solution, and the vial was centrifuged (300 RCF, 5 minutes) in order to precipitate the particles. After 
centrifugation and supernatant removal, 4 ml of Milli-Q water were added to the vial that is then 
sonicated until complete dispersion of the particles. Filtration with a Regenerated Cellulose (RC) 
filter with 0.2 µm pores diameter followed. The solution was then cleaned from unreacted polymer 
through 3 cycles of centrifugation (450 RCF, 30 minutes) in pure Milli-Q water, using a 30 kDa MWCO 
15 ml Amicon (Merck) filter. A typical final volume for the water-transferred sample was around 300 
µl. 
Dynamic Light Scattering (DLS) analyses of water dispersed nanoparticles 
Water stable particles’ aggregation state and hydrodynamic size distribution were evaluated using 
Dynamic Light Scattering measurements. Particles’ hydrodynamic size distribution was measured 
using a Malvern Zeta Sizer operated in the 173° backscattered mode on a highly diluted aqueous 
solution. All measurements were performed at room temperature (20°C). Curves shown are 
resulting from averaging three curves obtained from 10 measurements each. 
Cation exchange reaction with Cu+ on zinc sulfide (ZnS) nanoparticles 
Into a plastic Eppendorf vial, water suspension of ZnS nanoparticles, water solution of Cu2+ 
(containing 1.8 times the molar amount of S present in the nanocrystals) and a water solution of 0.1 
M ascorbic acid (containing 5 times the moles of Cu2+ used), were mixed with water up to 300 µl. 
The mixture was reacted for 60 minutes at 37°C. The solution was then transferred into a 0.5 ml 100 
kDa MWCO Amicon centrifuge filter and water was added up to 400 µl in order to dilute the sample. 
Three cycles of Amicon centrifugation (4000 RCF, 4 min) were performed in order to remove 
released zinc and the excess of ascorbic acid. All the washing fractions collected from the three 
centrifugation steps were measured through ICP-OES analyses. After the third washing, the filter 
containing radiolabeled nanocrystals was removed and inserted upside down in a new Eppendorf 
vial and centrifuged for 30 seconds at 4000 RCF and the collected NPS solution (30 – 35 μL) was 




Elemental analyses through Inductively Coupled Plasma Optical Emission 
Spectrometry (ICP-OES) 
Samples composition and elements ratio were evaluated through elemental analyses. Elemental 
analyses were performed using an Inductively Coupled Plasm- Optical Emission Spectroscopy (ICP-
OES) instrument (Thermo Fisher, iCap 6000). Small volumes (5 µL - 25 µL) of particles suspension 
were digested in 1 mL of Aqua Regia in a volumetric flask. After one night of digestion at room 
temperature, flask was filled up with Milli-Q water and filtered through 0.2 µm PTFE membrane 
prior to the measurement. 
Radiolabeling of ZnS nanoparticles 
Into a plastic Eppendorf vial, a quantity of 64Cu:CuCl2 corresponding to an activity of 18.5 MBq (0.500 
mCi, 2.03×10-12 mol of 64Cu, total copper 1.32×10-10 mol) and 150 μL of 0.3 M MES buffer (pH 5.6) 
were added. The pH of the solution was then brought to a value around 6 by 2 M NaOH addition, in 
amounts depending on the pH of the received 64CuCl2 solution (typically, 6 μL of 2 M NaOH were 
used in order to adjust the pH of 35 μL of starting solution). Once the solution was brought to desired 
pH, 10 μL of ascorbic acid (0.1 M) were added as a reducing agent together with ZnS NPs aqueous 
solution, containing a number of sulfur moles equal to 7.7 times the moles of total Cu (II) used 
(1.02×10-9 moles of sulfur). Finally, the reaction mixture was incubated at 37°C for 60 minutes. After 
the incubation, 1 μL of the reaction mixture was spotted on instant Thin Layer Chromatography-
Silica Gel (iTLC-SG) chromatography paper (Agilent technology) and the iTLC was developed in 0.1 
M EDTA (pH = 7.5) as mobile phase. The dried ITLC plates were exposed on an Imaging Plate for 30s 
and the results were analyzed on an appropriate imaging system (FLA-9000, Perking Elmer) in order 
to measure radiochemical yields of the reactions. Each RCY average value and related error bar are 
resulting from at least three different experiments performed in the same experimental conditions.  
Concentration and purification of the solution of radiolabeled nanocrystals 
The washing and concentration of the nanocrystals after the radiolabeling procedure has been 
performed using 0.5 mL 100 kDa MWCO Amicon centrifugal filters (Merck). After the radiolabeling, 
the reaction mixture (approximatively 300 μL) was transferred to an Amicon filter inserted in an 
Eppendorf plastic vial and Milli-Q water added up to 500 μL. After 4 minutes of centrifugation at 
4000 RCF, the filter containing radiolabeled nanocrystals was removed and inserted upside down in 
a new Eppendorf vial and centrifuged for 2 minutes at 2000 RCF. Through a dose calibrator (VDC-
603, Comecer) the activity of the final nanocrystals’ solution was measured and compared with the 
activity value obtained from the measurement of the reaction mixture after radiolabeling reaction 
in order to calculate the purification yield. Each purification yield average value and related error 
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2 Chapter 2: Synthesis of multifunctional nano-
heterostructures 
2.1. Introduction 
2.1.1. Janus nanoparticles: properties and parameters influencing their synthesis 
Janus nanoparticles (JNPs), named after the double-faced Roman god, are compartmentalized 
particles with two sides having different chemical properties or polarity.1 The great importance of 
such materials in merging different physical and chemical properties in one single nanostructure 
was already realized by Nobel laureate P. G. de Gennes in 1991.2 From that year on, the synthesis of 
inorganic Janus NPs was further developed and optimized, increasing exponentially the number of 
reported procedures to obtain this kind of nanomaterial. 3–8 Several JPNs have been reported in 
literature, having shapes ranging from the spherical shape to disk, rod, hybrid or more complicated 
dumbbell or snowman shapes (see Figure 2.1). 8 
Depending on the shape and on the composition of the different heterostructures’ domains, these 
materials have been demonstrated to be useful in many different applications, including 
catalysis,9,10 micromotors,11–13displays14,15 and biosensors.16–18 Recently, the possibility to merge 
domains with completely different properties in one single nano-heterostructure and the 
opportunity to tune these properties have attracted the interest of researchers working in the 
development of nanomaterials for biomedical applications, who, in the last decade, have thoroughly 
studied the processes happening at the domains’ interfaces and worked in the development of 
nanoparticles for cancer theragnostic.19–21 Of particular interest for the scientific community is that 
these multiple-domain nano-heterostructures maintain the properties of each single domain and, 
Figure 2.1: Schematic illustration of typical Janus nanostructures. 




in addition, new properties can also arise from the presence of an interface between the different 
materials. As an example, gold nanoparticles have shown increased catalytic effect for CO after 
being attached to a metal oxide domain.22 The presence of such additional properties in JNPs is 
commonly explained by junction effects, arising from the transfer of electrons from one domain to 
the other.23 Apart from their shape, JNPs can also be categorized depending on the chemical nature 
of the domains composing the heterostructure: polymeric, inorganic, and polymeric-inorganic.24 In 
last two decades, many efforts have been made in order to develop colloidal synthesis procedures 
for inorganic Janus nano-heterostructures, formed by two (or more) distinct domains permanently 
joint through chemical bonding interfaces (i.e., without any molecular bridges).25 Most of those 
procedures rely on the growth of a second domain on the surface of a preformed nanoparticle. This 
mechanism is commonly referred to as “seeded growth” (or “seed mediated growth”) being the 
starting preformed nanoparticles defined as “seeds”. In order to obtain those two (or more) 
domains heterostructures,26 it is critical to favor the heteronucleation of the second material on 
seeding NPs (against the homonucleation that is the formation of separate second material NPs 
surrounding the seeds). 
In the classical nucleation theory,27 thermodynamic energies that have to be taken into account for 
nucleation and growth are described by the excess Gibbs free energy (ΔGr) of the system (shown in 
equation 2.1, where ΔGS and ΔGV are the free energy contributions from the surface and the bulk, 
respectively). 
∆𝐺𝑟 = ∆𝐺𝑠 + ∆𝐺𝑣  
Equation 2.1: Total Gibbs free reaction energy dependence on ΔGS (free energy contribution of the surface) and ΔGv (free energy 
contribution of the bulk) during nanoparticles homogeneous nucleation. 
While ΔGV is influenced by the cubic radius of the forming nucleus, by the molar volume (Vm) of the 
material and by the normalized concentration of reaction species under equilibrium conditions (S), 
ΔGs is influenced by the squared radius of the forming nucleus and by the surface free energy per 
unit area (γ). If ΔGr is negative, nucleation is taking place. For heterogeneous nucleation on a seed, 
equation 2.1 becomes equation 2.2. 
∆𝐺𝑟 = ∆𝐺𝑠 + ∆𝐺𝑣 + ∆𝐺𝑖𝑛𝑡𝑒𝑟  
Equation 2.2: Total Gibbs free reaction energy dependence on ΔGS (Gibbs free energy contribution of the surface), ΔGv (Gibbs free 
energy contribution of the bulk) and ΔGinter (Gibbs free energy contribution of the solid/solid interface) during nanoparticles 
heterogeneous nucleation 
The additional term (ΔGinter) is related to the formation of a new solid/solid interface between the 
two materials, which depends on the interface’s surface free energy per unit area (γinter) and on the 
surface of the interface (Sinter) (see equation 2.3). 
∆𝐺𝑖𝑛𝑡𝑒𝑟 = 𝛾𝑖𝑛𝑡𝑒𝑟 ∗ 𝑆𝑖𝑛𝑡𝑒𝑟  
Equation 2.3: Gibbs free energy contribution of the solid/solid interface dependence on γr (interface’s surface free energy per unit 





Generally, heteronucleation is favored over homonucleation (heteronucleation energy barrier 
(ΔGhet) is lower than homogeneous nucleation one (ΔGhom)). However, depending on the interplay 
between many different parameters (lattice mismatch, surfactants, precursor concentration, 
reaction temperature, etc.) both homonucleation and heteronucleation can occur when attempting 
a seeded-growth nano-heterostructure synthesis.28 A key parameter determining the morphology 
of the formed heterostructure is the lattice mismatch between the two materials.29 When the lattice 
mismatch is low (usually within 1—3%) core-shell structures are formed (associated to high 
interface surface, Sinter in equation 2.3).30 On the contrary, when lattice mismatch is high (associated 
to increased values of interface’s surface free energy per unit area, γinter in equation 2.3), the surface 
of the interface is reduced, leading to dumbbell-like (or snowman-like) shaped heterostructures 
(non-centrosymmetric structures).31 Interestingly, several studies reported that the interface strain, 
given by the lattice mismatch, can be reduced by the growth of amorphous domains32 or amorphous 
shells, which can be then transformed into a crystalline domain by subsequent heating.33  
2.1.2. Synthesis procedures for JNPs having an iron oxide and a chalcogenide domain 
Among the wide amount of literature on JNPs, only few heterostructures composed by an iron oxide 
and a semiconductor domain are reported. In particular, the group of professor Moonsub Shim 
thoroughly studied the mechanism underlying the formation of iron oxide-chalcogenide 
heterostructures.28 The synthesis they exploited was a one-pot (second domain is grown directly in 
the reaction mixture of the formed seeds) seeded-growth of CdS, ZnS and HgS on γ-Fe2O3 preformed 
seeds. The influence of many parameters, such as lattice mismatch and annealing time and 
temperature on the number of formed heterojunctions was investigated.34 Also, they reported that, 
when the lattice mismatch is high, such as between iron oxide and chalcogenides NPs, a small size 
of the used seeds can help overcoming interfacial strain more effectively, thus helping the growth 
of a larger second domain.35 This is of key importance in the case of the aimed heterostructures 
(comprising a magnetic domain exploitable in hyperthermia). Indeed, hyperthermia performances 
are strongly influenced by the size of the magnetic domain, having smaller iron oxide particles 
usually poor performances.36 Few other procedures were reported in order to obtain either core-
shell37,38 or dumbbell like39–43 γ-Fe2O3@MX (M = transition metal, X = chalcogen). However, when 
measured, their magnetic properties were not optimal and, consequently, these magnetic-
chalcogenide domains JNPs were tested for MRI only.44 In 2006, Weili Shi et. al.45 reported another 
interesting approach for the synthesis of iron oxide-chalcogenide multi-domain heterostructures. 
Together with the synthesis of core-shell PbS@Fe3O4 they were also able to obtain Fe3O4@Au@PbS 
and Fe3O4@Au@PbSe heterostructures. These JNPs synthesis was achieved exploiting preformed 
Au@Fe3O4 dimers as seeds and growing PbS and PbSe on the surface of gold NPs. As in most of 
previously mentioned cases, the performances in biomedical application of these trimers were not 
investigated. However, the possibility of using gold NPs as “linkers” between the magnetic and the 
chalcogenide domains for JNPs exploitable in biomedical applications remains of high interest. 
Indeed, Au@Fe3O4 heterostructures have been widely reported in literature,46–48 and among them, 
some, such as the ones developed by Pablo Guardia and other members of Teresa Pellegrino’s 
research group, has shown outstanding efficiency when used in magnetic hyperthermia.19,49 Also, 
gold nanoparticles (or other noble metal or noble metal alloys nanoparticles) have been reported 




NPs as “linkers” between magnetic and chalcogenide domains an exploitable strategy in order to 
fulfill our aim. 
In the following chapter, results obtained from the trials to merge in a single nano-heterostructures 
a magnetic nanoparticle or heterostructure, among the ones developed in this group, reported to 
be efficient in magnetic hyperthermia (iron oxide nanocubes55,56 or gold-iron oxide dimers19,49) with 
a chalcogenide domain able to incorporate 64Cu ions (such as previously reported CuS57 or newly 




2.2. Results and discussion 
2.2.1. Synthesis of γ-Fe2O3@ZnS heterostructures 
First approach attempted in order to fulfill the aim of this project was to grow directly zinc sulfide 
domains on the surface of magnetic nanoparticles. A one-pot seeded growth synthesis for these 
heterostructures, using γ-Fe2O3 NPs as starting seeds, has already been reported in literature.28 This 
reaction is based on the seeded growth of ZnS domains on in-situ preformed γ-Fe2O3 seeds. γ-Fe2O3 
seeds are synthesized through thermal decomposition of Fe(CO)5 in octyl ether (OE), in the presence 
of surfactant molecules (oleic acid, OLAC). ZnS domain was then grown by direct addition of 
precursors (zinc acetate and sulfur powder) and surfactants (tri octyl phosphine oxide, TOPO) to 
crude γ-Fe2O3 reaction mixture. The synthesis pot is then annealed at different temperatures 
(250°or 280°C) for different times (60 minutes or 180 minutes). Representative TEM pictures of the 
particles obtained reproducing this procedure are shown in Figure 2.2. 
In accordance with reported data, for all the conditions tested (Figure 2.2a-c), the heterostructures 
obtained were composed of 6 - 8 nm average diameter size iron oxide nanoparticle cores decorated 
with few ZnS particles with an average diameter of about 1-2 nm. XRD analyses, shown in Figure 
2.3, confirmed the precence of both low-cristallinity ZnS (only main ZnS sphalerite peak is detectable 
as a shoulder placed at 28° degress of the iron oxide Bragg peak at 30° degrees) and of γ-Fe2O3 
domains (broad Bragg peaks corresponding to main γ-Fe2O3 reflections are present at 2θ = 30°, 
35.6°, 43.4°, 57.3° and 62.8°). 
Properties of the iron oxide domains exploited as seeds in this procedure were far different from 
the aimed ones in our research plan, having poor crystallinity and small size. This detail is of key 
importance since poor quality magnetic domains lead to a low heating efficiency,36 severely 
compromising the final performances of γ-Fe2O3@ZnS heterostructures in magnetic hyperthermia. 
c a b 
Figure 2.2: Representative TEM pictures of the obtained γ-Fe2O3@ZnS samples. Annealing temperature and time used in these 




Consequently, this procedure to grow ZnS domains on top of iron oxide NPs had to be suitable 
modified in order to exploit as seeds the highly performing iron oxide nanocubes (IONCs) developed 
in our group.55 
2.2.2. Synthesis of IONC@ZnS heterostructures 
The procedure previously used for γ-Fe2O3@ZnS heterostructures was adapted to a two-steps 
approach, using pre-formed iron oxide nanocubes (IONCs) as seeds for the subsequent growth of 
ZnS domains. IONCs nanocubes of 16 ± 2 nm (see Figure 2.4a) were synthesized using standard 
procedure developed by our group, a thermal decomposition of iron (III) acetyl acetonate in a 
solvents mixture of di benzyl ether (DBE) and squalene, using decanoic acid as surfactant. Since the 
typical iron content of one IONCs sample produced in this synthesis is lower if compared to that of 
γ-Fe2O3 seeds synthesized in the original procedure, the mmol of iron used in the synthesis were 
scaled down by ten times (from 1.5 mmol used in the original synthesis to 0.15 mmol in the two-pot 
growth of ZnS on IONCs). Accordingly, zinc and sulfur precursors’ amount was scaled down, keeping 
the same Fe:Zn:S ratio used in the original procedure (6:1:1:) while, initially, solvent and surfactants 
amount were kept the same. Figure 2.4b shows a representative TEM image of particles resulting 
from this first trial, using 60 minutes of annealing at 280°C. 
 
 
Figure 2.3: XRD pattern of the γ-Fe2O3@ZnS sample resulting from following literature procedure compared with expected 




Figure 2.4b clearly shows that both the size and the well-defined cubic shape of the iron oxide 
nanocubes (see Figure 2.4a) have suffered a strong modification during the ZnS growth procedure, 
presenting smaller size and rounded shape, which indicated that IONCs underwent a decomposition 
process. In addition, it is unclear the successful nucleation of ZnS domains. To understand what was 
the cause of the decomposition of IONCs, a complete study on the influence of different parameters, 
such as the kind of solvent and the surfactant amounts was carried out. The influence of the solvent 
was investigated replacing OE with 1-Octadecene (ODE). The influence of the surfactants (OLAC or 
TOPO) was investigated removing either one or both of them in the reaction batch. All these trials 
were performed without adding any zinc of sulfur precursor and performing the annealing at 280°C 
for 60 minutes, as done in the first synthesis. For all the trials, the same batch of IONCs was used, in 
order to be able to separately study the influence of solvents and surfactant without any other 
difference in the procedures. Results obtained from these investigations are shown in Figure 2.5. 















Figure 2.5: Representative TEM pictures obtained from investigations on different parameters causing cubes decomposition during 
an annealing at 280°C for 60 minutes. a) OE used as solvents and only OLAC used as surfactant, b) OE used as solvent and only TOPO 
used as surfactant, c) OE used as solvent and no surfactants, d) ODE used as solvents and only OLAC used as surfactant, e) ODE used 
as solvent and only TOPO used as surfactant, f) ODE used as solvent and no surfactants. 
b a a 
Figure 2.4: Representative TEM pictures of 16 ± 2 nm edge length IONC a) before and b) after the attempt of 




Solvents influence was evaluated from the trials done without adding any surfactants. Looking at 
pictures in Figure 2.5c (OE as solvent) and Figure 2.5f (ODE as solvent) can be seen how, although 
the influence is minimal, octyl ether seems to be a most suitable solvent for this procedure with 
respects to 1-octadecene, producing the latter one minimal aggregation of the IONCs. Regarding 
the surfactants, it is clear that both OLAC and TOPO are boosting cubes decomposition during the 
annealing. Oleic acid, in particular, is changing the shape and size of the nanocubes, producing either 
big cubes (up to 50 nm) surrounded by decomposed particles with OE (Figure 2.5a) or badly-shaped 
smaller particles with ODE (Figure 2.5d). TOPO is giving aggregation when used with OE (Figure 2.5b) 
while when ODE is used as solvent, it is causing also clear decomposition of the cubes. Interestingly 
it seemed that the effect of OLAC was amplified when OE was used as solvent (compare Figure 2.5a 
and 2.5d) while TOPO effect was prominent when ODE was used (compare Figure 2.5b and 2.5e). It 
is worth to mention that during this procedure TOPO is required, not only as surfactant for the 
forming ZnS NPs, but also, and most importantly, in order to allow the solubility of zinc precursor 
(zinc acetate) in OE. Consequently, TOPO could be scaled down with Zn(Ac)2 amount but it could 
not be completely removed. Instead, OLAC was used to stabilize the forming -Fe2O3 seeds, so it 
could be removed from the procedure since the IONCs used as seeds are already covered with a 
surfactant, decanoic acid, and hence stable in solution after the centrifuge washings steps. Thus, in 
order to avoid IONCs decomposition during annealing, a new procedure was set up, scaling down 
the amount of TOPO used (by ten times, together with Zn(Ac)2 amount) and completely removing 
OLAC from reaction mixture. Results of the syntheses performed with this optimized procedure are 
shown in Figure 2.6. 
As expected, although particles aggregation was observed, using the optimized parameters the 
IONCs are not decomposing. However, the nucleation of ZnS on the surface of IONCs and thus the 
formation of IONCs-ZnS heterostructures was not observed, although the presence of small (<5 nm) 
aggregates of nanoparticles surrounding the nanocubes (see red circles in figure 2.6b), likely due to 
the isolated nucleation of Zn compounds, is clear. In order to identify the composition of these small 
aggregates, scanning transition electron microscopy (STEM) imaging and energy dispersive X-ray 
spectroscopy (EDS) elemental mapping were performed on one of these samples. Results obtained 
from these analyses are shown in Figure 2.7. 
Figure 2.6: a) Representative TEM picture of a ZnS@IONCs sample synthesized with the optimized procedure, b) higher 






From STEM image (Figure 2.7a) both the cubes and the small particles aggregates were clearly 
distinguishable. Elemental mapping for iron (Figure 2.7c) clearly indicates that this element is 
localized in the cubes area whereas zinc (Figure 2.7e), even though it has a low number of counts, 
seems to be mostly in the spaces between the cubes, where small particles’ aggregates are localized. 
Oxygen (Figure 2.7d) seems to be allocated both on the cubes and in the interstitials between them 
while sulfur seems to be mainly on cubes’ aggregates but the small number of counts does not allow 
to obtain his accurate distribution. In order to have a complete picture of the final sample 
composition and to clearly identify the aggregates between IONCs, XRD analyses were performed 
(see Figure 2.8). 
 
Figure 2.7: a) High Angle Annular Dark Field (HAADF) image of ZnS@IONC sample, b) HAADF image of 
EDS elemental mapping area c) iron distribution obtained through EDS elemental mapping, d) oxygen 
distribution obtained through EDS elemental mapping, e) zinc distribution obtained through EDS 
elemental mapping, f) sulfur distribution obtained through EDS elemental mapping. 
Figure 2.8: Experimental XRD pattern obtained from a ZnS@IONC sample in 
comparison with the expected reflection for iron oxide (ICSD code: 247035), 




All the expected maximum intensity reflections for iron oxide were evident in the experimental 
pattern that was showing clear sharp Bragg peaks indicating optimal crystallinity. The only reflection 
that was not possible to attribute to iron oxide was the one at 2θ = 33.6°. This Bragg peak can be 
indexed with the [002] reflection of ZnS sphalerite (ICSD code: 41985) or with the [111] reflection 
for cubic ZnO (ICSD code:38222). For ZnS however, the [002] reflection should be much less intense 
of the one of the main [111] reflection at 2θ = 29°. Since the expected reflection for ZnS at 29° was 
not present and since the [111] reflection of ZnO at 33.6° is cubic ZnO main reflection, the particles 
were unambiguously identified as made of ZnO. Other reflections coming from ZnO nanoparticles 
are not present in the experimental XRD pattern probably because of the small quantity and low 
crystallinity of those particles. 
2.2.3. Synthesis of Au@FeOy heterostructures 
Since the direct growth of ZnS particle directly on the surface of IONCs gave unsatisfactory results, 
other paths were considered in order to achieve the desired heterostructures with a magnetic 
domain and a chalcogenide domain. Among the highly performing magnetic materials developed in 
our research group, together with IONCs, also Au@FeOy dimers were synthesized.19 Gold-Iron oxide 
dimers have been reported as promising in different applications, ranging from catalysis10,58 to 
biomedicine.59 Indeed, in these heterostructures, the gold domain can be exploited for imaging 
technique like Surface Enhanced Raman Spectroscopy (SERS)60, computer tomography (CT)61 or in 
photothermal therapy (PTT)62 while the iron oxide domain can be used both in Magnetic Resonance 
Imaging (MRI)59 or as heat mediator in magnetic hyperthermia (MHT).63 With respect to MHT, gold-
iron oxide dimers have shown outstanding Specific Absorption Rate (SAR) values,19 comparable to 
the ones of IONCs. Consequently, the possibility to merge a chalcogenide domain with Au@FeOy 
heterostructures, using gold NPs as “linkers” between iron oxide and a chalcogenide domain was 
also investigated. 
The synthesis method of those heterodimers relies on the in-situ growth of iron oxide domains on 
the surface of pre-formed gold nanoparticles through the hot injection of Fe(CO)5 at 150°C in 
presence of OLAC and oleyl amine (OLA)  (acting as surfactants) and using ODE as solvent. Iron 
precursor is then decomposed during an annealing step at 200°C. The size of the iron oxide domains, 
and therefore their magnetic properties, can be tuned (from 16 ± 2 nm to 25 ± 4 nm) by modifying 
the annealing time at 200°C (from 30 to 90 minutes). Key point of this synthesis is to introduce Cl - 
ions, which have been found to improve the crystallinity of the iron oxide domains, with gold 
precursor (HAuCl3), allowing thus the growth of those domains already at 200°C whereas in the 
absence of Cl- ions, the growth takes place only at 300°C. Together with Au@FeOy dimers of the 
mentioned size, this synthesis also produces smaller dimers and isolated gold NPs (see Figure 2.9a). 
In order to isolate the desired dimers from those byproducts, the as-synthesizes sample is washed 
with isopropanol, dispersed in chloroform and subjected to magnetic separation using a 0.4 T 
magnet for 180 minutes. The fraction collected was dispersed again in chloroform for subsequent 





Phase composition of these dimers was identified through XRD analyses, whose results are shown 
in Figure 2.10. The reflections obtained in experimental patterns are perfectly matching the ones 
expected for cubic gold and iron oxide, with no possibility to discriminate accurately between γ-
Fe2O3 and Fe3O4 NPs phases using XRD.  
 
a b 
Figure 2.10: Representative XRD pattern of an Au@FeOy dimers sample and comparison 
with expected reflection for gold (ICSD code 611625) and iron oxide (ICSD code 247035). 
Figure 2.9: Representative TEM pictures of Au@FeOy dimers sample with mean iron oxide size of 20 ± 2 nm before 




Magnetic properties of the dimers’ samples were evaluated through a Superconducting Quantum 
Interference Device (SQUID) magnetometer. Figure 2.11 shows the field dependence of the 
magnetization at 10 K and 298 K (RT) (Figure 2.11a), together with Zero-Field-cooled (ZFC) heating 
and Field-cooled (FC) cooling magnetization vs. temperature curves (Figure 2.11b), obtained for a 
sample of dimers, whose iron oxide domain size was 25 ± 4 nm. 
Parameters determined through these measurements are reported in Table 2.1. 
Table 2.1: Parameters measured through SQUID analyses on a sample of Au@FeOy with 25 ± 4 nm iron oxide domain size.  
Temperature HC Mmax 
(K) (Oe) emu/giron 
298 K 20 106 
10 K 200 113 
Maximum magnetization values of these particles (113 emu/giron at 10 K and 106 emu/giron at RT) 
are in line with the ones reported before for Au@FeOy dimers synthesized following this 
procedure19. From ZFC-FC curves particles can be identified as blocked (and consequently 
ferrimagnetic) in the range of temperature tested (5K- 400K) as expected given the large size of the 
magnetic domains. Reduction of the magnetization in FC curves when moving from higher to lower 
temperature is an indication of interparticle interaction64 as already clearly shown by TEM images 
in Figure 2.9. Magnetization versus temperature curves (Figure 2.11b) do not show the typical 
Verwey transition (expected, for magnetite nanoparticles, near 120 K)65 associated with the 
presence of magnetite. However,  P. Guardia et al. reported that for dimers obtained through the 
same synthetic route, a mixture of maghemite and magnetite is expected, as determined through 
Mössbauer spectroscopy, showing a proportion between maghemite (γ-Fe2O3) and magnetite 
(Fe3O4) of, respectively, 46 ± 2 % and 54 ± 2 %.19 
2.2.4. Synthesis of Au@Cu2-xS heterostructures 
Once confirmed the possibility to successfully reproduce the growth of a magnetic domain on gold 
NPs, different trials were carried on to couple Au NPs with a chalcogenide domain suitable for 
Figure 2.11: Results obtained from the magnetic characterization on a sample of Au@FeOy dimers with 25 ± 4 nm iron oxide 
domain: a) zero field cooled MH curves recorded in the range ± 70 kOe at 10 K (red line) and 298 K (blue line), insert: low field 






radiolabeling such as the previously reported copper sulfide57 or zinc sulfide (synthesis, 
characterization and radiolabeling reported in chapter 1). 
As first step, small (≃ 4 nm) gold nanoparticles (see Figure 2.12a) were synthesized following a 
reported procedure66. Briefly, the particles were synthesized using HAuCl4 as gold precursor and 
Tert-butyl ammine-borane complex as reducing agent in presence of Oleyl amine and using tetralin 
as solvent. Particles were then precipitated with isopropanol, centrifuged and dispersed in 
chloroform for further experiments.  
In order to be able to grow a copper sulfide domain on these particles, according to the procedure 
reported by Wang et al.50, they need to be dispersed in oleyl amine. Consequently, the chloroform 
dispersing the gold NPs was evaporated through bubbling and substituted with same amount of 
oleyl amine. 
The synthesis of the Au@Cu2-xS dimers is accomplished through the growth of Cu2-xS domains on 
preformed gold NPs. First, the Au NPs oleylamine solution is mixed with the copper precursor 
(CuCl2×2H2O) with an Au: Cu molar ratio of 1:20 in oleyl amine. Copper sulfide domains nucleation 
is then started by the injection at 180°C of di-tert-butyl disulfide (TBDS), with a sulfur amount equal 
to 20 times the equivalents of Cu precursor used. Then the reaction mixture is annealed at that 
temperature for 70 minutes. Resulting Au@Cu2-xS heterostructures are shown in Figure 2.12b. 
The shape of the formed copper sulfide domains is hexagonal with a side-to-side length of 26 ± 2 
nm. Interestingly, the size of gold NPs used as seeds is growing during the process, from 3.7 ± 0.5 to 
7 ± 2 nm this suggesting that, other than growing the copper sulfide domains, the reaction is also 
affecting gold NPs. To further characterize these dimers, XRD analyses were performed (see Figure 
2.13). 
Figure 2.12: Representative TEM pictures of a) 3.7 ± 0.5 nm gold NPs used as seeds; b) Au@Cu2-xS dimers with 






XRD analyses confirmed the presence of copper sulfide although with low crystallinity. Interestingly, 
these analyses also revealed the presence of a gold-copper alloy (about 20 % of copper, based on 
the XRD pattern) instead of pure gold phase. This means that some of the big excess of copper used 
in the synthesis (20 times more than gold) entered gold NPs during the annealing to give an alloy, 
this giving a possible explanation for the increase in gold NPs size during the synthesis. 
2.2.5. Synthesis of Au@ZnS heterostructures 
Before going on with the merging of the chalcogenide and the magnetic domain using gold NPs as 
“linkers”, trials in order to grow also a ZnS domain on gold NPs were also carried on. With this 
purpose exactly the same seeds and procedure used for Au@Cu2-xS dimers (that is Au:Zn molar ratio 
1:20 and annealing temperature of 180°C) replacing CuCl2×2H2O with ZnCl2 as zinc precursor were 
employed. Using this procedure, no ZnS NPS were nucleated (see Figure 2.14a). Given the already 
large amount of Zinc precursor used in the procedure, ZnS domains growth was triggered increasing 
the temperature of TBDS injection and of annealing from 180°C to 260°C (see Figure 2.14b). 
Figure 2.13: Experimental XRD pattern for a sample of Au@Cu2-xS in comparison with the 
expected reflections for hexagonal copper sulfide (ICSD code: 69756), for gold (ICSD code: 





While using  an annealing temperature of 180°C is not sufficient for the nucleation of ZnS 
nanoparticles, in the sample synthesized using an annealing temperature of 260°C were found, 
other than increased-size gold NPs, also low-diffracting isolated domains with irregular shape. To 
identify those low-diffracting domains, STEM imaging and EDS quantitative analyses were carried 
out (See Figure 2.15). 
Elemental analysis performed on the two population of particles in the sample gave a Zn:S ratio of 
1:1 for darker particles (brighter in bright field TEM) while brighter particles in STEM images were 
found to be made of Au with low amount (6%) of Zinc. In order to have additional informations on 
this sample, XRD analyses were also performed. 
Figure 2.14: Representative TEM pictures of Au@ZnS samples synthesized using an Au:Zn molar ratio of 1:20 
and an annealing temperature of 180°C (a) and 260°C (b) 
a b 
Figure 2.15: Representative HAADF images of an Au@ZnS sample synthesized using an Au:Zn ratio of 1:20 and an 





XRD analyses (see Figure 2.16) clearly show the presence of both Au and ZnS phases as expected 
from the results of EDS quantitative analyses. Noteworthy, ZnS particles nucleated using this 
procedure have a cubic sphalerite srtucture, while copper sulfide nucleated on the top of gold NPs 
in Au@Cu2-xS dimers had a less ordered hexagonal structure. Also, in this case, only pure gold phase 
and no alloy was present, meaning that, even using a higher temperature (260°C instead of 180°C), 
zinc was not producing an alloy with gold nanoparticles as copper did during Au@Cu1.8S nano-
heterostructures syntheses. From this first trial it was clear that, at least using a 1:20 molar ratio 
between gold content in Au NPs and Zn precursor, an annealing temperature of 180°C was too low 
to obtain ZnS nucleation while at 260°C ZnS domains were formed but the ZnS domains were 
homonucleating. In order to try to trigger the formation of the desired heterostructures, different 
annealing temperature (220°C, Figure 2.17a and 240°C, Figure 2.17b) were used. None of them 
allowed to obtain Au@ZnS dimers but only isolated low-diffracting domains surrounding gold NPs. 
Figure 2.16: XRD experimental pattern for an Au@ZnS sample synthesized using an Au:Zn 
molar ratio of 1:20 and an annealing temperature of 260°C in comparison with the 
expected reflection for gold (ICSD code: 611625) and zinc sulfide (ICSD code: 41985). 
a b 
Figure 2.17: Representative TEM pictures of Au@ZnS samples synthesized using an Au:Zn ratio of 




Fixing the annealing temperature to 240°C, also the influence of the Au:Zn molar ratio was tested, 
scaling it down to 1:10, 1;5 and 1:2.5 (see Figure 2.18) and keeping the Zn:S ratio to 1:20. 
With none of these trials, clearly shaped Au@ZnS nano-heterostructures were formed. Indeed, only 
badly shaped isolated low-diffracting domains were found in samples synthesized with Au:Zn ratios 
of 1:10 (Figure 2.18a) or 1:5 (Figure 2.18b) while only the gold NPs used as seeds were found in the 
sample synthesized employing a 1:2.5 Au:Zn ratio. This behavior is suggesting a different growth 
mechanism with respect to the one of Au@Cu2-xS dimers and this difference could depend on the 
structure of the sulfide phase formed during the reaction. Indeed, the copper sulfide phase growing 
on cubic phase gold (ICSD code: 611625) or gold-copper alloy (ICSD code: 58431), has a less 
symmetric hexagonal crystal lattice (ICSD code: 69756) while ZnS is nucleating with a cubic crystal 
lattice (ICSD code: 41985). Based on these observations, it can be hypothesized that its less ordered 
crystal lattice, and the formation of an AuCu alloy, promotes the growth of Cu2-xS on gold NPs while 
the growth is not possible in the case of more ordered cubic ZnS crystals. 
2.2.6. Synthesis of FeOy@Au@Cu2-xS heterostructures  
In order to grow a copper sulfide domain on Au@FeOy dimers, different trials were carried out in 
order to check the influence of different parameters on the particles obtained. First, a synthesis was 
performed using exactly the same parameters used in Au@Cu2-xS synthesis. In this synthesis, the 
starting seeds were Au@FeOy dimers dispersed in chloroform, which were mixed with the copper 
precursor (CuCl2×2H2O) in oleyl amine. Later on, the seeds’ solvent (chloroform) was evaporated 
through a 10 minutes annealing step at 100°C under N2 gas flux, before performing TBDS injection 
and Au@Cu2-xS growth at 180°C for 70 minutes. Representative TEM pictures of the particles 
obtained are shown in Figure 2.19. 
a b c 
Figure 2.18: Representative TEM pictures of samples synthesized using an annealing temperature of 240°C and a) Au:Zn molar 




The product of this synthesis was a mixture of isolated hexagonal particles (presumably copper 
sulfide) together with heterostructures made of gold and of differently shaped (triangular o platelet-
like) low diffracting domains. No trace of the starting Au@FeOy seeds was found. These results 
probably indicated a ripening process of iron oxide domains, related to reaction environment and 
temperature.67 
In order to avoid Au@FeOy seeds ripening, the reaction was repeated using a lower annealing 
temperature (160°C). The sample resulting from this synthesis (see Figure 2.20a) is mainly made of 
Au@FeOy dimers with a third domain attached on the surface of the gold NPs. Together with the 
three domains heterostructures (trimers from now on), also few unreacted Au@FeOy and many 
isolated low diffracting particles (presumably copper sulfide domains) were present. In order to 
remove these non-magnetic particles, magnetic separation was done on the synthesis products 
using a 0.4 T magnet for 180 minutes. Particles collected with the magnetic separation and the 
resulting supernatant are respectively shown in Figure 2.20b and 2.20c. 
While in the recollected magnetic fraction (see Figure 2.20b) mainly trimers or Au@Fe3O4 dimers 
are present, the non-recollected fraction (Figure 2.20c) is a mixture of Au@Fe3O4 dimers with small 
iron oxide domains and isolated Cu2-xS particles. Interestingly, the shape of the iron oxide domains 
in the two fractions is different: quasi-spherical domains are found in the fraction that did not move 
to the magnet while well-faceted iron oxide domains moved to the magnet, this suggesting their 
a b c 
Figure 2.19: Representative TEM pictures of the particles obtained adapting the Au@Cu2-xS 
heterostructures synthesis to the use of Au@FeOy dimers as seeds. 
Figure 2.20: Representative TEM pictures of a) as-synthesized trimers, b) magnetic fraction recollected through 180 minutes 




improved magnetic properties. The collected fraction of the sample was dispersed in 10 mL of 5% 
OLAC solution in chloroform, in order to improve stability. 
In order to check the influence of the chloroform (dispersing Au@FeOy dimers) in the reaction batch, 
a new synthesis was set up, substituting the annealing at 100°C under N2 flux with a 60 minutes 
vacuum degassing step at 40°C. TEM picture of the sample synthesized evaporating the chloroform 
at 100°C under N2 flux (a) and picture of the sample synthesized evaporating the chloroform at 40°C 
under vacuum (b) are compared in Figure 2.21. 
From TEM pictures, the samples seemed similar with no clear difference in trimers yield or third 
domain shape. XRD analyses (see Figure 2.22) were performed in order to acquire additional data 
to see if the chloroform evaporation procedure had an influence in final sample properties. 
a b 
Figure 2.21. Representative TEM pictures of trimers’ samples synthesized removing chloroform from reaction batch 




In both cases, reflection for Au and FeOy coming from starting seeds are clearly present. In the 
sample obtained with the procedure in which the chloroform was evaporated under N2 flux at 100°C 
(Figure 2.21a), also additional Bragg peaks at 2θ =34° and 2 θ =42° and a broad band around 2θ =30° 
are present. These Bragg peaks are too narrow to be associated with a nanostructure68,69 and were 
impossible to index with any phase that could be resulting from the reaction mixture. Indeed, in the 
sample synthesized removing chloroform from reaction batch using vacuum degassing (Figure 
2.22b) these additional features of the diffraction pattern are not present, suggesting the hypothesis 
ascribing them to the presence of impurities in the reaction mixture degassed through N2 bubbling 
at 100°C. None of the samples presented Bragg peaks that confirmed the presence of any of the 
many possible (e.g. chalcocite, digenite) crystalline phases for copper sulfide (in Figure 2.22 is shown 
as reference the hexagonal Cu1.8S phase (ICSD code 69756) that was formed during Au@Cu2-xS 
dimers synthesis).  
a 
b 
Figure 2.22: Experimental XRD diffraction patterns of trimers’ samples synthesized removing chloroform 
from reaction batch through (a) 10 minutes annealing at 100°C under N2 flux and (b) 60 minutes 
degassing under vacuum at 40°C. Both the experimental patterns are compared with the expected 





In all the syntheses, before the magnetic separation of the samples, together with the trimers also 
few unreacted Au@FeOy and isolated Cu2-xS NPs were formed. In order to reduce this byproducts 
formation, the influence on particles obtained of the feed ratio between Au content in gold NPs and 
Cu precursor amount was tested. Keeping the ratio between the moles of Cu precursor and moles 
of sulfur provided by TBDS fixed to 1:20 as in the original synthesis, different trials with Au:Cu molar 
ratios of 1:40, 1:20, and 1.13.3 were performed. Results are shown in Figure 2.23. 
When an Au:Cu feed ratio of 1:40 is used (Figure 2.23a) many isolated Cu2-xS NPs were formed. On 
the other hand, both in the sample synthesized using 1:20 ratio and in the sample with Au:Cu ratio 
of 1:13.3 less isolated domains are present. In particular, in the as synthesized sample produced 
using a Au:Cu molar ratio of 1:13.3, three domain heterostructures are the main part (≃85%, based 
on statistic performed on at least 200 particles) of the particles found in TEM analyses and only few 
isolated low diffracting domains and Au@FeOy dimers are present, this demonstrating the 
importance to select an appropriate  Au:Cu molar ratio in order to achieve optimal heterostructures’ 
yield. 
Another parameter that had an influence on synthesis products was the length of the annealing 
performed at 160°C. Increasing times for the annealing step (120 and 240 minutes) were tested in 
order to check the influence of this parameter on the size, shape and crystallinity of the third domain 
growing on Au@FeOy dimers. Figure 24 shows representative TEM pictures of samples synthesized 
using the standard annealing time (70 min, Figure 2.24a), and 120 and 240 minutes (Figure 2.24b, 
2.24c). 
a b c 
a b 
c 
Figure 2.23: Representative TEM pictures of trimers synthesized using and Au:Cu ratio of (a) 1:40, (b) 1:20 and (c) 1:13.3. 





Although trimers were formed in all the three samples, there is a clear difference between the 
shapes of the forming third domain. With short annealing (70 minutes) the additional domain 
growing on Au@FeOy dimers is badly shaped, with concavities and irregular boundaries. When the 
annealing is increased to 120 minutes, third domain becomes more defined with a mixture of shapes 
(either badminton-like or platelet-like). Finally, with 240 minutes annealing, third domain is 
definitely larger, with the same shape distribution (badminton-like + platelet-like) as in previous 
case. These results demonstrate the effect of the longer annealing time on the third domain’ 
growth: being the annealing temperature relatively low (160°C) more time is needed for the third 
domains’ growth in order to achieve larger sizes and definite shape. 
In order to check if these differences in third domains’ shape were having an effect also on 






Figure 2.25: Experimental XRD diffraction patterns of trimers samples synthesized using an annealing at 
160°C of (a) for 70 minutes (b) for 120 minutes and (c) for 240 minutes. All experimental patterns are 
compared with the expected reflections for gold (ICSD code 611625), iron oxide (ICSD code 247035) and 




While, in terms of XRD pattern, sample synthesized with 70 minutes of annealing and sample 
synthesized with 120 minutes of annealing are similar (Figure 2.25a and Figure 2.25b, respectively), 
the diffraction pattern of the sample synthesized using longer annealing (240 minutes, Figure 2.25c) 
clearly differs from the others, showing, apart from the expected reflections for Au and FeOy 
particles (present in all the three diffractograms), also numerous Bragg peaks ascribed to the 
presence of a low-ordered copper sulfide phase. Noteworthy, the phase of the copper sulfide 
nanoparticles growing on the surface of Au NPs of Au@FeOy dimers is not hexagonal as the one that 
was growing in Au@Cu2-xS dimers synthesis but has a much less symmetric triclinic roxbyite 
structure with Cu29S16 stoichiometry (Cu1.81S). One of the possible explanations for this different 
phase could be the different temperature at which the Cu2-xS phase is grown. Indeed, lower 
temperature growth could give a less ordered crystal structure.  
The stoichiometry of the copper-deficient copper sulfide crystals was also confirmed by inductively 
coupled atomic emission spectroscopy (ICP-OES), by which a Cu/S ratio equal to 1.80 was 
determined, in good accordance with the expected stoichiometry of the roxbyite phase. 
Using the optimized parameters, that are 60 minutes of degassing step at 40°C, 240 minutes 
annealing at 160°C and an Au:Cu:S molar ratio of 1:13.3:266, it is possible to tune the size of the 
third domain (Cu1.81S) by changing the concentrations of the precursors (CuCl2×2H2O, FeOy@Au 
seeds and TBDS) used in the reaction. The molar concentration of Cu in reaction batch was tuned 
from 0.05 M to 0.02 M with two intermediate steps (0.04 M and 0.03 M). TEM pictures and size 
dispersion graphs of the five different samples are shown in Figure 2.26. Since in all of these reaction 
the ratio between gold copper and sulfur coming from the three precursors was kept the same 









Figure 2.26: Representative TEM pictures and related size dispersion graph of the Cu1.8S 
domain of sample synthesized using a Cu molar concentration of (a-b) 0.05 M, (c-d) 0.04 M, 




Although the clear distinction of the Cu1.81S domain from the FeOy domain can be made only in the 
case of clearly platelet shape and, consequently, the number of particles measured is relatively low 
(≃100), there is a clear trend in size, as shown in Figure 2.26. When lowering the concentrations of 
the three precursors in the reaction batch, the size of the copper sulfide domain is reducing from 
33 ± 5 nm, (0.05 M Cu concentration), to 15 ± 3 nm (0.02 M Cu concentration) with 19 ± 4 nm (0.04 
M) and 17 ± 4 nm (0.03 M) as intermediate points. An additional trial was performed using a 
concentration of 0.01 M but in this case, no clear presence of Cu1.81S domain was found (see Figure 
2.27) and only FeOy@Au were composing the sample. 
In order to acquire additional information on this trend in decreasing size, XRD analyses of the 





Figure 2.27: Representative TEM pictures of a sample synthesized using a molar concentration 
of copper of 0.01 M. 
Figure 2.28: Experimental XRD patterns for three samples of trimers synthesized using a molar 
concentration of copper of (a) 0.05 M, (b) 0.03 M, (c) 0.02 M. All experimental patterns are 
compared with the expected reflections for gold (ICSD code 611625), iron oxide (ICSD code 




Copper sulfide is clearly present in both the samples synthesized with copper molar concentration 
of 0.05 M (Figure 2.28a) and 0.03 M (Figure 2.28b). In third sample (Figure 2.28c), synthesized with 
a Cu molar concentration of 0.02 M, two main peaks of the roxbyite phase (2θ = 47° and 2θ = 49°) 
are present, however the absence of the other peaks (such as the ones at 2θ = 31° and 2θ = 34°) 
could indicate a low crystallinity or low amount of copper sulfide domains. Similarly to what was 
observed with annealing time, the precursors’ concentration has a clear influence on the 
crystallinity of the newly formed Cu2-xS domains: when the concentration is low, copper sulfide 
domains are either not formed (0.01 M, Figure 2.27) or grown with poor crystallinity (0.02 M, Figure 
2.26g-h and Figure 2.28c) while when high concentrations are used (0.05 M, Figure 2.26a-b and 
Figure 2.28a) copper sulfide domains are larger and with higher crystallinity. 
In order to furtherly study the structural properties of the three phases, HR-TEM measurements of 
the three domains composing the particles of the sample synthesized using a copper concentration 
of 0.05 M were performed. Results are shown in Figure 2.29. 
In the first picture (Figure 2.29a) the monocrystalline nature of the iron oxide domain is clearly 
observed. The crystal structure of those domains has been confirmed to be cubic. Also, in the case 
of gold NPs (HR TEM in Figure 2.29c and FTT in Figure 2.29e) the phase structure that was found 
through XRD analyses has been confirmed. As already reported in literature gold nanoparticles 
exhibit multiple twinning.70 Noteworthy, the presence of twinning in metal nanoparticles (and 
especially in gold) has been reported to be a key parameter allowing the growth of highly anisotropic 
domain when these nanoparticles are used as seeds in seeded-growth procedures71. In Cu1.8S 
domains, the high density of structural defects (e.g. stacking faults, highlighted in Figure 2.29d) 
made difficult to find a single-crystal for zone-axis identification and consequently not possible to 
identify the crystal phase. 
Figure 2.29: a) and c) Representative HR-TEM pictures of FeOy@Au@Cu1.81S trimers, b) Fast Fourier Transform (FFT) of a selected 
area of picture a, d) Fast Fourier Transform (FFT) of area indicated with “1” in picture c, e) Fast Fourier Transform (FFT) of area 
indicated with “2” in picture c. For Au and FeOy domains, the FFT images are respectively indexed with the reflections for cubic Au 
(ICSD code 611625) and for cubic γ-Fe2O3 (ICSD code 247035). 





EDS mapping (Figure 2.30) shows the composition of the three domains in the FeOy@Au@Cu2-xS 
nano-heterostructures. 
Energy Dispersive X-ray Spectroscopy quantitative analyses performed on the domains identified as 
made of copper and sulfur (see Figure 2.31), show a Cu/S ratio of 1.99 ± 0.4. Considering the error 
related to this technique, this value is matching the Cu/S ratio measured with ICP-OES (1.80) and 
the one expected for a roxbyite structure (1.81) 
An interesting property of these three domains nano-heterostructures is the possibility to have two 
localized surface plasmon resonances (LSPR), displayed at different absorption wavelengths, in one 
single nanostructure. First LSPR should be coming from the metallic gold NPs, whose absorption 
band has been reported to be centered at approximatively 520 nm72 for spherical 20-50 nm Au NPs, 
while a second absorption band should be arising from the presence of sub-stoichiometric copper(I) 
sulfide domains73. The absorption wavelength and the intensity of this second surface plasmon 
resonance has been reported to be strongly dependent on the stoichiometry of the copper sulfide 
phase (Cu2-xS, 0< x <1)74.  
During the formation of the FeOy@Au@Cu2-xS trimers, absorption in the visible light wavelength 
range (500 nm – 800 nm) was checked through spectroscopy measurements. Measurements were 




Figure 2.30: HAADF image (a) and EDS elemental analysis mappings for Au, Fe, Cu (b) and Au, O, S (c) of a sample of 
FeOy@Au@Cu2-xS trimers. 
Figure 2.31: Spectrum obtained from quantitative Energy Dispersive X-ray Spectroscopy on multiple copper sulfide domains of 




formation) in order to monitor gold NPs plasmon absorption peak position. Results obtained from 
the measurements in chloroform are shown in Figure 2.32. 
Interestingly, with the growth of additional domains, the peak related to gold NPs LSPR is red-
shifting. Indeed, while for gold NPs seeds the absorption is peaked at 524 nm (in good agreement 
with values reported in literature for small Au NPs), this peak is moved to 552 nm for Au@FeOy 
dimers and 588 nm for FeOy@Au@Cu2-xS. This same behavior was found in all the sample of trimers 
synthesized, with small differences when varying the size of the three domains. Together with the 
red-shifting, also a broadening of the absorption band is taking place. The red-shift of the gold NPs 
plasmon in Au@FeOy dumbbells is already reported in literature46 and ascribed to the presence of 
the interface between Au and FeOy, resulting in reduced electron population on Au. A red-shift in 
gold plasmon is also reported in the case of Au@Cu2-xS dimers50, similarly to the case of Au@FeOy, 
this shift can be ascribed to the growth of the Cu2-xS domain that is reducing electron density on the 
surface of the gold nanoparticle. This red-shift of the gold plasmon is of particular interest for 
biomedical application since after the growth of the additional iron oxide and copper sulfide 
domains, the tail of gold LSPR absorption band is entering the NIR biological window (NIR‑I: 650–
950 nm), and because of this can be used in photothermal therapy75. In order to also check the 
presence of the plasmon given by the copper-deficient copper sulfide domain, absorbance of 
trimers’ sample was measured also in the Infrared Region with a long-range measurement (500-
2000 nm). Spectrum resulting from the measurement of the absorbance of the chloroform 
dispersion of one trimers’ sample is shown in Figure 2.33. 
Figure 2.32: Visible (500-800 nm) spectra of gold NPs (purple line), Au@FeOy dimers (black line) and 
FeOy@Au@Cu2-xS trimers (green line), all particles were dispersed in chloroform. All curves are normalized on 




Long-range spectrum reveals, together with gold plasmon, also a band centered around 1300 nm 
ascribable to copper-deficient copper sulfide. The band is broad and with low relative intensity, as 
expected when having a Cu2-xS domain with such a stoichiometry76 and is centered in the second 
NIR biological window (1000 nm – 1350 nm) 
Magnetic properties of FeOy@Au@Cu2-xS were measured through SQUID magnetometry and 
compared with the ones of Au@FeOy dimers used as seeds for that particular sample of trimers (see 
Figure 2.34). 
Figure 2.33: VIS-IR (500-2000 nm) spectrum of a sample of trimers, negative peak 
centered at 1700 nm and features around 1400 nm and 1850 nm are resulting from 




Figure 2.34: Results obtained from magnetic measurements. a) Zero field cooled MH curves recorded in the range ± 70 kOe at 10 K 
(red line) and 298 K (blue line) on a sample of trimers having a 25 ± 4 nm iron oxide domain, insert: low field region of the MH curves 
at 10 K and 298 K; b) ZFC heating and FC cooling curves in the range 5 K – 400 K recorded using a 50 Oe field on a sample of trimers 
having a 25 ± 4 nm iron oxide domain; c) Parameters measured through SQUID measurement on a sample of FeOy@Au@Cu1.81S with 
25 ± 4 nm iron oxide domain. d) Comparison between zero field cooled MH curves recorded in the range ± 70 kOe at 10 K for a sample 
of trimers having a 25 ± 4 nm iron oxide domain (red line) and for a sample of dimers having a 25 ± 4 nm iron oxide domain (blue line) 
Magnetic properties of the trimers are similar to what was found in the case of Au@FeOy dimers 
(see paragraph 2.2.3), having the nanoparticles a high maximum magnetization (118 emu/giron at 10 
K and 110 emu/ giron at 298 K). The small difference between these values and the ones obtained 
from Au@FeOy with same iron oxide size (maximum magnetization of trimers is larger (+4%) at both 
temperatures), could be due to the error related to the measurement of iron content of each sample 
(ICP-OES measurements, 10 % error). Similarly to the case of dimers, trimers are blocked at RT (thus, 
trimer displays also a ferrimagnetic behavior at RT) and interacting as it can be clearly seen form 
ZFC-FC measurements results (Figure 2.34b). Interestingly, when comparing MH curves of dimers 
and trimers both at 298K and 10 K (see Figure 2.34d for curves comparison at 10 K), it is clear that 
trimers have a diamagnetic contribution at high fields that is not present in the hysteresis loop of 
dimers sample. This diamagnetic contribution was ascribed to the presence of Cu2-xS domains that, 
when x is between 0 and 0.2, are reported to be diamagnetic77. The similarity between the magnetic 
properties of trimers and the one of dimers make of FeOy@Au@Cu1.81S trimers a possible candidate 
material to be used with good performances in magnetic hyperthermia cancer treatment.  
a 
b  
Temperature HC MMAX 
(K) (Oe) emu/giron 
298 K 8 110 
5 K 221 118 




2.3. Conclusions and outlook 
Different trials were carried out in order to be able to merge in one single nano-heterostructure 
highly performing magnetic materials (iron oxide nanocubes and Au@FeOy dimers developed in this 
research group) and a chalcogenide domain offering the possibility of incorporating 64Cu (I) ions 
(demonstrated for Cu2-xS and for ZnS nanoparticles). 
Trials to grow ZnS nanoparticles directly on the surface of Iron oxide nanocubes (IONCs) were 
unsuccessful, resulting in the growth of small ZnO particles surrounding IONCs with no clear 
formation of heterojunctions. 
The possibility of using gold nanoparticles as “linkers” between the iron oxide and a chalcogenide 
domain was also tested. While it has been possible to grow Au@Cu2-xS dimers following a reported 
procedure, the modification of that procedure for the formation of Au@ZnS did not succeed. 
Indeed, the synthesis procedure resulted in either no nucleation of ZnS nanoparticles (with mild 
reaction parameters) or in the homonucleation of ZnS without the formation of any solid-solid 
interface (when more severe reaction conditions were used). 
Adapting the synthesis of Au@Cu2-xS to the use of Au@FeOy has brought to the successful synthesis 
of FeOy@Au@Cu2-xS trimers. During the synthesis of these trimers, it is possible to vary the synthesis 
conditions (precursors’ concentration) in order to tune the size of the novel Cu2-xS domain from 15 
± 3 nm to 33 ± 5 nm. 
Cu2-xS domains are nucleated with low ordered roxbyite crystal structure, the crystals are highly 
defected and are growing on the surface of the twinned gold NPs. The nano-heterostructured 
trimers have two LSPRs: one due to the gold domain and centered at 588 nm, the second, due to 
the presence of the copper-deficient copper sulfide domain is centered at 1322 nm. Magnetic 
properties of the trimers are not significantly different from the ones of the dimers, apart from a 
diamagnetic contribution at high field caused by the presence of the copper sulfide domain. 
The excellent magnetic properties (comparable with the one of the highly performing in 
hyperthermia IONCs and Au@FeOy) of the trimers, together with two plasmonic absorption in the 
first and the second NIR biological windows, make of these heterostructures, once transferred to 





2.4. Experimental procedures 
One-pot synthesis of γ-Fe2O3@ZnS heterostructures28 
γ-Fe2O3 NCs were synthesized by thermal decomposition of iron pentacarbonyl (Fe(CO)5) in the 
presence of capping molecules according to a previously reported procedure. After 11 mmol of oleic 
acid (OLAC) in 11 mL of octyl ether (OE) were vacuum-degassed at 100°C for at least 30 min, 1.5 
mmol of Fe(CO)5 were injected under N2 atmosphere. The reaction mixture was refluxed at T = 
290°C for 60 minutes. The γ-Fe2O3@ZnS heterostructures were synthesized by direct addition of 
sulfur and zinc reagent to the γ-Fe2O3 NCs reaction mixture. 0.25 mmol of sulfur powder were added 
to the flask containing crude γ-Fe2O3 NC reaction mixture at 100°C and stirred for 5 min. A solution 
of 0.25 mmol zinc acetate, and 1.034 mmol of tri octyl phosphine oxide (TOPO) in 1 mL of OE, which 
was vacuum-dried previously at 100°C, was then injected dropwise within one minute at 80°C. After 
10 min of stirring at 80°C, temperature was raised to values ranging from 230°C to 280°C. The 
reaction mixture was allowed to anneal at high temperature for times ranging from 60 to 180 
minutes and then cooled down to room temperature. Obtained nanoparticles were then purified 
from unreacted precursors and excess surfactants by dispersing them in chloroform and then 
precipitating with ethanol and centrifuging. After three centrifuging steps (2600 RCF, 5 minutes) 
using acetone as precipitant the particles were dispersed in chloroform to form a stable suspension. 
Synthesis of iron oxide nanocubes (IONCs)55  
The IONCs of edge length 16 ± 2 were prepared according to a procedure previously developed in 
this group55. Briefly, into a 100 mL three-neck flask, 15 mL of di benzyl ether (DBE), 10 mL squalane, 
1 mmol iron (III) acetyl acetonate and 5.5 mmol of decanoic acid were dissolved. After degassing for 
120 min at 65°C, the mixture was heated up to 200°C at a rate of 3°C/min and maintained at that 
temperature for 150 minutes. Later, the reaction temperature was increased to 310°C (with a rate 
of 7°C/min) and the reaction was carried on for sixty more minutes. After cooling down the solution 
to room temperature, acetone was added as precipitant and the mixture was centrifuged at 2600 
RCF for 20 minutes. After repeating the centrifuging procedure twice, the obtained particles were 
dispersed in chloroform. 
Seeded growth of ZnS particles on IONC seeds 
In order to grow ZnS domains on IONCs, a chloroform solution of the nanocubes ( 0.15 mmol in 
iron) was mixed with 11 mL of OE and 11 mmol of OLAC and degassed under vacuum at 100°C for 
60 minutes. After the degassing, 0.025 mmol of sulfur powder were added to the reaction mixture 
and the batch was annealed for 10 minutes. After cooling to 80°C a solution of 0.025 mmol zinc 
acetate, and 1.034 mmol of TOPO in 1 mL of octyl ether, that was previously degassed at 100 °C, 
was injected. After 10 min of stirring at 80 °C, temperature was raised to 280 °C and the reaction 
mixture was allowed to anneal by stirring at that temperature for 60 minutes and then cooled to 
room temperature. After three centrifuging steps (2600 RCF, 5 minutes) using acetone as precipitant 




HR-TEM imaging, HAADF STEM imaging and EDS analyses 
On some selected samples, crystal structure was analyzed by means of High Resolution Transition 
Electron Microscopy (HR-TEM) while chemical composition was evaluated exploiting energy-
dispersive X-ray spectroscopy (EDS), performed in high angle annular dark field scanning TEM 
(HAADF-STEM) mode. HR-TEM imaging, HAADF-STEM imaging and EDS analyses were carried out 
using a JEOL JEM-2200FS microscope equipped with a Schottky emitter working at an accelerating 
voltage of 200 kV, a CEOS spherical aberration corrector for the objective lens, and a Bruker Quantax 
400 system with a 60 mm2 XFlash 5060 silicon drift detector (SDD). EDS analyses were performed 
drop-casting NCs suspensions (both in organic solvent and in water) on carbon coated nickel grids. 
The EDS spectra were quantified using the Cliff- Lorimer method on Zn Kα, Fe Kα, O Kα, S Kα, Au Lα 
and Cu Kα and the reported STEM-EDS maps were obtained by integrating the intensities over the 
same peaks. 
Au@FeOy dimers synthesis19 
In a 100 ml three necked flask, equipped with a magnetic stirrer and connected to a standard 
Schlenk line set up, 0.1 mmol of HAuCl4×3H2O were dissolved in a solution containing 1 ml of Oleic 
Acid (OLAC), 3 ml of Oleyl amine (OA) and 20 ml of 1-octadecene (ODE). The mixture was heated to 
95°C and degassed for 35 minutes. The flask was then switched to inert atmosphere (N2 gas) and 
heated to 150°C. At this temperature, a solution of 0.6 mmol of Fe(CO)5 in degassed ODE was 
injected into the reaction batch and the temperature increased to 200°C. The solution was then 
annealed for different amounts of time, ranging from thirty to ninety minutes. The reaction batch 
was then cooled to room temperature and the obtained product washed by means of centrifugation 
(2600 RCF 15 minutes) and redispersion using isopropanol as precipitant and chloroform as solvent. 
After supernatant removal, the washed particles were transferred using 40 ml of chloroform in a 40 
ml glass vial. The Au-FeOy dimers were then recollected to a 0.4 T magnet for 180 minutes. After 
supernatant removal, the particles were re-dispersed in 10 ml of chloroform in a 20 ml vial and 
sonicated at RT for 30 minutes. When Au@FeOy dimers had to be used as seeds in other synthesis, 
they were dispersed in a 5% solution of OLAC in CHCL3 (500 µl of Oleic Acid + 9.5 mL of chloroform) 
in order to improve stability. 
SQUID magnetometer analyses 
On some selected samples, the variation of the sample magnetization when changing external field 
(hysteresis loops or magnetization curves) or temperature (ZFC-FC curves) were measured using a 
super-conducting quantum interference device (SQUID) from Quantum Design (MPMS XL equipped 
with Evercool Dewar). Samples preparation was performed by drop casting chloroform solution of 
particles with known concentration onto 100 mg of Teflon film. The sample was allowed to dry 
overnight. Magnetization curves were measured from -70 to +70 kOe at 10 K and 298 K upon zero 
field cooling (ZFC). Zero field cooled (ZFC) and field cooled (FC) curves were recorded with a field of 
50 Oe in the temperature range 5 K – 400 K (1.5 K/min in 2.99 K increments) to measure the thermal 
dependence of the magnetization. The background signal coming from 100 mg of Teflon tape and 




Synthesis of gold nanoparticles67 
Au NPs were obtained using a literature reported procedure.66 In a 50 mL three necked flask, a 
solution of tetralin (10 mL), oleyl amine (OA, 10 mL), and 0.1 g (0.25 mmol) HAuCl4 was prepared in 
air at room temperature (RT = 23 °C) and magnetically stirred under N2 flow for 10 min. A reducing 
solution containing 43 mg (0.5 mmol) of Tert-butyl ammine-borane complex, tetralin (1 mL), and OA 
(1 mL) was mixed by sonication and injected into the precursor solution. The reduction was 
instantaneously initiated and the solution changed to a deep purple color within few seconds. The 
mixture was allowed to react at R.T. for 60 minutes before isopropanol was added to precipitate the 
Au NPs. The Au NPs were collected by centrifugation (6300 RCF, 5 minutes), washed again with 
isopropanol, dispersed in chloroform and then transferred, through evaporation and redispersion, 
in OA. 
Seeded growth of Au@Cu2-xS nano-heterostructures50 
In a typical preparation of Au-Cu2−xS NCs, 85.2 mg (0.5 mmol) of CuCl2·2H2O, 7 mL of OA, and 3mL 
of an Au–OA (0.025 mmol Au) solution were successively introduced to a 25 mL four-neck flask 
connected to a Schlenk line. The mixture was fully flushed with nitrogen at room temperature and 
then heated to 180 °C. The nucleation and growth of Cu2−xS on the surface of the Au NCs was then 
initiated by the injection of 1 mL of di-tert-butyl disulfide (TBDS) (10 mmol). The reaction mixture 
was kept at 180 °C for 70 min to allow the NCs to grow. The flask was then rapidly cooled down to 
room temperature and the resulting NCs suspension was precipitated with isopropanol and 
centrifugation (2600 RCF, 5 minutes) and dispersed in chloroform for three cycles. 
Seeded growth of Au@ZnS nano-heterostructures 
In a typical synthesis, different amounts of ZnCl2, 7 mL of OA, and 3mL of Au–OA solution (0.025 
mmol of Au) were successively introduced to a 25 mL four-neck flask connected to a Schlenk line. 
The mixture was fully flushed with nitrogen at room temperature and then heated to annealing 
temperature. The nucleation and growth of ZnS nanoparticles was consequently started by the 
injection, of an amount of TBDS equal to twenty times the amount of zinc precursor. The reaction 
mixture was kept at the annealing temperature for 70 min. The flask was then rapidly cooled down 
to room temperature and the resulting NCs suspension was precipitated with isopropanol and 
centrifugation (2600 RCF, 5 minutes) and dispersed in chloroform for three cycles. 
FeOy@Au@Cu2-xS synthesis 
8 mL of oleyl amine, chloroform solution of Au@FeOy dimers (gold content equal to 1/13.3 of copper 
precursor used) and an amount of CuCl2×2H2O varying from 0.4 mmol to 0.1 mmol were degassed 
for 60 minutes at 40°C in order to remove CHCl3. After the temperature was increased to 160°C, an 
amount of di-Tert-Butyl Disulfide (TBDS) with sulfur content equal to twenty times copper precursor 
used was injected and the reaction batch annealed at that temperature for 240 minutes. Reaction 
mixture was then transferred to three 50 mL falcon tubes and precipitated through the addition of 
isopropanol and centrifuging (2600 RCF, 7 minutes, 2 cycles). Resulting precipitate was dispersed in 
chloroform and precipitated again with isopropanol and centrifuging. After the washings, particles 





Absorption spectra of the samples were measured exploiting UV−VIS−NIR spectroscopy. Optical 
extinction spectra, of both chloroform and water stable sample, were acquired, both in the range 
500-800 nm and in the range 500-2000 nm, on a Varian Cary 5000 UV−vis−NIR absorption 
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3 Chapter 3: FeOy@Au@Cu2-xS nano-
heterostructures as probes for magnetic 
hyperthermia, nuclear medicine and 
photothermal therapy. 
3.1. Introduction 
3.1.1. Treating cancer using heat with hyperthermia treatments 
More than two thousand year ago, the father of medicine, Hippocrates (479 – 377 B.C.), was already 
aware of the potential of heat in the treatment of diseases.1 Indeed, hyperthermia, the artificial 
temperature increase, of the body or of a tissue, above the normal temperature set by the 
thermoregulation system of an organism,2 is nowadays a widely used cancer treatment.3,4 This 
treatment can be used both as stand-alone therapy5 or in combination with other treatments (e.g. 
chemotherapy, radiotherapy or surgery)6–10 with the latter option being more effective.11 
Hyperthermia treatments are commonly differentiated based on the achieved temperature12: mild 
hyperthermia treatments are accomplished in a range of temperatures from 40 to 48°C while for 
higher temperatures the treatments are defined as coagulation13 (>50°C), or thermal ablation14 (60 
to 90°C). Biological mechanism of cancer cells’ death subjected to hyperthermia treatments are 
various and still objects of study.15,16 
 Figure 3.1: Impact of hyperthermia in activation of the immune response and 
inhibition of pancreatic cancer cell DNA repair. ECM: Extra Cellular Matrix; HSP: Heat 




Other than direct cell death, many other effects of hyperthermia treatments such as altered blood 
flow17,18, inhibition of DNA repair pathways19,20 and activation of immunological response21,22 are 
reported (see Figure 3.1). 
Hyperthermia can be administered to patients through three different methodologies: whole body 
hyperthermia, regional hyperthermia and local hyperthermia.12 Whole-body hyperthermia (WBH) 
is usually performed on metastatic cancers23 and applied through thermal chambers, hot water 
blankets or infrared radiation. The treatment is usually administered under general anesthesia and 
the temperature can be increased up to 42°C for 1 hour (extreme WBH) or kept in the range 39.5°C 
– 41°C for 3-4 hours (moderate WBH). Main advantage of these treatments is the homogeneous 
thermal distribution and the possibility to hit extended metastatic cancers, however, many 
complications such as cardiac disorders, changes in the coagulation system (thrombocytopenia and 
disseminated intravascular coagulation), and permeability of the capillary endothelia are 
reported.10,24 Regional hyperthermia (also called part body hyperthermia) is employed to treat large 
parts of body (such as abdomen, pelvis or thighs) and is usually performed through external 
applicators producing microwaves25 or radiofrequencies26 or through perfusion27. Local (or targeted 
hyperthermia), on the other hand, is used to treat small areas (≤ 6 cm) either superficially located 
(skin) or accessible through body cavities (esophagus, rectum). Similarly to regional hyperthermia, 
lasers,28 microwaves,29 or ultrasounds30 can be used to reach the aimed temperature in local 
hyperthermia treatments. In last decades,31,32 many efforts were made in order to be able to exploit 
nanoparticles with different composition for local hyperthermia treatments. Main advantage of 
using nanoparticles for thermal treatments is the possibility to target a small area of tumoral tissue 
avoiding unspecific heating and overcoming the limitation of standard local hyperthermia 
treatments to superficial cancers. Another possibility related to the use of nanoparticles is, either 
exploiting their intrinsic properties or functionalizing their surface, to merge hyperthermia with 
other diagnosis or treatment applications, in order to exploit them as theragnostic agents.33–35 
In order to be able to exploit nanoparticles for hyperthermia treatments, they have to be stable in 
aqueous media. Since as-synthesized particles are usually dispersed in organic solvents (hexane, 
chloroform or toluene), reproducible and high-yield water transfer procedures are needed. 36 In the 
group were this thesis was carried out, a broad portfolio of water transfer procedures for 
nanocrystals with different compositions has been developed. In particular, water transfer of metal 
oxide nanoparticles has been accomplished through a polymer coating (PC) procedure37 
(intercalating the ligand on the surface of the nanocrystal with an amphiphilic ligand) or through the 
exchange of the hydrophobic ligands on the surface of iron oxide particles with new amphiphilic 
ligands (ligand exchange procedure, LE) with catechol or carboxy groups anchoring nanocrystals’ 
surface38,39. In the case of Au@FeOy dimers, the phase transfer of the heterostructures in water was 
successfully accomplished40 replacing the hydrophobic ligands with gallol-polyethylene glycol (GA-
PEG), which covers both the iron oxide and the gold domain for their water stabilization. Copper-
deficient copper sulfide nanocrystals covered with oleyl amine have been reported to be 
transferable in water using thiol-based amphiphilic polymers (e.g. methoxy-PEG2000-SH).41 The 
water transfer of the newly synthesized trimers (see Chapter 2) has been accomplished through the 





3.1.2. Magnetic hyperthermia cancer treatments using magnetic nanoparticles 
One possibility in order to perform thermal treatments using nanoparticles is given by the 
application of an alternating magnetic field (AMF) to a tissue where magnetic nanoparticles (MNPs) 
are dispersed. The use of magnetic nanoparticles as heating mediators in magnetic hyperthermia 
treatments (MHT) was already reported in 1957.42 From that pioneering study the interest on this 
clinical methodology increased and today clinical phase II studies are led by MagForce company, in 
hospital Charité in Berlin.43,44 When magnetic nanoparticles are stimulated through an alternating 
magnetic field, three different mechanisms can results in thermal energy production45 (see Figure 
3.2): Néel relaxation (rotation of the magnetic moment of the particle overcoming anisotropy 
energy barrier, Figure 3.2a), Brownian relaxation (mechanical rotation of the MNPs with friction 
against the surrounding medium, Figure 3.2b) and hysteresis losses (shifting of domains walls that 
takes place in multi-domain MNPs, Figure 3.2c). 
Relative contribution of each of the three mechanisms is depending on many different parameters 
such as material composition, size, shape, magnetic anisotropy and grade of agglomeration of 
MNPs.46–49 In particular, the size of the nanoparticles plays an important role on the heating 
mechanism. Indeed, under a certain value of diameter (called critical diameter, dcr) the formation 
of domains wall is no more thermodynamically favored and each particle is formed by a single 
magnetic domain. The value of  this critical diameter is changing from one magnetic material to 
another (see Figure 3.3).50 
Figure 3.2: a) Rotation of the moment within the MNPs, overcoming their anisotropy energy barrier that leads to Néel Loss; 
b) mechanical rotation of the MNPs that results in friction with the environment and lead to Brown losses; c) movement of 
domain walls in multi-domain MNPs that leads to hysteresis loss. Reprinted with permission from reference 45. 





Below this critical diameter, hysteresis losses contribution is lost and the Néel and Brownian 
relaxations are the main heating mechanisms. Interplay between these two different mechanisms 
is given by particles’ magnetic anisotropy, size, shape and solvent viscosity.48,51,52 In general, smaller 
particles in high viscosity solvents tend to heat through Néel relaxation while larger particles in low 
viscosity solvents are usually undergoing Brownian relaxation. Combining all these parameters, 
many efforts have been made in order to be able to obtain magnetic nanoparticles with appropriate 
parameters for being used in high efficiency magnetic hyperthermia treatments.53–55 
Heating performances of nanoparticles in magnetic fluid hyperthermia are usually evaluated 
through specific absorption rate (SAR o also SLP, specific loss power) values. SAR is defined as the 
power dissipated by MNPs per unit of mass. Two different methodologies (see Figure 3.4) are 
commonly used to assess hyperthermia efficiency of a MNPs sample56. The most common approach 
to determine SAR values is based on a calorimetric method (see Figure 3.4a). In this method, while 
MNPs’ aqueous solutions are exposed to an AMF with given amplitude and frequency, the 
temperature increase is recorded through a fluoro-optic thermometer fiber probe over a period of 
time. AMF is applied through a magnetic induction heating system consisting of a water-cooled coil 
connected to a high power radio frequency generator. From the heating curve, SAR is calculated 











Equation 3.1: Formula used to calculate SAR from calorimetric method 
where C is the specific heat capacity of water per unit volume (4185 J×L-1×K-1), m is the concentration 
of magnetic material in solution (g×L-1 of Fe) and dT/dt is the slope of the measured heating curve. 
Although measurement chamber is isolated in order to reduce heat losses, these measurements are 
generally performed in non-adiabatic condition and, consequently, slope is measured from only the 
first seconds of measurements. The other methodology employed to evaluate efficiencies of 
Figure 3.3: Single domain threshold diameter size for spherical nanoparticles of 
different materials. Calculated on the base of bulk materials parameters. 




samples in magnetic hyperthermia experiments is the magnetometric method. In this method, 
dynamic magnetization M(t) of the sample is measured under an alternated magnetic field and 








Equation 3.2: Formula to calculate SAR from magnetometric method 
where f is the frequency of the applied field and c the magnetic material concentration. 
Both methodologies are commonly used in order to study dynamic magnetic properties of magnetic 
nanoparticles under the application of alternated magnetic fields.38,48,57 In particular, although 
calorimetric method is the most commonly used technique in order to measure SAR values of 
magnetic nanoparticles,37,58 the magnetometric method has currently been proven useful in order 
to investigate the influence of different parameters on the dynamic magnetic properties of 
nanoparticles.39,48 In order to be able to compare the SAR values obtained for trimers with the ones 
obtained for the magnetic heterostructures used as seeds for their synthesis (Au@FeOy dimers),40  
in this manuscript, SAR values have been measured through the calorimetric method. Hysteresis 
loops obtained by magnetometric method have been used in order to correlate the hyperthermia 
efficiencies of the different samples with their dynamic magnetic properties. 
In last decades, many different nanomaterials suitable for magnetic hyperthermia treatments were 
developed. Among them, the most commonly used are FDA approved iron oxide nanoparticles37,59–
61 or mixed ferrite nanocrystals such as cobalt ferrite,58,62,63 zinc ferrite64,65 or manganese ferrite.66,67 
Currently, efforts of the researchers working in this field are oriented towards the development of 
nanomaterials with higher efficiencies (larger SAR values). Indeed, an increased SAR value would 
allow to scale down the amount of nanoparticles employed in each treatment and, consequently, 
to reduce the cytotoxicity of the nanomaterial.68 In order to pursue this goal, also magnetic nano-
heterostructures, such as Fe(0)@iron carbide69 or soft core-hard shell70 structures, were 
synthesized and found to have increased hyperthermia efficiencies if compared to the single 
material nanoparticles. 
Figure 3.4: Diagrams of the different approaches used to evaluate the heating efficiency of magnetic nanoparticles: (a) calorimetric 
method: the changes in the temperature of the sample are recorded while it is exposed to an AMF and SLP is calculated from the 
initial slope of the sample’s heating curve; and (b) magnetometric method, which involves the measurement of the AC hysteresis loop 





3.1.3. Photothermal therapy using nanoparticles 
Another class of hyperthermia therapies in which nanomaterials are widely used are photothermal 
treatments (photothermal therapy, PTT). In these treatments, temperature increase is obtained 
through photothermal transducing agents (PTAs) that are harvesting energy from appropriate 
electromagnetic radiations and converting it into heat. Most commonly used nanoparticles as PTAs 
are the one exhibiting localized surface plasmon resonance (LSPR).71,72 Localized surface plasmon 
resonance (see Figure 3.5) is the collective oscillation of the free electrons of a nanoparticle resulting 
from the interaction with an electromagnetic wave.73–75 
The intensity of the local electromagnetic field generated by this phenomenon on the surface of the 
nanoparticles can be orders of magnitude greater than those of the incident radiation.76 This high 
intensity local fields are directly influencing the radiative and non-radiative properties of the 
plasmonic nanoparticles. Indeed, once exited, a plasmon can decay following two paths: non-
radiatively, resulting in absorption of the exciting light; or radiatively, resulting in radiation 
scattering. Radiative decay of excited plasmonic nanoparticles is the base of their use as contrast 
agent in computer tomography (CT)77,78 or in surface enhanced Raman spectroscopy (SERS)79,80 
imaging. On the other hand, non-radiative decay through electron–electron collisions and electron–
lattice phonon coupling is the phenomenon on which photothermal therapy is based on. The 
predominant decay mechanism of excited nanoparticles is influenced by many different factors such 
as shape and size (as an example, 20 nm spherical nanoparticles are almost completely decaying by 
non-radiative processes),81 consequently the properties of the nanoparticles have to be carefully 
tuned based on the aimed application. 
M. A. El-Sayed group82–84 thoroughly studied, through ultrafast dynamics, the mechanism behind 
heat production in photothermal heating by plasmonic nanostructures (see Figure 3.6). 
Briefly, photoexcitation of the free electrons gas, resulting in rapid non-equilibrium heating, is 
followed by relaxation through electron–electron scattering. This results in rapid increase in the 
surface temperature of the metal, followed by cooling to equilibrium by energy transfer through 
Figure 3.5: Schematic diagram showing localized surface plasmon resonance in nanoparticles, 




electrons and lattice phonons coupling. Finally, the lattice cools via phonon–phonon coupling and 
resulting heat is dissipated through the nanoparticle’s surrounding media. 
A key parameter, when designing plasmonic nanoparticles to be used as PTAs, is the wavelength 
absorption corresponding to the plasmon resonance. Indeed, the laser radiation used to excite 
plasmonic nanoparticles has to be able to reach nanoparticle without being absorbed from the 
surrounding tissues since this would reduce the energy of the incoming radiation and would damage 
healthy tissues. Typically, for this purpose, laser radiations with wavelengths in the near infrared 
region (NIR) are used.85 Indeed, the scattering and absorption of NIR radiation by human tissues is 
lower if compared to the one obtained with visible light or UV light lasers.86 In particular, tissues’ 
absorption and scattering of laser radiation is negligible (radiation can travel through tissues with 2 
– 3 cm path length) in the three so-called NIR biological windows (see Figure 3.7). 
First NIR window is ranging from 650 nm to 950 nm, while the second and the third ones are 
between 1000 nm and 1350 nm and between 1500 nm and 1800 nm, respectively. 
Among all the nanoparticles investigated for the application in photothermal therapy, gold 
nanoparticles of different sizes and shapes are the most studied and promising.87–89 Absorption of 
Figure 3.6: Schematic diagram representing the conversion of light into heat by plasmonic nanostructures Reprinted with 
permission from reference 75. 
Figure 3.7: Absorption spectrum of human skin showing the first, second and third NIR windows. 




Au nanospheres is usually centered in the range between 500 nm and 600 nm with larger particles 
having higher absorption wavelength. These spherical nanoparticles are usually exploited with laser 
having wavelengths in the 1st NIR biological window90 targeting the absorption tail of the gold NPs 
plasmonic peak. Another class of gold nanomaterial widely exploited for photothermal treatments 
are gold Nanorods (NRs)91,92. The peculiarity of the Au NRs is to have, due to their shape anisotropy, 
two plasmon resonances: transverse plasmon resonance, usually centered between 500 and 550 
nm, and longitudinal resonance between 650 nm and 850 nm. This second absorption wavelength 
can be tuned to higher values by increasing NRs’ aspect ratio.93 Photothermal treatments exploiting 
other gold nanostructures such as nanoshells (GNSs),94,95 or nanostars (GNSTs)96,97 have also been 
reported. Together with gold, also other noble metals nanocrystals, such as Pt or Pd98,99 have been 
demonstrated to be effective when used as PTAs in PTT. 
In 2010, Chen and coworkers indicated copper deficient copper sulfide nanocrystals as candidate 
material to be used as PTAs in photothermal therapy using a 808 nm laser.100 Although in this 
pioneering study the power density used (> 24 W/cm2) was more than 70 times higher than the safe 
value for biological applications (0.33 W/cm2),101 its publication leaded the way to many further 
studies on this class of materials. Indeed, in last two decades, many studies were carried out in 
which performances of copper-deficient copper sulfide nanoparticles were increased by changing 
either shape or stoichiometry of the material.41,102–105 
In this chapter, after illustrating the development of a quantitative and reproducible water transfer 
procedure for FeOy@Au@Cu2-xS, are shown and discussed the results obtained by photothermal 
and magnetic hyperthermia characterization of FeOy@Au@Cu2-xS trimers. In addition, also the 
results obtained from radiolabeling experiments performed in collaboration with Dr. Nisarg 





3.2. Results and discussion 
3.2.1. Water transfer of FeOy@Au@Cu2-xS heterostructures  
First step in order to check the possibility to use the newly synthesized FeOy@Au@Cu2-xS in 
biomedical applications was to find a reliable and reproducible procedure to transfer those particles 
in aqueous media. The phase transfer of FeOy@Au@Cu2-xS trimers in aqueous media is a challenging 
task being these heterostructures composed of three different domains with different surface 
chemistry and with different ligands stabilizing them in organic solvent. Considering the synthetic 
route developed for the formation of the trimers (see Chapter 2), oleic acid is expected to cover iron 
oxide surface whereas oleyl amine is expected to cover both gold and copper sulfide domains. 
Consequently, in ligand exchange procedures used for the water transfer of trimers, ligands having 
catechol groups were used for the replacement of oleic acid on iron oxide domains whereas thiol 
terminated ligands were employed to stabilize in water Au and Cu2-xS moieties. Consequently, 
different trials were carried on using both commercial polymers (poly(maleic anhydride-alt-1-
octadecene), PMAO and CH3O-PEG2000-SH) or molecules synthesized in our lab (α-nitrodopamine-
ω-carboxy-poly(ethylene glycol), ND-PEG1500-COOH106 and poly-catechol-PEG900). 
First water transfer trials were carried out using ND-PEG1500-COOH (Figure 3.8a) synthesized by Dr. 
Helena Gavilan Rubio as amphiphilic ligands for the iron oxide domain (using 70 equivalent of tri 
ethyl amine for each ND-PEG1500-COOH molecule in order to deprotonate its carboxy an catechol 
groups) and CH3O-PEG2000-SH (Figure 3.8b) to substitute oleyl amine molecules covering gold and 
copper sulfide domains. 
In these first attempts, both the amphiphilic polymers were mixed together (one-step approach) 
with the chloroform solution of the sample and let under vigorous shaking overnight. After the 
shaking, sample was extracted with a toluene/water mixture in a separating funnel and the resulting 
aqueous phases dialyzed (using a cellulose membrane with MWCO = 50 kDa) in order to remove 
excess polymer. 





Figure 3.9 shows a representative TEM picture and DLS size distribution (by intensity) of a water 
stable sample obtained following this procedure. 
Using this procedure, trimers can be transferred in water with good stability (see DLS results in 
Figure 3.9b). However, as it is clearly shown by TEM analyses of the sample (see Figure 3.9a), 
together with the water transferred trimers, also traces of organic dirt and partially decomposed 
domains are present. In addition, many isolated domains (if compared with as-synthesized sample, 
see chapter 2) are surrounding water stable trimers, this indicating that a domain (presumably Cu2-
xS) is detaching from the heterostructures during the water transfer procedure. Water transfer 
procedure yield, measured by ICP-OES, was of only ≂ 25 %. Since the results obtained from this first 
procedure where unsatisfactory, a new two-step procedure was set up. Amounts of reactants, 
extraction and purification procedures remained the same as in previous trial. However, in this case, 
first chloroform solution of CH3O-PEG2000-SH was added to the sample, and the reaction mixture 
let under vigorous shaking overnight. Afterwards, the chloroform solution of ND-PEG1500-COOH 
and the corresponding TEA base were added and an additional step of overnight shaking was added 
before extraction and purification. 
Figure 3.9: a) Representative TEM picture of a water stable sample of trimers water transferred using a one-step approach 
with ND-PEG1500-COOH and CH3O-PEG2000-SH and b) related DLS hydrodynamic size distribution graph by intensity. 
a b 




Results, shown in Figure 3.10, clearly indicate a better quality of the sample obtained through water 
transfer procedure if compared to the ones obtained with the one-step methodology. While DLS 
results (Figure 3.10b) are similar to the ones obtained in previous case, TEM analyses (see Figure 
3.10a) are showing no organic dirt nor decomposed domains. Moreover, in this case the yield for 
the water transfer procedure was increased up to ≂ 40%. These results clearly indicate that the two-
step procedure is more convenient for the water transfer of these kind of heterostructures, having 
three domains with completely different surface chemistry. 
In order to further improve the efficiency of the water transfer procedure (in particular in terms of 
procedure’s yield), additional trials were carried out using a multi-dentate poly-catechol-PEG900 
ligand (see formula in Figure 3.11) developed and synthesized by Dr. Than Binh Mai, instead of the 
previously used mono-dentate ND-PEG1500-COOH ligand. 
Figure 3.10: a) Representative TEM picture of a water stable sample of trimers water transferred using a two-step approach 
with ND-PEG1500-COOH and CH3O-PEG2000-SH and b) related DLS hydrodynamic size distribution graph by intensity. 
Figure 3.11: Formula of poly-catechol-PEG900 used as ligand stabilizing iron 
oxide domains in water. 
a b 




The idea leading to the use of this polymer was to increase stability of the trimers using a multi 
dentate molecule (each polymer molecule has five catechol units). Indeed, has been previously 
reported that multi-dentate polymers provides an higher long-term stability of water transferred 
nanoparticles if compared to their mono-dentate counterparts107. The procedure used was again a 
two-step ligands addition followed by overnight shaking. Instead of doing an extraction, the water 
stable particles were separated from organic phase through addition of hexane, mild centrifugation 
and redispersion in water of the precipitated particles. Excess polymer in this case was not removed 
trough dialysis but through Amicon (100 kDa MWCO) washings. TEM and DLS results obtained using 
this new procedure are shown in Figure 3.12. 
Results obtained by both TEM and DLS analyses are similar to the ones obtained in the two-step 
procedure performed using ND-PEG-COOH. However, in this case, the yield calculated for the water 
transfer procedure is higher (> 80 %). This increased efficiency of the water transfer procedure 
demonstrates that multi-dentate ligands are effectively increasing the stability of the water stable 
particles and leading to diminished nanoparticles’ loss during the procedure 
After obtaining excellent results with the two-step procedure employing CH3O-PEG2000-SH and 
poly-catechol-PEG900, the possibility to water transfer FeOy@Au@Cu2-xS trimers using only 
commercially available polymers was also tested. To fulfill this aim, a polymer coating procedure 
using poly-(maleic anhydride)-alt-1-octadecene (PMAO) was set-up and results obtained were 
compared with the best ones obtained with ligand exchange procedures. The polymer coating 
procedure developed in our group108 relies on the intercalation of an amphiphilic polymeric shell on 
the hydrophobic surface of the nanoparticle. The shell is formed due to the favorable interactions 
between the alkyl chains of the surfactants coating the organic solvent-stable nanoparticles and the 
hydrophobic regions of the used polymer. This process is different from the ligand exchange 
procedure where the surface chemistry of the as-synthesized nanoparticles is a key parameter for 
the choice of the amphiphilic polymer. Indeed, in polymer coating, the formation of the polymeric 
shell around the particles is less influenced by the type of surfactant covering the nanoparticles and 
by the specific inorganic material that forms the nanocrystal cores. For these reasons, using this 
procedure, it has been reported the water transfer of different types of hydrophobic 
nanoparticles.109 This advantage of the polymer coating procedure is of key importance for particles 
Figure 3.12:a) Representative TEM picture of a sample of trimers water-trasferred using a two-step approach 
with poly-catechol-PEG900 and CH3O-PEG2000-SH b) related DLS hydrodynamic size distribution graph by 
intensity. 
a b 




such as the newly synthesized FeOy@Au@Cu2-xS trimers, in which the different composition of the 
three domains in the heterostructure does not allow the use of one single amphiphilic ligand, as 
conventionally used for ligand exchange procedures of homostructures. Another advantage of this 
procedure is that the used polymer is commercially available and cost-effective. For the water 
transfer of the trimers through polymer coating, the standard procedure108 has been adapted with 
some modifications. The procedure starts with the mixing of sample solution with PMAO in a large 
amount of chloroform (50 mL, in order to guarantee trimers’ stability in a diluted solution) with a 
ligands/nm2 ratio of 500 (considering total trimers’ surface). After stabilization through mild 
sonication, the chloroform is evaporated using rotavapor. Since the intercalation between ligands 
and PMAO is taking place during the removal of the solvent, the optimization of the chloroform 
evaporation step is a key task when performing polymer coating. Having the trimers a large size 
(sum of the three domain-lengths is generally above 50 nm), the parameters were set up in order 
to have a solvent evaporation as gentle as possible, in order to guarantee a proper coating of the 
particles. Using a bath temperature of the rotavapor of 50°C and a rotation speed of 140 rpm, 
chloroform was evaporated through three pressure steps. Pressure was first set to 800 mbar for 30 
minutes and to 700 mbar for 30 minutes more. Solvent was then evaporated at 650 mbar for 1 hour 
and finally the pressure was reduced to 600 mbar until complete drying of the product (usually 2 
more hours). The dried black precipitate was then brought back to solution using 20 mL borate 
buffer and sonication at high temperature (65°C was set as starting temperature of the sonication 
batch) for at least 2 hours. After, the sample’s volume was reduced (to about 3 mL) through Amicon 
tube filters (100 kDa MWCO) centrifugation. The sample was finally loaded on top of a sucrose 
gradient (from top to bottom: 2 mL of 20 m/v %, 3 mL of 40 m/v % and 3 mL of 60 m/v % in an ultra-
centrifugal tube) for ultracentrifugation. Ultracentrifugation in sucrose gradient is used to separate 
the coated particles from the unreacted free polymer that, being lighter, is not migrating through 
the gradient during the procedure. However, high centrifugation speed could cause precipitation 
and aggregation of larger particles. In order to optimize ultracentrifugation parameters, the 
migration of the sample inside sucrose gradient was monitored after 30, 45, 60 and 75 minutes of 




After 30 minutes of ultracentrifugation (Figure 3.13a), based on the color, most of the sample was 
still in fraction one (20 m/v %) of the sucrose gradient. In order to have most of the particles lying 
in the second fraction (40 % sucrose m/v %), for a proper separation from free polymer, the sample 
had to be centrifuged for 75 minutes. At this point (see Figure 3.13d) most of the particles are 
localize in two bands, corresponding to the interfaces between 1st and 2nd fraction and the one 
between 2nd and 3rd fraction with a small amount in the second fraction. This is indicating a size 
distribution in the polymer coated nanoparticles that, consequently, are not moving coherently 
inside the gradient. Likewise, many particles are also found in the bottom of the ultracentrifuge 
tube, indicating that larger particles are aggregating and that the ultracentrifugation should be 
stopped. As clearly indicated by Figure 3.13e, excess polymer is only localized in first fraction of the 
gradient. After removal of the polymer, fraction 2 and 3 of the gradient were recovered. Part of the 
sample was stuck onto the bottom of the ultracentrifuge tubes and was not possible to recover. 
Recovered fractions were then washed from the sucrose through Amicon washings. After 
concentration, the sample was characterized and compared with results obtained for 
FeOy@Au@Cu2-xS trimers water transferred using ligand exchange procedure with CH3O-PEG2000-
SH and poly-catechol-PEG900. 
In Figure 3.14, TEM, DLS, and gel electrophoresis characterizations for a sample of polymer-coated 
trimers are shown and compared with the results obtained performing water transfer through a 
ligand exchange procedure on the same starting trimers’ sample. 
  
Figure 3.13:Digital photograph of a sample of trimers after polymer coating and after a) 30 
minutes of ultracentrifugation at 13700 RCF; b) 45 minutes of ultracentrifugation at 13700 
RCF; c) 60 minutes of ultracentrifugation at 13700 RCF; d) 75 minutes of ultracentrifugation 
at 13700 RCF; d) digital photograph of sample shown in d) under UV-light irradiation. 




From DLS size distribution (shown in Figure 3.14c) is clear that, as was happening for the trimers 
when transferred with ligand exchange procedure employing CH3O-PEG2000-SH and poly-catechol-
PEG900, the polymer coating is transferring particles in water without producing any aggregate. In 
addition, from TEM pictures (see Figure 3.14a), no trace of aggregates formation was found. 
Interestingly, although the starting sample on which the two water transfer procedures were carried 
on was the same (with average diameters of 20 ± 3 nm for Cu2-xS domains, 21 ± 5 nm for iron oxide 
domains and 12 ± 1 nm for gold NPs), in the case of the sample water transferred through polymer 
coating, the hydrodynamic size distribution peak is centered around 80 nm while for the ligand-
exchanged sample the peak is at 100 nm. This difference between the DLS analyses outcome of the 
two water transfer procedures could suggest that the larger or the more interacting among the 
trimers are lost during the ultracentrifugation of polymer-coated sample (fraction found on the 
bottom of the ultracentrifuge tube). This loss is largely reflected in the calculated procedure yield 
for polymer coating. Indeed, while ligand exchange procedure was able to quantitatively (≥ 80%) 
Figure 3.14: Comparisons of the properties of a trimers’ sample when water transferred with polymer coating or ligand 
exchange procedure. a) representative TEM picture of trimers water transferred through polymer coating; b) 
representative TEM picture of trimers water transferred through ligand exchange; c) comparison of DLS hydrodynamic 
size distribution graph (by intensity) for polymer coated trimers (blue line) and ligand exchanged trimers (red line); d) 
image acquired under visible light of gel electrophoresis run (45 min, 100 V, 1% agarose gel) of polymer coated trimers 
(1) and ligand exchanged trimers (2); e) image acquired under ultraviolet light  of the same gel electrophoresis run of 
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transfer to water the trimers, with polymer coating procedure the process’ yield drops to only 15 
%. In Figure 3.14d and 3.14e, are shown digital photographs of gel electrophoresis runs for the two 
water-transferred samples, acquired under both visible (Figure 3.14d) and UV (Figure 3.14e) light. 
The difference in the results obtained with the two samples should be ascribed both to the different 
size distribution and to the different zeta potential of the water-transferred particles (measured z 
potential was -34 mV for polymer-coated trimers and -19 mV for ligand-exchanged trimers). Most 
importantly, pictures acquired under ultraviolet light (Figure 3.14e) show that there are no traces 
of free polymers (both PMAO and poly-cathecol-PEG900) in the two samples, thus indicating that 
the cleaning protocols were successful. 
In order to be able to select the best water transfer procedure for trimers, polymer coated and 
ligand exchanged (procedure employing CH3O-PEG2000-SH and poly-catechol-PEG900) 
heterostructures were also compared based on their heating efficiency when used in magnetic 
hyperthermia treatments. First, hyperthermia efficiencies of the two sample were evaluated and 
compared through calorimetric Specific Absorption Rate (SAR) measurements using alternating 
magnetic fields (AMF) with frequencies between 105 and 300 kHz and amplitudes between 12 kA/m 
and 32 kA/m. SAR was calculated according to the formula and the procedure explained in 
experimental section. Results obtained are shown in Figure 3.15. 
Both the samples show good heating efficiencies, with the one of the polymer-coated sample being 
higher than the one of the trimers water transferred through ligand exchange (566 ± 6 W/g for the 
ligand-exchanged sample and 688 ± 1 W/g for the polymer-coated sample at 300 kHz, 24 kA/m). 
This difference could be explained by the aforementioned quality and size selection, taking place 
during ultracentrifugation step of the polymer coating procedure. In order to further deepen the 
understanding of this behavior, AC hysteresis loops of the two differently water transferred samples 
were measured using the same field parameters. Results obtained on the two samples, using fields 
with frequencies of 200 kHz and 300 kHz and amplitudes of 12 kA/m and 24 kA/m are shown, in 
Figure 3.16. 
Figure 3.15: Comparison of SAR vs field amplitude data obtained from the same sample of trimers water transferred with 
polymer coating (blue lines) and with ligand exchange (red lines); a) data obtained using a field frequency of 217 kHz; a) data 





While the coercivity of the loops of the two samples is similar, the value of the maximum 
magnetization achieved is higher in the case of polymer-coated nanoparticles (76 Am2/kg vs 53 
Am2/kg when a field with frequency of 300 kHz and an amplitude of 24 kA/m was used). The 
different shape of the loops directly reflects on the measured values for loops’ area (2748 mJ/kg vs 
2064 mJ/kg when a field with frequency of 300 kHz and an amplitude of 24 kA/m was used) this 
resulting in the difference in SAR measured through calorimetric measurements. The fact that 
polymer-coated trimers can achieve a higher value of maximum magnetization under same field 
conditions, strengthen the hypothesis of the polymer coating operating a quality selection of the 
transferred particles. Larger, or more interacting, particles are lost during the ultracentrifuge step 
of water transfer procedure and only best performing particles are remaining in the water stable 
sample. 
Despite this difference in the hyperthermia performances favors polymer coating, ligand exchange 
procedure was selected as the candidate procedure for the water transfer of trimers given the 
higher yield (≥ 80 % vs 15 %) and the straightforwardness and reproducibility of the procedure in 
which less parameters have to be tuned and monitored. Consequently, on the sample transferred 
with this latter procedure, also UV-VIS-IR and XRD analyses were performed in order to check 
whether plasmonic absorption or crystalline phase of the sample were modified or not. Results are 
shown in Figure 3.17. 
a b 
Figure 3.16: AC hysteresis loops obtained from a sample of trimers water transferred through polymer coating (continuous 
lines) or ligand exchange (dashed lines) measured using a) alternated fields with frequency of 200 kHz and amplitudes of 
12 kA/m (black lines) and 24 kA/m (blue lines); b) alternated fields with frequency of 300 kHz and amplitudes of 12 kA/m 




The XRD pattern of the water-transferred trimers (see Figure 3.17a) is comparable with the one 
obtained for the trimers in chloroform (see Figure 2.25c), all the expected reflections for cubic gold, 
cubic iron oxide and triclinic roxbyite copper sulfide are present. In both the VIS-NIR (500 – 1200 
nm) spectra (shown in Figure 3.17b) Au and Cu2-xS plasmon absorption are clearly recognizable. Both 
the absorption peaks are blue-shifted in case of the water-transferred sample. This shifting of the 
plasmonic absorption bands has to be ascribed to the change of dispersing solvent and to the 
chemistry of the amphiphilic ligand stabilizing the surface of the FeOy@Au@Cu2-xS.110 
3.2.2. Magnetic hyperthermia performances of FeOy@Au@Cu2-xS heterostructures 
In order to be able to compare the hyperthermia efficiency of the FeOy@Au@Cu2-xS trimers with 
the one of the dimers, which were used as starting seeds for the synthesis of these novel 
heterostructures, a sample of dimers (Au@ FeOy) was transferred to water using the same ligand 
exchange procedure adopted for trimers. Noteworthy, the sample of dimers transferred and 
measured is the same used as seeds in the synthesis for that particular sample of trimers. This was 
planned in order to be able to evaluate the contribution due to the third domain growth only, out 
ruling any influence on the heating performances coming from the differences in either the gold (15 
± 3 nm in both samples) or iron oxide domain (26 ± 4 nm in both samples). TEM pictures of the 







Figure 3.17: a) Experimental XRD pattern of a sample of water transferred trimers compared with expected reflections for 
Au (ICSD code 611625), iron oxide (ICSD code 247035) and Cu29S16 (ICSD code 185807); b) VIS-NIR (500-1200 nm) spectrum 
of a sample of trimers in chloroform (red line) and of the same sample after water transfer (blue line), spectra are 




TEM pictures of water transferred dimers (Figure 3.18a) and trimers (Figure 3.18b) show the good 
quality of both the samples. DLS and UV-VIS-NIR characterization for the water transferred dimers 
and trimers whose hyperthermia efficiencies are compared in Figure 3.19. 
No traces of aggregates were found, the hydrodynamic diameter of trimers is obviously bigger than 
the one of dimers, due to the presence of the additional copper sulfide domain. These results 
demonstrate how the water transfer procedure developed for FeOy@Au@Cu2-xS can be used with 
excellent results also for the water transfer of FeOy@Au dimers, in substitution of the already 
reported ligand exchange procedure employing gallol-poly(ethylene glycol) (GA-PEG).40 Comparing 
the UV-VIS-NIR (500 nm – 1200 nm) spectra, it is clear that, whilst the small differences in the 
position of the absorption peak related to the presence of the gold plasmon, the plasmonic 
absorption at high wavelengths (starting at about 850 nm) is completely absent in the dimers’ 
sample. Given the good results obtained for the water transfer or the dimers, magnetic 
hyperthermia performances of the two heterostructures were measured and compared (see Figure 
3.20). 
Figure 3.19: a) comparison of DLS size distribution graph (by intensity) for dimers (red line) and trimers (blue line); b) 
comparison of VIS-NIR (500-1200 nm) spectra of water dispersed dimers (red line) and trimers (blue line). 
a b 
Figure 3.18: a) representative TEM picture of a sample of dimers water transferred through ligand exchange 
procedure using poly-cathechol-PEG900 and CH3O-PEG2000-SH; b) representative TEM picture of a sample 
of trimers water transferred through ligand exchange procedure using poly-cathechol-PEG900 and CH3O-
PEG2000-SH. 
b a 
PDI = 0.20 







kA/m 12 16 20 24 32 
Dimers 46 99 166 248 315 
Trimers 39 92 131 192 302 
kHz 217 
kA/m 12 16 20 24 
 
Dimers 99 194 330 441 
 
Trimers 77 156 290 430 
 
kHz 300 
kA/m 12 16 20 24 
 
Dimers 134 251 438 686 
 
Trimers 97 227 357 565 
 
Figure 3.20: a-c) SAR vs field amplitude graphs for Au@FeOy dimers (blue lines) and FeOy@Au@Cu2-xS trimers (red lines) using a field 
frequency of a) 105 kHz; b) 217 kHz; c) 300 kHz. For all frequencies, field amplitudes of 12 kA/m, 16 kA/m, 20 kA/m and 24 kA/m were 
used. For 105 kHz frequency, data obtained using a field amplitude of 32 kA/m are also shown; d) table with SAR performances of 
dimers and trimers samples when different field amplitudes and frequencies are applied. Both the measured samples had an iron 
oxide domain with 26 ± 4 nm average size. 
In all cases, heating performances of the trimers are slightly worse than the ones of the dimers. This 
difference could be due to the increased size of the trimers, hindering particles rotation. However, 
when using frequencies and fields below the H×f limit value of 5×10-9 A/(m×s) (commonly 
considered the maximum value of the field×frequency product that is safe for human tissues)111, 
that are, among the measurements performed, the ones at 105 kHz (12 kA/m, 16 kA/m, 20 kA/m, 
24 kA/m and 32 kA/m) 217 kHz (12 kA/m, 16 kA/m, 20 kA/m) and 300 kHz (12 kA/m, 16 kA/m), the 
SAR values obtained using FeOy@Au@Cu2-xS trimers, are in line with the ones obtained for other 
magnetic heterostructures reported for hyperthermia applications.112 Dynamic magnetic properties 




of AC hysteresis loops. Results obtained using alternated magnetic fields with frequencies of 200 
kHz and 300 kHz and amplitudes of 12 kA/m and 24 kA/m are shown in Figure 3.21. 
From the AC hysteresis loops is clear that, as already expected from SAR values, there is only small 
difference between the dynamic loop of dimers and trimers, this resulting in similar heating 
performances when used in magnetic hyperthermia. These results demonstrated how, fulfilling the 
first task of this work, a chalcogenide domain can be grown on Au@FeOy dimers without 
compromising their excellent performances for magnetic fluid hyperthermia. 
3.2.3. Radiolabeling with 64Cu of FeOy@Au@Cu2-xS heterostructures 
Once confirmed that the performances of Au@FeOy dimers as heating probes under the application 
of an alternating magnetic field are preserved after the growth of the copper sulfide domain, 
radiolabeling reactions, following the protocol used for ZnS nanoparticles in Chapter 1, were carried 
out. The final goal of these nano-heterostructures is to be used as multifunctional probes feasible 
to be exploited both in radiotherapy and hyperthermia, the latter requiring a relatively high iron 
concentration in order to be effective. Being the typical molar ratio between iron and copper in 
water stable trimers’ samples between 1.4 and 2, the amount of nanocrystals used had to be tuned 
accordingly in order to have iron concentration similar to the ones used in hyperthermia 
experiments (1-3 g/L). The percentage ratio between radioactive 64Cu used and the copper present 
in FeOy@Au@Cu2-xS nanocrystals was defined as 64Cu feed percentage ratio (64Cu×100/CuNCs). 
Different trials, using varied 64Cu feed percentage ratios where performed, in order to check the 
related radiochemical yields. Similarly to what has been done for ZnS nanoparticles, all the 
experiments were performed using an amount of 64CuCl2 (2.03×10-12 moles) corresponding to an 
activity of 18.5 MBq (500 μCi), consequently 64Cu/CuNCs has been reduced by increasing the amount 
of trimers nanocrystals used.  
Radiolabeling reactions and subsequent purification were carried out following the same procedure 
(see Figure 3.22) used for ZnS NPs, using ascorbic acid as biocompatible mild reducing agent for the 
reduction of the introduced 64Cu (II) ions to 64Cu(I). 
Figure 3.21: AC hysteresis loops of a sample of trimers (continuous lines) and dimers (dashed lines) having a 26 ± 4 nm iron oxide 
domain. a) Measurements performed using fields with frequency of 200 kHz and fields of 12 kA/m (black lines) and 24 kA/m (blue 






Three sets of radiolabeling reaction were set up in order to evaluate the radiochemical yields of the 





CuNCS 64Cu RCY 
(%) (moles) (moles) (%) 
1% 2.03×10-10 2.03×10-12 9.5 
0.1% 2.03×10-9 2.03×10-12 31.5 
0.01% 2.03×10-8 2.03×10-12 97 
b
 
Figure 3.23: a) table with parameters used in different trials of radiolabeling reactions; b) radiochemical yield obtained for three sets 
of reaction carried out using [64Cu]/[CuNCs] percentage ratios of 1 %, 0.1 % and 0.01 %. 
While in the case of 1% and 0.1% 64Cu feed percentage ratios the radiochemical yield of the reaction 
is below 50%, in the case where a 0.01 % 64Cu/CuNCs percentage ratio was used, the average 
radiochemical yield obtained was of 97 %, meaning that the used 64Cu is almost quantitatively 
incorporated inside the FeOy@Au@Cu2-xS nanocrystals. This value is almost two times the one 
reported before for radiolabeling of water stable copper sulfide nanocrystals (49%)113 and similar to 
the one reported for 64Cu:CuS nanocrystals synthesized using a mixture of CuCl2 and 64CuCl2.114  
Although with such high radiochemical yield the purification of the nanocrystals solution from free 
radioactive copper is not needed, during our experiments radiolabeled particles were cleaned using 
one Amicon purification step (see Figure 3.22), in order to get rid of excess ascorbic acid and to 
concentrate the sample. 




To evaluate the stability of the particles during this washing step, similarly to what was done for ZnS 
nanoparticles, activity of all the washing fractions were measured through a dose calibrator and 
compared with the starting activity measured from the reaction batch after the incubation of 1 hour 
at 37°C. Three trials were carried out adding different amounts of a 0.0049 M CYS-PIMA-PEG2000 
solution. CYS-PIMA-PEG2000 is a multi-dentate ligand that has been previously used (see chapter 1) 
for the stabilization in water of chalcogenides nanocrystals. Results obtained using 0, 20 μL and 50 
μL of 0.0049 M CYS-PIMA-PEG2000 solution are compared, based on radiochemical yield and on the 
yield of the purification process, in Figure 3.24. 
First important result is that RCY, although being reduced from 97 % in the case no stabilizing agent 
was used to 93 % when increasing amounts of CYS-PIMA-PEG2000 were added, is over 90 % in any 
case. This indicates that the addition of a thiol-terminated agent, potentially able to chelate free 
64Cu ions, is not significantly affecting the amount of activity successfully incorporated in the 
nanocrystals. On the other hand, while increasing the amount of CYS-PIMA-PEG2000 added, the 
yield of the purification process is drastically improved from 64 % (when no CYS-PIMA-PEG2000 was 
added) to 84 % (when 50 μL of CYS-PIMA-PEG2000 solution were added). In order to further study 
the fate of 64Cu (I) during the purification process in the three cases, activity data obtained from the 
different fractions of the washings are compared in table 3.1. 
 
Figure 3.24: Radiochemical yield (bars) and purification yield (red line) obtained for radiolabeling 




Table 3.1: Percentage of starting activity measured during purification steps of three radiolabeling reaction performed (1) without 
adding any stabilizing agent (2) adding 20 µL (3) adding 50 µL of a 0.0049 M solution of CYS-PIMA-PEG. Vial: activity remained in the 
reaction vial after the transfer of the solution in Amicon filter; Washing: percentage of activity recovered in the bottom of the 
Eppendorf vial after centrifugation; Filter: percentage of activity stuck in the Amicon filter cartridge after nanocrystals solution 
recovery; Recovered: percentage of activity of the final nanocrystals solution; Lost: percentage corresponding to the difference 
between the initial activity and the activities measured during purification steps. 
From the results obtained is clear that the addition of even small amounts of a stabilizing agent is 
increasing the stability of the radiolabeled nanocrystals both during the radiolabeling reaction and 
during the centrifuging step. The loss of stability during the radiolabeling reaction can be evaluated 
by the amount of activity that is remaining stuck in the reaction vial. When no stabilizing agent is 
added, 16 % of the activity is found in the reaction vial while this amount is reduced to 4 % and 3 % 
when 20 μL and 50 μL of 0.0049 M CYS-PIMA-PEG2000 are respectively added. This demonstrates 
that CYS-PIMA-PEG2000 addition helps improving the stability of the nanocrystals during the 1 hour 
incubation, consequently reducing the amount of 64Cu that is loss in the reaction vial. Stability of 
the crystals during the centrifuging step can be evaluated through the amount of activity found in 
the cartridge of the Amicon filter used for crystals purification and concentration. This amount is 
decreased when the amount of CYS-PIMA-PEG2000 added to the radiolabeling reaction is increased. 
Indeed, while in reaction n°1 17 % of the activity was found in the filter, with 50 μL of 0.0049 M CYS-
PIMA-PEG2000 this value was reduced to 7 %. The column indicated as “lost” in table 3.1 reports 
the difference between the starting activity value and the ones measured during purifications step, 
considering other losses that were not measured during these experiments. These losses, whose 
values are in any case low, could be due to nanocrystals remaining inside micropipette tips used for 
sample transfer to Amicon or to natural decay of 64Cu (0.66 % during 10 minutes of purification). 
The obtained results demonstrated that, if a purification and washing procedure is needed to clean 
the sample from unreacted reagents and to reduce radiolabeled nanocrystals’ solution volume, few 
microliters (20 – 50 μL) of a 0.0049 M CYS-PIMA-PEG2000 solution can be added in order to 
guarantee perfect stability and quantitative activity recovery. 
In order to further study the process, a scaled-up reaction employing “cold” (non-radioactive) CuCl2 
was performed reproducing the conditions of the radiolabeling reactions that were previously 
carried out. In order to have a reliable picture of the radiolabeling reaction, the reaction was set up 
considering not only radioactive copper corresponding to the 18.5 MBq activity used (2.03×10-12 
moles of Cu), but the total (“hot” plus “cold”) amount of copper used in the radio labeling 
experiments. This value is 1.32×10-10 moles of Cu at production time and it is increasing over time 
with radioactive copper decay. Consequently, the ratio between non-radioactive CuCl2 and CuNCs 
used was calculated accordingly. All the other parameters where kept the same as in radiolabeling 
reactions, included the addition of 0.0049 M CYS-PIMA-PEG as stabilizer agent. After the reaction, 
sample was cleaned using the Amicon filter washing procedure already used in the case of 
radiolabeled crystals. Results obtained by TEM, VIS-NIR and DLS analyses on this trimers’ sample are 
shown in Figure 3.25. Also, DLS hydrodynamic size distribution graph and VIS-NIR spectra of the 
sample before reaction with CuCl2 are reported for comparison. 
Reaction CYS-PIMA-PEG RCY Vial Washing Filter Recovered Lost 
N° (µL) (%) (%) (%) (%) (%) (%) 
1 0 97 16 0 17 64 3 
2 20 93 4 0 12 80  4 




TEM picture in Figure 3.25a shows how the FeOy@Au@Cu2-xS trimers are not changing shape or size 
(compare with TEM picture in Figure 3.12a) during the reaction with CuCl2. As DLS size distribution 
graphs reported in Figure 3.25b show, trimers are losing part of their stability during the reaction 
and purification step. Indeed, hydrodynamic size distribution of the trimers after the reaction with 
“cold” CuCl2 is broader and shifted to higher values if compared to the one of the starting sample. 
Although the amount of copper used in the reaction is reduced (copper coming from CuCl2 was 0.65 
% of the copper already present in the nanocrystals), from Figure 3.25c it can be seen that in the 
sample measured after the reaction, while the absorption peak related to gold LSPR is preserved, 
the absorption peak ascribed to the presence of copper-deficient copper sulfide domains 
completely disappeared. This situation is typical of Cu2-xS domains with x = 0115 and could be 
explained with the incorporated Cu (I) ions filling the holes in nanocrystal lattice. 
In order to further study the radiolabeling process on trimers, the same procedure was performed 
on Au@FeOy dimers. In particular, this study was set up in order to understand if the radiolabeling 
was specifically taking place on the copper sulfide and to be able to out rule the possibility of 
nonspecific radiolabeling. Being copper element absent in dimers’ chemical composition, the 
amount of Au@FeOy used in the reactions was tuned in order to have the same iron content used 
in radiolabeling of FeOy@Au@Cu2-xS heterostructures (when a 0.01 % 64Cu/CuNCs percentage ratio 
was used). Reactions were performed without the addition of CYS-PIMA-PEG2000 in order to avoid 
introducing another potential source of activity withdrawal. Results are shown in Figure 3.26. 
Figure 3.25: a) Representative TEM picture of a sample of FeOy@Au@Cu2-xS trimers after “cold” reaction with CuCl2 and Amicon filter 
purification; b) DLS size distribution graph (by intensity) of a sample of FeOy@Au@Cu2-xS trimers after “cold” reaction with CuCl2 and 
Amicon filter purification (blue line) compared with DLS size distribution graph (by intensity) of the same sample before the reaction; 
c) UV-VIS-NIR (500 nm -1200 nm)  spectrum of a sample of FeOy@Au@Cu2-xS trimers after “cold” reaction with CuCl2 and Amicon filter 
purification (blue line) compared with UV-VIS-NIR (500 nm -1200 nm) spectrum of the same sample before the reaction. 
a b c 





Surprisingly, also the radiolabeling of the dimers resulted in 64Cu incorporation in nanocrystals. This 
incorporation of 35 % of 64Cu used could be ascribed either to the chelation of some 64Cu ions by 
thiol groups of CH3O-PEG2000-SH molecules stabilizing gold and copper sulfide domains or to 
unspecific labeling from Au or FeOy domains. In order to further study these radiolabeling reactions, 
EDTA challenge for the radiolabeled dimers and trimers was performed by adding to the reaction 
batch, after the incubation with 64Cu:CuCl2, 150 μL of 0.5 M EDTA and checking the percentage of 
activity in the crystal fraction (RCY) through iTLC every 60 minutes for 3 hours. Results obtained are 
shown in Figure 3.27. 
Figure 3.27: Percentage of activity in the nanocrystals fraction (RCY) 
measured during EDTA challenge on radiolabeled dimers (red line) and 
trimers (blue line) every 60 minutes for 3 hours. 
Figure 3.26: Radiochemical yields obtained for radiolabeling reactions, 
performed using same reaction parameters, on dimers (green bar) and 




Interestingly, while the activity incorporated in trimers’ sample is reduced of only 8% after 3 hours 
of EDTA challenge, already after 2 hours dimers lost 16 % of their bounded 64Cu, reducing the 64Cu 
present in nanocrystals fraction of the TLC to 19 %. This indicates that 64Cu affinity for the trimers 
is higher if compared to the one of the dimers, candidating the former as a better material for the 
aimed use as radioisotope ions carriers. 
3.2.4. Photothermal performances of FeOy@Au@Cu2-xS heterostructures 
Another interesting property of the FeOy@Au@ Cu2-xS trimers that can be used in biomedical 
applications is the presence of two LSPRs: the one of the gold nanoparticles acting as bridge 
between FeOy and Cu2-xS domains and the one related to the presence of copper-deficient copper 
sulfide domains. The localized surface plasmon resonance absorbance peaks of Au and Cu2-xS 
domains are (see Figure 3.17b) respectively centered, in the water transferred samples, at 554 nm 
and around 1200 nm. The band of gold NPs’ absorption is partially inside first NIR biological window 
(650 nm – 950 nm) while the absorption of Cu2-xS domains is centered inside the second NIR 
biological window (1000 nm – 1350 nm). Indeed, both Au116 and Cu2-xS102 nanoparticles have been 
reported to be used in photothermal therapy. In order to combine together measurements of 
photothermal heating with measurements of magnetic hyperthermia heating (DUAL experiments), 
a special set-up had to be designed. Indeed, the capillary containing trimers’ water stable sample 
had to be centered both with the coil of the hyperthermia set-up used (DM3 Series, NanoScale 
Biomagnetics) and with the laser beam. To achieve this aim, a custom sample holder was 3D-printed 




Sample holder was designed in order to properly shine the laser in the middle of the capillary while 
it is standing in the center of the hyperthermia set up solenoid. Moreover, the holder is designed in 
order to avoid the laser to directly hit the thermal probe, producing unspecific heating. The distance 
between laser optic and sample’s capillary was set to be 4 cm: at this distance the laser beam has a 
diameter corresponding to the width of the capillary (3 mm diameter, 0.07065 cm2 surface). The 
capillary holder has a window of 4 mm, through which the samples is exposed to the laser. The 
absence of unspecific heating given by the laser was confirmed by measuring the heating curve of 
the empty capillary (see Figure 3.28c). Results obtained irradiating trimers’ sample (50 μL, [Fe] = 2.8 
g/L, [Cu] = 1.6 g/L [Au] = 4.0 g/L) for 5 minutes using a 808 nm laser with power density of 4.67 
W/cm2 are shown and compared with the ones obtained on MilliQ water in Figure 3.29a. The 
reproducibility of the photothermal heating was tested through cycles of seven minutes laser 
irradiation (see Figure 3.29b). 
Figure 3.28: a) Graphical representation of the custom 3D-printed sample holder used for photothermal 
measurements and for DUAL (laser + magnetic hyperthermia) measurements; b) custom sample holder inserted in 
DM3 series hyperthermia set up and coupled with 808 nm laser; c) Heating curve of the empty capillary under 808 






While after 5 minutes of laser irradiation the temperature of water is substantially unchanged (ΔT 
= 1.3 °C), the temperature of trimers’ sample after the same time was increased by 33°C.This 
temperature increase is in line with the one reported for photothermal experiments performed on 
Fe3O4@CuS heterostructures under similar conditions.117 As shown in Figure 3.29b, FeOy@Au@Cu2-
xS trimers can be used for multiple cycles of laser heating since photothermal performances are not 
significantly reduced after the first heating ramp. Dual (laser irradiation + alternating magnetic field) 
heating curve was measured using same laser parameters and applying AMF with amplitude of 24 
kA/m and frequency of 120 kHz. Results are shown in Figure 3.30. 
 
Figure 3.29: a) Heating curves (5 minutes) obtained by water (black line) and by trimers’ sample (red line) irradiation using a 808 nm 
laser with power density of 4.67 W/cm2; b) test of laser heating reproducibility with seven minute cycles using same laser parameters. 
a b 
Figure 3.30: Heating curves (5 minutes) obtained from FeOy@Au@Cu2-xS 
trimers under AMF (24 kA/m, 120 kHz, black line), 808 nm laser irradiation (4.67 




When merging 808 nm laser irradiation with AMF application, the temperature increase of sample’s 
solution is 39.6°C, this demonstrating the possibility to combine the two different heating modalities 
in order to obtain higher treatment efficiency (maximum temperature increase reached for 
hyperthermia treatment only is 8°C). Heating efficiency of the FeOy@Au@Cu2-xS trimers was also 
tested using lower laser power density (2 W/cm2). Indeed, for a bio-safe application, the limit value 
in order to avoid skin damage is reported to be of 0.33 W/cm2.101 Results are shown in Figure 3.31. 
Heating curves obtained by trimers under laser irradiation are strongly dependent on the power 
density used. Indeed, when the power density is reduced to 2 W/cm2 the increase in temperature 
is of only 4.5°C. This is probably related to the low absorption of the water-transferred trimers at 
the used wavelength of 808 nm (see Figure 3.17b). One possibility to increase heating output with 
low laser power density could be to use lasers with smaller wavelength (remaining in NIR first 
biological window), a zone of FeOy@Au@Cu2-xS spectrum where gold LSPR absorbance is more 
intense. Also, it could be possible, by changing synthesis parameters, to tune copper sulfide LSPR in 
order to have higher absorption intensity at lower wavelengths, exploiting lasers in the second NIR 
biological window (1000 nm – 1350 nm) One last possibility could be to try to design 
heterostructures using, instead of spherical gold nanoparticles as linkers between magnetic and 
chalcogenide domains, gold nanorods having one of their two LSPRs centered around 800 nm. 
  
Figure 3.31: Heating curves (5 minutes) of FeOy@Au@Cu2-xS 
trimers obtained under irradiation with 808 nm laser using a power 




3.3. Conclusions and outlook 
Different procedure and polymers (both commercially available and synthesized by researchers of 
our group) were used in order to phase transfer to water the newly synthesized FeOy@Au@Cu2-xS 
trimers. Best results were obtained employing: i) a ligand exchange procedure with poly-catechol-
PEG900 and CH3O-PEG2000-SH; or ii) a polymer coating procedure with Poly-(Maleic Anhydride-alt-
1-Octadecene). Both water transfer procedures preserved the morphology of the nano-
heterostructures, while providing them excellent stability in aqueous media. Trimers transferred 
through polymer coating show slightly better hyperthermia performances, probably due to an 
inherent quality-sorting process. However, the simplicity of the ligand exchange procedure and its 
quantitative yield (> 80 % versus a yield of 15 % for polymer coating procedure), made this 
procedure the candidate for the experiments further performed. 
Hyperthermia performances of ligand exchanged FeOy@Au@Cu2-xS trimers were measured both 
through calorimetry and AC hysteresis loops measurements and compared with the one obtained 
for Au@FeOy dimers with same iron oxide size and transferred to water with same procedure. SAR 
values obtained for trimers are similar to the one obtained for the excellently performing dimers 
and, when using Hf factors below the limit for safe clinical application (Hf ≤ 5×10-9 A/(m×s)), their 
properties (302 W/g when a field with frequency of 105 kHz and an amplitude of 32 kA/m were 
used) are in line with the values obtained with other magnetic heterostructures reported for 
hyperthermia applications. 
Trimers were employed for aqueous phase radiolabeling reactions using 64CuCl2. Using an activity 
of 18.5 MBq and a percentage ratio between added 64Cu and copper in nanocrystals (CuNCs) of 0.01 
%, it has been possible to incorporate 97 ± 3 % of the activity in the nanocrystals. Particles have 
been demonstrated to be stable during radiolabeling and subsequent purification procedure upon 
the addition of a small volume of 0.0049 M CYS-PIMA-PEG2000 solution. These experiments 
candidate FeOy@Au@Cu2-xS nano-heterostructures as an efficient carrier for 64Cu ions (and, 
eventually, 67Cu ions). To the best of our knowledge, this is the first nano-heterostructure having a 
magnetic domain with excellent magnetic hyperthermia performances joint with another domain 
able to incorporate quantitatively 64Cu ions. 
FeOy@Au@Cu2-xS nano-heterostructures were also tested in photothermal experiments both as 
stand-alone technique or in combination with magnetic hyperthermia (DUAL treatments). In order 
to perform DUAL measurements a custom 3D-printed sample holder was designed and used. While 
using an AMF with frequency of 120 kHz and amplitude of 32 kA/m, a temperature increase of 8 °C 
degrees was achieved in the sample’s solution after 5 minutes, this value raised to 39.6 °C degrees 
in the case of DUAL treatment, which was performed by irradiating the sample with a 808 nm laser 
with 4.67 W/cm2 power density. The heating performances under 808 nm laser irradiation of the 
trimers are strongly correlated to the power density. Indeed, while the temperature increase is of 
33°C degrees after 5 minutes irradiation with a power density of 4.67 W/cm2, this value drops to 
only 4°C in case of a power density of 2 W/cm2. These preliminary results obtained for photothermal 
heating of FeOy@Au@Cu2-xS trimers could be consistently improved by tuning wavelength 
absorption of both the gold and the copper-deficient copper sulfide domains by changing either 




3.4. Experimental procedures 
FeOy@Au@Cu2-xS water transfer though ligand exchange using ND-PEG1500-COOH 
and CH3O-PEG2000-SH: one-step procedure 
1 mL of particles solution was mixed in a 40 mL glass vial with a 2mg/mL chloroform solution of 
CH3O-PEG2000-SH in order to have a ligands/nm2 ratio of 300 (based on gold and copper sulfide 
domains’ surface) and with a 0.05 M solution of ND-PEG1500-COOH in order to have a ligands/nm2 
ratio of 300 (based on iron oxide domains’ surface). Tri ethyl amine in amount equal to 70 
equivalents of the ND-PEG1500-COOH was also added to the solution. Mixture was left under 
vigorous shaking at room temperature overnight. The sample was then recovered with toluene and 
extracted with MilliQ water two times. Resulting aqueous phases were recollected and bubbled with 
N2 gas for at least two hours in order to remove traces of organic solvents. After the bubbling, 
aqueous phases were sonicated for 1 hour at 65°C and concentrated to a volume smaller than 10 
mL using a 100 kDa MWCO Amicon filter. Resulting solution was then transferred in spectrum labs 
dialysis membrane (MWCO = 50 kDa) and dialyzed against water for two days. Water transfer was 
then completed by centrifuge concentration (400 RCF, 10 minutes) through 100 kDa MWCO Amicon 
filter up to a volume equal or smaller the one of the starting organic solvent-stable sample (1 mL). 
FeOy@Au@Cu2-xS water transfer though ligand exchange using ND-PEG1500-COOH 
and CH3O-PEG2000-SH: two-steps procedure 
1 mL of particles solution was mixed in a 40 mL glass vial with a 2 mg/mL chloroform solution of 
CH3O-PEG2000-SH in order to have a ligands/nm2 ratio of 300 (based on gold and copper sulfide 
domains’ surface). After overnight shaking at room temperature, a 0.05 M solution of ND-PEG1500-
COOH in order to have a ligands/nm2 ratio of 300 (based on iron oxide domains’ surface) and tri 
ethyl amine in amount equal to 70 equivalents of the ND-PEG1500-COOH were added to the 
solution and the mixture was shaken for one more night at room temperature. The sample was then 
recovered with toluene and extracted with MilliQ water two times. Resulting aqueous phases were 
recollected and bubbled with N2 gas for at least two hours in order to remove traces of organic 
solvents. After the bubbling, aqueous phases were sonicated for 1 hour at 65°C and concentrated 
to a volume smaller than 10 mL using a 100 kDa MWCO Amicon filter. Resulting solution was then 
transferred in spectrum labs dialysis membrane (MWCO = 50 kDa) and dialyzed against water for 
two days. Water transfer was then completed by centrifuge concentration (400 RCF, 10 minutes) 
through 100 kDa MWCO Amicon filter up to a volume equal or smaller the one of the starting organic 
solvent stable sample (1 mL). 
FeOy@Au@Cu2-xS water transfer though ligand exchange using poly-catechol-PEG900 
and CH3O-PEG2000-SH 
1 mL of particles solution was mixed in a 40 mL glass vial with a 2mg/mL chloroform solution of 
CH3O-PEG2000-SH in order to have a ligands/nm2 ratio of 300. For this ratio, only the surface of the 
Au NPs and Cu2-xS domains was taken into account. After overnight shaking at room temperature 
(RT = 25°C), a chloroform solution of multi-dentate (five catechol groups per molecule) poly-




catechol solution added was calculated in order to have a ligands/nm2 ratio of 300, considering only 
FeOy domains’ surface. Tri ethyl amine (in [TEA] : [Catechol] molar ratio of 10:1) was further added 
to the mixture that was then let under shaking for another night. Afterwards, chloroform was 
evaporated from the vial through bubbling, 2 mL of THF were added to dissolve the IONCs and an 
excess amount of hexane (10 folds of volume) was added to induce the precipitation of ligand-
exchanged particles. After 15 minutes of centrifugation at 300 RCF, the supernatant was then 
discarded and the process repeated one more time. After the second washing, particles were 
dispersed in water and, after 5 minutes sonication at RT, excess ligands were removed by means of 
centrifugal filtration. A 15 mL Amicon filter with molecular weight cut off (MWCO) of 100 kDa was 
used and 5 cycles of centrifuge washings (400 RCF, 10 minutes) were used in order to get rid of the 
free ligands. 
FeOy@Au@Cu2-xS water transfer through polymer coating with poly-(maleic 
anhydride-alt-1-octadecene) 
As synthesized hydrophobic trimers were transferred to water by means of poly(maleic anhydride-
alt-1-octadecene) (PMAO) using a protocol developed by our group with minor modifications.108,109 
1 mL of the starting trimers samples is mixed with PMAO (with a ligands/nm2 ratio of 500) in 50 mL 
of chloroform. Sample is then stabilized through sonication at 65°C. Chloroform is then evaporated 
using rotavapor with a batch temperature of 50°C and a rotation speed of 140 rpm. After 30 minutes 
rotavapor evaporation with 800 mbar pressure, followed by 30 minutes at 700 mbar, solvent was 
then evaporated at 650 mbar for 1 hour. As last step, the pressure was reduced to 600 mbar until 
complete drying of the product (usually 2 hours more). The dried black precipitate was then 
solubilized using 20 mL borate buffer and sonication at high temperature (65°C set as starting 
temperature of the sonication batch) for at least 2 hours. After, the sample’s volume was reduced 
(to about 3 mL) through Amicon tube filters (100 k Da MWCO) centrifugation. The sample was finally 
loaded on top of a sucrose gradient (from top to bottom: 2 mL of 20%, 3 mL of 40% and 3 mL of 60% 
in an ultra-centrifugal tube) for ultracentrifugation in order to separate the coated particles from 
the unreacted polymer. 75 minutes of ultracentrifugation at 13700 RCF followed. Excess of polymer 
is then removed by means of a syringe and particles are cleaned from the sucrose and concentrated 
to 300 µL through centrifuge washings using 15 mL 100 kDa MWCO Amicon filter. 
Gel electrophoresis 
Gel electrophoresis was employed to evaluate water transferred trimers migration in a solid agarose 
matrix (1 % m/V agarose gel, 50 mg agarose in 50 mL TBE buffer). Samples were loaded on the matrix 
together with orange G visualizing dye and electrophoresis run was performed in tris-borate-EDTA 
(TBE) buffer applying a voltage of 100 V for 45 minutes. 
Calorimetric measurements of Specific Absorption Rate 
A commercially available set-up (DM1 Series, NanoScale Biomagnetics) was used to assess 
hyperthermia performance of gold–iron oxide dimers and of iron oxide-gold-copper sulfide trimers. 
50 µL of an aqueous solution of nanoparticles’ sample (with concentration ranging from 1 to 3 
giron/L) were placed in a sample holder and introduced in the instrument. The device can apply fields 




During alternated magnetic field application, temperature was measured through a fluoro-optic 
thermometer fiber probe (Luxtron Corp.) every 0.25 s. Reported SAR values and error bars were 
calculated respectively from average value and standard deviation of at least three experimental 











where C is the specific heat capacity of water (4185 J×L-1×K-1), m is the concentration (g×L-1 of Fe) of 
magnetic material in solution and dT/dt the slope of the measured heating curve. In the used 
system, measurements were carried out under non-adiabatic conditions. For this reason, when 
measuring the slope of the curve dT/dt only the first few seconds of the temperature vs. time curve 
were taken into account. 
AC hysteresis loops measurements 
AC hysteresis loops were measured using a custom-made device for AC magnetic measurements 
(IMDEA). Hysteresis loops were recorded using different field’s amplitudes (12 – 16 - 20 - 24 kA/m) 
and frequencies (100-200-300 kHz). Experiments were performed on both dimers and trimers, using 
40 μL of sample with iron concentrations in the range 1giron/L – 3 giron/L. 
Radiolabeling of FeOy@Au@Cu2-xS trimers 
Into an Eppendorf tube, a quantity of 64CuCl2 corresponding to an activity of 18.5 MBq and 150 µL 
of 0.3 M MES buffer (pH 5.6) were added. The pH of the solution was then brought to a value around 
6 by 2 M NaOH addition, in amounts depending on the specific activity and on the pH of the received 
64CuCl2 solution (typically, 6 µL of 2 M NaOH were used in order to adjust the pH of 35 µL of starting 
solution). Once the solution was brought to desired pH, 10 µL of ascorbic acid (0.1 M) as a reducing 
agent and NPs solution, (containing 10000 times the equivalent of 64Cu (II) used for 0.01 % 
64Cu/CuNCS percentage ratio), were added. In order to stabilize the nanocrystals during the 
radiolabeling, 50 µL of a 0.0049 M aqueous solution of CYS-PIMA-PEG were added. After the 
addition of the stabilizing agent, the reaction mixture was incubated at 37°C for 60 minutes. Then, 
1 μL of the reaction mixture was spotted on iTLC-SG chromatography paper (Agilent technology) 
and the iTLC was developed in 0.1 M EDTA (pH = 7.5) as mobile phase. The dried ITLC plates were 
exposed on an Imaging Plate for 30 seconds and the results were analyzed on an appropriate 
imaging system (FLA-9000, Perking Elmer). 
Concentration and purification of the solution of radiolabeled nanocrystals 
The washing and concentration of the nanocrystals after the radiolabeling procedure has been 
performed using 0.5 mL 100 kDa MWCO Amicon centrifugal filters (Merck). After the radiolabeling, 
the reaction mixture (approximatively 300 µL) was transferred to an Amicon filter inserted in an 
Eppendorf vial and MilliQ water added up to 500 µL. After 4 minutes of centrifugation at 4000 RCF, 
the filter containing radiolabeled nanocrystals was removed and inserted upside down in a new 
Eppendorf vial and centrifuged for 2 minutes at 2000 RCF. Through a dose calibrator (VDC-603, 
Comecer) the activity of the final nanocrystals’ solution was checked and the percentage of activity 




EDTA challenge on radiolabeled FeOy@Au@Cu2-xS trimers and Au@ FeOy dimers 
In order to perform EDTA challenge, 150 µL of EDTA 0.5 M were mixed to the radiolabeling batch of 
dimers and trimers and incubated for 3 hours at 37°C. Through iTLC the percentage of radioactive 
64Cu incorporated in the nanocrystals has been checked after 60, 120 and 180 minutes. 
Measurements of photothermal and DUAL modality heating performances of 
FeOy@Au@Cu2-xS trimers 
50 μL of trimers’ sample with the same concentration used for a typical magnetic hyperthermia 
experiment ([Fe] = 2.8 g/L, [Cu] = 1.6 g/L [Au] = 4.0 g/L) are inserted in a glass capillary, placed in a 
custom-made 3D-printed sample holder. 808 nm laser with different power densities (4.67 W/cm2 
or 2 W/cm2) is irradiated on the sample. Distance between laser optic and sample is 4 cm, laser spot 
size on the capillary is 0.07065 cm2. For the DUAL treatment, the sample holder was positioned in 
the middle of the coil of a commercially available set-up (DM3 Series, NanoScale Biomagnetics) for 
hyperthermia measurements. Alternating magnetic field used for the DUAL measurements had a 
frequency of 120 kHz and amplitude of 24 kA/m. Temperature of the samples’ solution was 
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Figure A1: Size dispersion graph of water-transferred ZnS nanoparticles shown in Figure 1.7a. 
a b 
c 







Figure A 3: Size dispersion graph of IONCs sample shown in Figure 2.4a. 
Figure A 4: Size dispersion graphs of iron oxide and gold domains in FeOy@Au dimers shown in Figure 2.9; a) gold domains before 
magnetic separation; b) iron oxide domains before magnetic separation; c) gold domains after magnetic separation; d) iron oxide 












Figure A 5: Size dispersion graphs of a) gold NPs seeds shown in Figure 2.12a; b) gold domains shown in Figure 2.12b; c) Cu2-xS domains 
shown in Figure 2.12b. 








Figure A 7: Comparison of SAR data for the same sample of trimers water transferred with polymer coating (blue lines) and with 
ligands exchange (red lines), data obtained using a field frequency of 105 kHz and amplitudes of 12 kA/m, 16 kA/m, 20 kA/m, 24 kA/m 
and 32 kA/m. Lines are a guide to the eye. 
Figure A 8: AC hysteresis loops of samples of trimers water transferred through polymer coating (continuous lines) or ligand exchange 
(dashed lines) measured using a) alternated fields with frequency of 100 kHz and amplitudes of 12 kA/m (black lines) and 24 kA/m 
(blue lines); b) alternated fields with frequency of 100 kHz and amplitudes of 16 kA/m (red lines) and 20 kA/m (green lines); c) 
alternated fields with frequency of 200 kHz and amplitudes of 16 kA/m (red lines) and 20 kA/m (green lines); d) alternated fields with 








Figure A 9: AC hysteresis loops of a sample of trimers (continuous lines) and dimers (dashed lines) having a 26 ± 4 nm iron 
oxide domain measured using a) alternated fields with frequency of 100 kHz and amplitudes of 12kA/m (black lines) and 24 
kA/m (blue lines); b) alternated fields with frequency of 100 kHz and amplitudes of 16 kA/m (red lines) and 20 kA/m (green 
lines); c) alternated fields with frequency of 200 kHz and amplitudes of 16 kA/m (red lines) and 20 kA/m (green lines); d) 
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The present dissertation is resulting from the work performed during the Ph.D. research activity 
carried out at the Italian Institute of Technology (IIT) under the supervision of Dr. Teresa Pellegrino 
(Nanomaterials for biomedical research line) and of the University of Genova. The thesis has been 
conducted in the framework of the ERC-founded project ICARO (ERC starting grant n° 678109, 
Principal Investigator: Dr. Teresa Pellegrino), whose main purpose is the development of novel 
inorganic nanostructures for radiotherapy and chemotherapy of cancer. Thus, this thesis aims to 
progress the field of nanomedicine. In particular, the first goal of this work is to synthesize 
innovative water stable chalcogenide nanoparticles, with the purpose of achieving nano-sized 
platforms capable of incorporating radioactive 64Cu ions, which would make such systems suitable 
for the use in radiotherapy and for positron emission tomography. The second goal is to explore the 
coupling of such chalcogenide nanocrystals with magnetic nanoparticles, which are already part of 
the nanoparticles’ portfolio available in the research group where this thesis was carried out. These 
nanoparticles have shown great potential for magnetic hyperthermia treatment of cancer and, in 
combination with radiotherapy, could result in a synergic and more effective cancer treatment. 
Thus, this thesis provides new ground in the rational design of multifunctional nano-
heterostructures for cancer diagnosis and therapy. 
Introduction: 
Cancer is one of the leading causes of death worldwide accounting for 9.6 million of deaths (almost 
17 % of all deaths globally, 20 % of all deaths in Europe) in 20181. Most commonly used therapies, 
other than surgery, are chemotherapy and radiotherapy. However, together with the large 
heterogeneity of cancers, many factors, such as, for example, multidrug resistance (MDR) in the 
case of chemotherapy and, for what regards radiotherapy treatments, the low sensitivity of hypoxic 
cancers to the ionizing radiations, can reduce the effectiveness of these treatments.2 This called for 
the development of new innovative cancer treatments, with higher specificity and causing less 
damage to surroundings healthy tissues. Among the different strategies investigated, the use of 
nanoparticles as remote probes for cancer diagnosis and treatment (nanomedicine) has widely 
attracted the attention of the research community in last two decades.3,4 Among the different 
classes of nanoparticles studied, inorganic nanoparticles are of particular importance due to their 
peculiar and tunable chemical and physical properties that can be used to add additional cancer 
treatment and diagnosis features to the nano-pharmaceutical.5 Among the wide number of 
inorganic nanoparticles with different composition studied for biomedical applications, three 
classes have been of particular interest for their chemical and physical properties: noble metal 
nanoparticles,6 semiconductors nanoparticles.7 and magnetic nanoparticles.8 Some of the 
nanoparticles reported for biomedical applications have intrinsic multimodal diagnosis and therapy 
features.9 Some examples are gold nanorods, that have been reported to be exploitable both in 
cancer cell imaging and photothermal therapy10, or copper sulfide nanocrystals that have been 
exploited for dual PDT and PTT treatment11 or for photoacoustic imaging-guided photothermal 
therapy.12 Iron oxide nanoparticles are also commonly studied for theragnostic, exploiting MRI (or 
MPI) as imaging technique and MHT for therapy13 and have recently been reported to be exploitable 




treatment and diagnosis modalities is of key interest for the future development of nanomedicine. 
Indeed, the development of multimodal treatment and diagnosis nano-platform, would permit to 
increase the efficiency of the treatments, this scaling down the amount, and related cytotoxicity,15 
of the nanoparticles used.16 In order to further enhance this possibility, researchers working on 
nanoparticles for biomedical applications started working on the development of nano-
heterostructures (NHs) composed of different nano-domains with different properties. This work 
was focused on the study of nano-heterostructures having different domains joint through a solid 
interface, this allowing to obtain multifunctional nano-objects with reduced size and to tune 
properties arising from the formation of the solid heterojunction.17 Moreover, particular interest 
was directed towards nano-heterostructures developed in order to combine multiple therapeutic 
modality overcoming the intrinsic limitations of each single therapy, with a special focus on the ones 
having a magnetic domain. 
Chapter 1: 
In the medical practice, radioisotopes can be used for two main applications: nuclear imaging and 
targeted radionuclide therapy (TRT). In both cases, an appropriate radioisotope is bound to a carrier 
that has the role to specifically bring the radioisotope to the tissue selected as target of the 
treatment or as area of interest for diagnosis. These pharmaceutical radiolabeled drugs are 
commonly referred to as radiopharmaceuticals. One of the most common nuclear imaging 
techniques is positron emission tomography (PET)18. Positron emission tomography is performed 
using radioisotopes that are decaying through the emission of positrons (i.e. positive electrons, β+). 
Targeted radionuclide therapy19–22 is a radiation therapy treatment performed using 
radiopharmaceuticals to deliver therapeutic radiation to targets inside the body. Main important 
advantage of targeted radionuclide therapy, when compared to standardly used external beam 
therapy, is its selectivity, allowing to ideally affect mainly cancer cells, reducing the unspecific 
damage to healthy tissues.23 Among all the radiometals used in PET imaging and TRT, of particular 
interest is 64Cu for its desirable relatively long half-life (12.7 h) and for the possibility to be used in 
theragnostic applications. Indeed, together with positron emission (17 % 0.655 MeV) suitable for 
PET imaging, 64Cu is decaying also through β- emission (39 %, 0.573 MeV) and electron capture (44 
%) that can be exploited in targeted radionuclide therapy. Another important advantage of 64Cu is 
that it is currently produced in many cyclotron facilities on a routine basis,24–26 making it an ideal 
candidate for the production of radio-therapeutic agents.27–29 Recently great interest was shown30–
32 towards the use of functionalized nanoparticles as radionuclide carriers. Most used strategy in 
order to radiolabel with 64Cu different nanocrystals is the use of suitable metal chelators anchored 
to the surface of the nanoparticles. Following this path, metal33, quantum dots34 and magnetic 
nanoparticles35 were successfully radiolabelled with 64Cu. Recently, new approaches for the 
incorporation of radioactive ions in nanocrystals were reported. Zhou et al36 in 2010 reported the 
synthesis of 64CuS nanocrystals using a mixture of “hot” (radioactive) and “cold” (non-radioactive) 
CuCl2 while Sun et al37 in 2014 reported the feasibility of a cation exchange reaction performed at 
60°C in organic solvent in order to introduce radioactive 64Cu in pre-synthesized CdSe/ZnS quantum 
dots. Main limitation of these procedures is the fact that the radioactive nuclide is introduced at an 
early stage of the material preparation pathway. The possibility of radiolabelling nanocrystals with 




phase intercalation reaction was investigated by researchers from the group in which this research 
activity was carried out.38 By means of intercalation reactions in aqueous solution it has been 
possible to successfully radiolabel CuS covelite nanocrystals with excellent results.  
The first chapter of this thesis deals with the synthesis, water transfer and radiolabeling of ZnS 
nanoparticles. A non-hydrolytic thermal decomposition synthesis route39 was exploited in order to 
obtain quasi-spherical nanoparticles with average diameter’s size of 9 ± 1 nm. As synthesized 
particles have a sphalerite cubic structure (ICSD card n° 77082) and are perfectly stable in hexane. 
In order to phase transfer to water the organic solvent-stable NPs, a ligand exchange procedure 
employing a multi-dentate amphiphilic polymer (cysteamine-poly-(isobutylene-alt-maleic 
anhydride)-polyethylene glycol, CYS-PIMA-PEG) was used in order to improve stability. This 
procedure allowed to obtain nanoparticles with perfect aqueous phase stability. Also, no 
appreciable change in crystalline structure or nanoparticles shape was found. On the water stable 
nanoparticles, cation exchange reactions with both radioactive and non-radioactive copper were 
carried out. Cation exchange with non-radioactive CuCl2, using a ratio between added Cu2+ and Zn2+ 
present in nanocrystals of 1.8:1 and ascorbic acid as mild reducing agent, were performed. Resulting 
nanocrystals, characterized by ICP-OES and XRD shown completely replacement of Zn (II) ions with 
Cu(I) ions. Exploiting an analogous procedure but using as copper source radioactive 64Cu:CuCl2 
radiolabeling reactions were performed on the water stable ZnS nanocrystals. Radiolabeling 
reaction resulted in high values of radiochemical yield (93%). Moreover, the excellent stability of 
the particles allowed to recover quantitatively (purification yield = 87%) the nanocrystals after 
radiolabeling reaction and subsequent purification process. The results obtained indicate ZnS 
nanoparticles as an efficient nano-platform for the use in radiotherapy and positron emission 
tomography, given the fast, reproducible and easily clinical-translatable radiolabeling procedure 









Figure 1: Experimental XRD pattern of a sample of ZnS nanoparticles before (b) and after (c) cation exchange reaction with 
non-radioactive Cu (Cuused : SNCs = 1.8), in comparison with expected reflections for cubic ZnS (a, ICSD code: 77082) and 
cubic Cu1.8S (d, ICSD code 57213); e) radiochemical yield (RCY) and purification yield (PY) of radiolabeling experiments 





Janus nanoparticles (JNPs), named after the double-faced Roman god, are compartmentalized 
particles with two sides having different chemical properties or polarity40. The great importance of 
such materials in merging different physical and chemical properties in one single nanostructure 
was already realized by Nobel laureate P. G. de Gennes in 1991.41 From that year on, the synthesis 
of inorganic Janus NPs was further developed and optimized, increasing exponentially the number 
of reported procedures to obtain this kind of nanomaterial. 42–47. Depending on the shape and on 
the composition of the different heterostructures’ domains, these materials have been 
demonstrated to be useful in many different applications, including catalysis48,49, micromotors50–
52,displays53,54 and biosensors55–57. Recently, the possibility to merge domains with completely 
different properties in one single nano-heterostructure and the opportunity to tune these 
properties have attracted the interest of researchers working in the development of nanomaterials 
for biomedical applications, who, in the last decade, have thoroughly studied the processes 
happening at the domains’ interfaces and worked in the development of nanoparticles for cancer 
theragnostic58–60. Of particular interest for the scientific community is that these multiple-domain 
nano-heterostructures maintain the properties of each single domain and, in addition, new 
properties can also arise from the presence of an interface between the different materials. In last 
two decades, many efforts have been made in order to develop colloidal synthesis procedures for 
inorganic Janus nano-heterostructures, formed by two (or more) distinct domains permanently joint 
through chemical bonding interfaces (i.e., without any molecular bridges)61. Most of those 
procedures rely on the growth of a second domain on the surface of a preformed nanoparticle. This 
mechanism is commonly referred to as “seeded growth” (or “seed mediated growth”) being the 
starting preformed nanoparticles defined as “seeds”. In order to obtain those two (or more) 
domains heterostructures62, it is critical to favor the heteronucleation of the second material on 
seeding NPs (against the homonucleation that is the formation of separate second material NPs 
surrounding the seeds). Among the wide amount of literature on JNPs, only few heterostructures 
composed by an iron oxide and a semiconductor domain are reported. 63–72 
In the second chapter of this thesis are described the results obtained by the different trials 
performed in order to couple in a single nano-heterostructure the developed ZnS nanoparticles or 
copper-deficient copper sulfide nanoparticles (previously reported to be exploitable as 
radioisotopes carriers) with highly performing magnetic nanoparticles (iron oxide nanocubes, 
IONCs)73 or nano-heterostructures (gold-iron oxide dimers, Au@FeOy)58. Initially, a reported 
synthesis procedure63 for the growth of ZnS domains on the surface of small γ-Fe2O3 nanoparticles 
has been adapted in order to grow ZnS domains on IONCs but these trials were not successful. Then, 
the possibility to grow chalcogenide domains on the surface of gold nanoparticles was investigated. 
While the growth of ZnS nanoparticles did not result in the formation of heterostructures, but only 
in homonucleation of ZnS domain around gold NPs used as seeds, following a reported procedure74 
it has been possible to successfully couple in a single heterodimer a gold NPs with a copper deficient 
copper sulfide domain. Subsequently, using the Au@FeOy dimers, developed in this group and 
having high magnetic hyperthermia efficiency, as seed for the growth of Cu2-xS domains, 
FeOy@Au@Cu2-xS were synthesized. The developed synthesis procedure allows, through the 




± 3 nm to 33 ± 5 nm. These FeOy@Au@Cu2-xS trimers were thoroughly characterized by TEM, XRD, 
SQUID magnetometry and UV-VIS-NIR spectroscopy. XRD analyses identified the crystal phase of 
the Cu2-xS as low ordered triclinic roxbyite. Trimers were found to have magnetic properties similar 
to the ones of the Au@FeOy dimers used as seeds a part from a diamagnetic contribution at high 
fields coming from copper sulfide domain. FeOy@Au@Cu2-xS also show two LSPR absorption bands, 
related to the presence of gold and copper sulfide domains. Both of them are exploitable for the 
application in photothermal therapy with laser having wavelength in the NIR biological windows. 
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Figure 2: Characterization for a sample of FeOy@Au@Cu2-xS trimers. HAADF image (a) and EDS elemental analysis 
mappings for Au, Fe, Cu (b) and Au, O, S (c); d) experimental XRD patterns compared with the expected reflections for 
gold (ICSD code 611625), iron oxide (ICSD code 247035) and roxbyite copper sulfide (ICSD code 185807); e) 
comparison between zero field cooled MH curves recorded in the range ± 70 kOe at 10 K, for a sample of trimers (red 
line) and for a sample of dimers (blue line) having iron oxide domains with same average size (25 ± 4 nm), f) VIS-IR 





Hyperthermia, the artificial temperature increase of the body or of a tissue above the normal 
temperature set by the thermoregulation system of an organism,75 is nowadays a widely used 
cancer treatment.76,77 This treatments can be used both as stand-alone therapy78 or in combination 
with other treatments (e.g. chemotherapy, radiotherapy or surgery)79–83 with the latter option being 
more effective.84 Hyperthermia can be administered to patients through three different 
methodologies: whole body hyperthermia, regional hyperthermia and local hyperthermia.85 In last 
decades,86,87 many efforts were made in order to be able to exploit nanoparticles with different 
composition for local hyperthermia treatments. Main advantage of using nanoparticles for thermal 
treatment is the possibility to target a small area of tumoral tissue avoiding unspecific heating and 
overcoming the limitation of standard local hyperthermia treatments to superficial cancers. Another 
possibility related to the use of nanoparticles is, either exploiting their intrinsic properties or 
functionalizing their surface, to merge hyperthermia with other diagnosis or treatment applications, 
in order to exploit them as theragnostic agents.88–90 One possibility in order to perform thermal 
treatments using nanoparticles is given by the application of an alternating magnetic field (AMF) to 
a tissue where magnetic nanoparticles (MNPs) are dispersed. The use of magnetic nanoparticles as 
heating mediators in magnetic hyperthermia treatments (MHT) was already reported in 195791. 
From that pioneering study the interest on this clinical methodology increased and today clinical 
phase II studies are led by MagForce company, in hospital Charité in Berlin.92,93 When magnetic 
nanoparticles are stimulated through an alternating magnetic field, three different mechanisms can 
results in thermal energy production94: Néel relaxation (rotation of the magnetic moment of the 
particle overcoming anisotropy energy barrier), Brownian relaxation (mechanical rotation of the 
MNPs with friction against the surrounding medium) and hysteresis losses (shifting of domains walls 
that takes place in multi-domain MNPs). Relative contribution of each of the three mechanisms is 
depending on many different parameters such as material composition, size, shape, magnetic 
anisotropy and grade of agglomeration of MNPs. Heating performances of nanoparticles in 
magnetic fluid hyperthermia are usually evaluated through specific absorption rate (SAR o also SLP, 
specific loss power) values. SAR is defined as the power dissipated by MNPs per unit of mass.  In last 
decades, many different nanomaterials suitable for magnetic hyperthermia treatments were 
developed. Among them, the most commonly used are FDA approved iron oxide nanoparticles73,95–
97 or mixed ferrite nanocrystals such as cobalt ferrite98–100, zinc ferrite101,102 or manganese 
ferrite103,104. Currently, efforts of the researched working in this field are oriented towards the 
development of nanomaterials with higher efficiencies (larger SAR values). Indeed, an increased SAR 
value would allow to scale down the amount of nanoparticles employed in each treatment and, 
consequently, to reduce the cytotoxicity of the nanomaterial.105 In order to pursue this goal, also 
magnetic nano-heterostructures, such as Fe(0)@iron carbide106 or soft core-hard shell107 structures, 
were synthesized and found to have increased hyperthermia efficiencies if compared to the single 
material nanoparticles. Another class of hyperthermia therapies in which nanomaterials are widely 
used are photothermal treatments (photothermal therapy, PTT). In these treatments, temperature 
increase is obtained through photothermal transducing agents (PTAs) that are harvesting energy 
from appropriate electromagnetic radiations and converting it into heat. Most commonly used 
nanoparticles as PTAs are the one exhibiting localized surface plasmon resonance (LSPR).108,109 A key 




absorption corresponding to the plasmon resonance. Indeed, the laser radiation used to excite 
plasmonic nanoparticles has to be able to reach nanoparticle without being absorbed from the 
surrounding tissues since this would reduce the energy of the incoming radiation and damage 
healthy tissues. Typically, for this purpose, laser radiations with wavelengths in the near infrared 
region (NIR) are used110. Indeed, the scattering and absorption of NIR radiation by human tissues is 
lower if compared to the one obtained with visible light or UV light lasers.111 In particular, tissues’ 
absorption and scattering of laser radiation is negligible (radiation can travel through tissues with 2 
– 3 cm path length) in the three so-called NIR biological windows . Among all the nanoparticles 
investigated for the application in photothermal therapy, gold nanoparticles of different sizes and 
shapes are the most studied and promising.112–114 Absorption of Au nanospheres is usually centered 
in the range between 500 nm and 600 nm with larger particles having higher absorption wavelength. 
These spherical nanoparticles are usually exploited with laser having wavelengths in the 1st NIR 
biological window115 targeting the absorption tail of the gold NPs plasmonic peak. Another class of 
gold nanomaterial widely exploited for photothermal treatments are gold Nanorods (NRs)116,117. The 
peculiarity of the Au NRs is to have, due to their shape anisotropy, two plasmon resonances: 
transverse plasmon resonance, usually centered between 500 and 550 nm, and longitudinal 
resonance between 650 nm and 850 nm. This second absorption wavelength can be tuned to higher 
values by increasing NRs’ aspect ratio.10 Photothermal treatments exploiting other gold 
nanostructures such as nanoshells (GNSs),118,119 or nanostars (GNSTs)120,121 have also been reported. 
Together with gold, also other noble metals nanocrystals, such as Pt or Pd122,123 have been 
demonstrated to be effective when used as PTAs in PTT. In 2010, Chen and coworkers indicated 
copper deficient copper sulfide nanocrystals as candidate material to be used as PTAs in 
photothermal therapy using a 808 nm laser.124 Although in this pioneering study the power density 
used (> 24 W/cm2) was more than 70 times higher than the safe value for biological applications 
(0.33 W/cm2),125 its publication leaded the way to many further studies on this class of materials. 
Indeed, in last two decades, many studies were carried out in which performances of copper-
deficient copper sulfide nanoparticles were increased by changing either shape or stoichiometry of 
the material.71,126–129  
In the third chapter, the newly synthesized trimers were transferred to water phase and tested for 
the aimed applications. Different strategies were explored in order to develop a reproducible and 
high-yield water transfer procedure. Among them, a two-step ligands exchange procedure 
employing CH3O-PEG2000-SH and poly-catechol-PEG900 as amphiphilic ligands resulted in aqueous 
phase stable trimers with high water transfer procedure yield (> 80 %). FeOy@Au@Cu2-xS trimers 
were also successfully transferred to water, although with lower yields if compared to previous 
procedure, using a polymer coating procedure and employing commercially available and cost-
effective poly-(Maleic Anhydride-alt-1-Octadecene). Lastly, the developed nano-platform showed 
great relevance in the field of nanomedicine. Indeed, when employed in magnetic hyperthermia, 
trimers resulted in high SAR values (302 W/g when a field with frequency of 105 kHz and an 
amplitude of 32 kA/m were used), preserving the excellent hyperthermia performances of the 
Au@FeOy used as seeds for their synthesis and thus in line with the best magnetic nano-
heterostructures reported so far. Radiolabeling reactions were performed on trimers, resulting in a 
radiochemical yield of 97 %, higher than any value reported so far for 64Cu incorporation in 
nanocrystals. Furthermore, the stability of the trimers during the radiolabeling and subsequent 




allowing to quantitatively recover the nanocrystals and the associated radioactivity. The 
performances of FeOy@Au@Cu2-xS trimers when used in photothermal heating were also tested 
under the exposure to 808 nm laser irradiation. Although the performances obtained with lower 
laser’s power density were limited, the possibility to tune the absorption wavelengths by means of 
changing gold and copper sulfide domain’s properties, gives space to further improvements for 
these multifunctional nano-heterostructures. To the best of our knowledge, the here described 
FeOy@Au@Cu2-xS trimers are the first ever reported nano-heterostructures able to combine in one 
single nano-object the possibility to perform magnetic hyperthermia, photothermal therapy and 
radiotherapy/positron emission tomography, thus allowing the possible development of more 
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Figure 3: a) Representative TEM picture of a sample of trimers water transferred using a ligand exchange 
procedure employing poly-catechol-PEG900 and CH3O-PEG2000-SH; b) related DLS hydrodynamic size 
distribution graph by intensity; c) SAR vs field amplitude graphs for Au@FeOy dimers (blue line) and 
FeOy@Au@Cu2-xS trimers (red line) having a 26 ± 4 nm iron oxide domain measured using a field frequency of 
217 kHz; d) AC hysteresis loops of a sample of trimers (continuous lines) and dimers (dashed lines) having a 26 
± 4 nm iron oxide domain performed using fields with frequency of 200 kHz and fields of 12 kA/m (black lines) 
and 24 kA/m (blue lines); e) radiochemical yield (bars) and purification yield (red line) obtained for 
radiolabeling reactions performed adding increasing amount of 0.0049 M CYS-PIMA-PEG2000 solution. f) 
heating curves (5 minutes) of FeOy@Au@Cu2-xS trimers obtained under irradiation with 808 nm laser using a 
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